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I. Preface 
Worldwide concern has been growing on the increasing distribution of endocrine 
disrupting chemicals (EDCs) during the last decade. The overall anxiety is caused by 
their effect on the endocrine system of wildlife and humans. While the influence on the 
reproductive systems of several animals has been thoroughly documented, the effects 
on human health are still the subject of intense debate. 
Establishing a causal relationship between the presence of EDCs in the environment 
and their possible effects on human health is a challenging quest. Besides their low 
physiologically active concentrations, the complex environmental matrices in which 
they are present, makes it very difficult to identify and quantify different EDCs.  
This problem can be tackled by a pre-concentration step before the actual analysis. 
In general, solid-phase extraction (SPE) of aqueous samples is a widly applied 
technique to enrich pollutants. With the current SPE cartridges, the extraction efficiency 
of the pollutants depends on their polarity. Thus polar compounds stay in the water 
sample while apolar compounds are retained on the solid phase. As a consequence the 
selectivity of the SPE is poor. A solid-phase material which could selectively bind the 
different EDCs would thus greatly simplify the analysis. 
This PhD will focus on the development of an artificial receptor that shows high 
affinity towards common EDCs and low or no affinity to other compounds present in 
environmental samples. By constructing this receptor on a solid phase, a new affinity 
based SPE material can be developed, resulting in a more accurate and selective 
determination of EDCs. 
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II. Introduction 
II.1. General Background 
Since World War II, the world has witnessed a large increase in the production of 
chemicals. Some of these chemicals, like pesticides, were designed for wide spread use 
in the environment. Others, like PCBs, were rather accidentally released into the 
environment by leakages or waste dumping. At the time, little or no attention was paid 
to the possible consequences that could result from the use and distribution of these 
chemicals. 
This ignorance changed with the publication of Rachel Carson’s Silent Spring in 
1962.1 This book documented for the first time the detrimental effects of pesticides on 
wildlife. More particularly, the link was proven between egg shell thinning of birds and 
the pollution of the surrounding environment with dichloro-diphenyl-trichloroethane 
(DDT). From this time, public awareness was born and grew ever since. 
Only three decades later, a new disturbing event was signalled in an article by Theo 
Colborn.2 This article described the deleterious influence that certain chemicals had on 
the development of endocrine systems. These endocrine disrupting chemicals (EDCs) 
were linked to reproductive problems like the decrease in fertility with birds and the 
demasculinisation and feminisation of fish. The last twenty years that followed this 
paper have witnessed a growing scientific concern, public debate and media attention 
over the possible effects in wildlife and humans that may result from exposure to 
chemicals that have the potential of interfering with the endocrine system.3  
                                                        
1 Carson, R. 1962. Silent Spring. Mariner Books, Boston, 400p. 
2 Colborn, T.; Saal, F. S. V.; Soto, A. M. Environmental Health Perspectives 1993, 101, 378-384. 
3 Matthiessen, P. Pure Appl. Chem. 2003, 75, 2197-2206. 
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The international programme for chemical safety (IPCS) defined endocrine 
disruptors as follows:4 
An endocrine disrupter is an exogenous substance or mixture that alters 
function(s) of the endocrine system and consequently causes adverse health 
effects in an intact organism, or its progeny, or (sub)populations. 
Currently, the European commission has listed 320 chemicals5 as possible EDCs. 
The list encompasses a variety of chemical classes, including natural and synthetic 
hormones, plant constituents, pesticides, compounds used in the plastic industry and in 
consumer products and other industrial by-products and pollutants. Some EDCs are 
persistent organic molecules and bio-accumulate in the food chain, others are rapidly 
degraded and excreted into the environment.  
In the next chapter a brief overview is presented of the mechanism of endocrine 
disruption and the effects on wildlife and humans. A focus will be put on estrogen 
related problems. Next, the different classes of EDCs are discussed and finally a 
summary is given of analytical strategies used for the determination of the potency and 
the concentration of EDCs. Though a complete review of scientific literature is beyond 
the scope of this chapter, the most important and disturbing events are listed. 
                                                        
4 WHO/IPCS Global assesment of the state-of-the-science of endocrine disruptors, 2002. 
5 Commission staff working document on the implementation of the community for endocrine disruptors, a range of 
substances suspected of interfering with the hormone systems of humans and wildlife, SEC (2004) 1372, COMM 
(2001) 262, SEC (2007) 1635, Brussels Belgium. 
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II.2. Endocrine disruption 
II.2.1. Mechanism of disruption 
Communication inside the body can proceed via fast, electrical signalling 
coordinated by the central nervous system or via slower, chemical signalling 
coordinated by the endocrine system. The chemical messengers employed by the latter 
are called hormones and consist of two classes: peptide hormones and steroid 
hormones. These hormones generate specific responses in other parts of the body by 
interacting with their specific receptor. The concentrations at which the hormones are 
present vary in time, but wild swings in concentrations are avoided so that a 
homeostasis is maintained. 
Chemicals originating from outside the body can influence the endocrine system via 
several pathways: 
- Binding to the hormone receptor and acting as an agonist (activating the 
receptor). 
- Binding to the hormone receptor and acting as an antagonist (deactivating 
the receptor). 
- Influencing the production, metabolism or transport of the endogeneous 
hormones. 
The most disturbing effects originate from the binding of chemicals with the 
hormone receptors at the cell surface, cytoplasm or nucleus.6 From these hormone 
receptors, especially the estrogen receptor (ER) seems to behave promiscuous.  
The estrogen receptor, part of the family of nuclear receptors, is a ligand-inducible 
transcription factor. With humans, two forms, ERα and ERβ, are present. Though they 
are very similar, the two receptor types have distinctly different localisations and 
                                                        
6 Harry, F.; Robert, G. Pure Appl. Chem. 2003, 75, 2181-2193. 
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concentrations within our body. Both are activated upon binding with small, lipophilic 
molecules. After activation, a dimer (e.g. ERβ− ERβ, ΕRα- ΕRα or ERβ- ERα) is 
formed and this complex binds to the cell’s DNA. The DNA is then transcribed into 
mRNA that leaves the nucleus to be translated in proteins. In this way, growth and 
reproduction of the body are regulated.  
The human estrogen receptor (hER) is unique in its ability to embrace a wide variety 
of non-steroidal compounds. This overall promiscuity can be ascribed to the large size 
of the hormone binding domain (HBD) which has an accessible volume (450 Å3), twice 
the size of estradiol (250 Å3).7 A distinct feature is a pincer like arrangement of amino 
acids around the phenolic ring of estradiol that imposes an absolute requirement on 
effective ligands to contain an aromatic ring. The length and the breadth of the estradiol 
skeleton are well matched by the receptor, but there are large unoccupied cavities at the 
two sides of the molecule. 
Consequently, a lot of chemicals can bind with the ER and influence the endocrine 
system. This will eventually result in a disturbed reproductive system and explains the 
observed phenotypes with decrease in fertility, change of sex, …8 
II.2.2. Effects on animals 
A direct effect of chemicals on the endocrine system of 
animals was observed in the 1980s with the alligator population 
of Lake Apopka, central Florida (USA). It was noticed that this 
population declined while the populations in the rest of 
Northern America increased. This decline was the consequence 
of the contamination of the lake with the pesticide dichloro-
diphenyl-dichloroethylene DDE.9 The pesticide pollution was linked to reproductive 
                                                        
7 Brzozowski, A. M.; Pike, A. C. W.; Dauter, Z.; Hubbard, R. E.; Bonn, T.; Engstrom, O.; Ohman, L.; Greene, G. 
L.; Gustafsson, J. A.; Carlquist, M. Nature 1997, 389, 753-758. 
8 Harrison, P. T. C.; Humfrey, C. D. N.; Litchfield, M.; Peakall, D.; Shuker, L. K. IEH assesment on environmental 
oestrogens: consequences to human health and wildlife; Page Bros.: Norwich, 1995. 
Cl Cl
Cl Cl
DDE
Figure  II.1: DDE. 
Chapter  II 
 7
abnormalities like a smaller penis size, lower plasma concentrations of testosterone and 
higher concentrations estradiol with juvenile, male alligators. 
Another notable and convincing biological response to the presence EDCs, is the 
production of the female fish hormone vitellogenin in male fish. Although this hormone 
is normally produced by the yolk of the female, high values of it have been found in 
male fish in a variety of water bodies in Europe, Japan and North America. In the UK, 
domestic waste effluents are a major source of pollution of the rivers.10 The effluents 
are contaminated with EDCs that cause the feminisation of male fish which is reflected 
in the production of vitellogenin. 
These two examples are only a few of the well documented effects on wildlife. The 
influence on animals continues to raise a lot of concern because it can be seen as an 
indicator for the overall contamination of the environment with EDCs. Indeed, 
problems with wildlife can be regarded as a warning for humans. 
II.2.3. Effects on human health: is there a problem? 
The effects on humans resulting from different 
chemicals are not only predicted by studying the effects on 
animals, some significant conclusions can be drawn from 
the DES case. Diethylstilbesterol or DES (Figure II.2) is a 
drug that was administered to several million women 
between the late 1930’s until its ban as a drug in 1971. The 
drug was described to prevent habitual abortion but was banned later on with the 
discovery that some women exposed in utero (the DES daughters) developed a vaginal 
cancer.11 Also an increased infertility and an irregular menstrual cycle were observed 
                                                        
 
9 Guillette, L. J.; Gross, T. S.; Masson, G. R.; Matter, J. M.; Percival, H. F.; Woodwar, A. R. Environ. Health 
Perspect. 1994, 102, 680-688. 
10 Tyler, C. R.; Routledge, E. J. Pure Appl. Chem. 1998, 70, 1795-1804. 
11Fisch, H.; Golden, R. Pure Appl. Chem. 2003, 75, 2181-2193. 
HO
OH
Diethilstylbesterol (DES)
Figure  II.2: DES.
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with the female offspring. Adverse effects on the male reproductive system resulting 
from the in utero exposure to DES consisted in a decreased sperm count, increased 
incidence in abnormal sperm and smaller penises. Because of the wide spread use of 
this drug, a clear relationship could be established between the use of the endocrine 
disrupting DES and the effects on humans. 
Nevertheless, there is a big difference between the high amounts of DES given to 
pregnant women and the low concentrations of EDCs present in the environment. DES 
was administered in high doses and is more active than endogenous estrogens while 
common pollutants with estrogenic activity are not only present in very low 
concentrations, they are also less active than the endogenous estrogens. Consequently, 
reports of low-dose effects of exogenous EDCs are highly controversial and subject of 
intense debate.12 
Exposure to EDCs does generate some concerns. This is because analysis of human 
data shows that there are human health effects in which EDCs can play a role. With 
males in particular the decrease in the sperm count/quality and the increase in testicular 
cancer have been linked to the exposure of estrogenic chemicals during the foetal 
development.13,14 For women, it has been proposed they begin menstruation and 
undergo sexual maturation (early puberty) at lower ages than usual because of the 
exposure to EDCs. Another effect that has been described to EDCs is the steadily 
increase in breast cancers over the past decades in different countries.15 
One of the reasons that makes it so difficult to establish causal relationships between 
EDCs and their effects is the time of exposure. For adults, contamination to EDCs can 
be corrected by the homeostasis mechanism. Exposure to EDCs during foetal and post-
natal life can however result in permanent changes because during this period the 
                                                        
12 a) Safe, S. H. Environ. Health Perspect. 2000, 108, 487-493. b) Safe, S. Toxicology 2004, 205, 3-10. c) Inoue, T. 
Pure Appl. Chem. 2003, 75, 2555-2561. 
13 Carlsen, E.; Giwercman, A.; Keiding, N.; Skakkebaek, N. E. Brit. Med. J. 1992, 305, 609-613. 
14 Moller, H. Eur. Urol. 1993, 23, 8-15. 
15 Wolff, M. S.; Toniolo, P. G.; Lee, E. W.; Rivera, M.; Dubin, N. J. Natl. Cancer I. 1993, 85, 648-662. 
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endocrine system is programmed. Wrong conclusions can be drawn from measuring the 
concentrations of EDCs in the blood of adult humans and for example the occurrence of 
breast cancer.16 
In conclusion, the effects of EDCs on the human health are unknown at this 
moment. More information is needed to accurately quantify the human burden of 
hormonally active environmental chemicals. 
II.2.4. Exposure 
There are numerous chemicals in the environment that are hormonally active. These 
include synthetic and natural hormones, industrial chemicals (insecticides, household 
detergents, …) and phyto-estrogens (plant derived). 
II.2.4.1. Natural and synthetic hormones 
Hormones produced by humans and animals are constantly excreted into the 
environment. Many of these hormones are peptides that are rapidly destroyed. 
However, the steroid hormones like estrogenic compounds (Figure  II.3) are very stable 
and not fully removed during waste water treatment. Human females excrete about 
5µg/day each of estrone and estradiol. When pregnant, women can excrete a 1000 fold 
of these hormones, depending on the stage of pregnancy.17 Next to human excretion, 
animals contribute to the estrogen production as well. Cows, sheep, pigs and chickens 
produce estrogens that are excreted in the urine and especially in the faeces. The natural 
estrogens represent one of the most active class of compounds that can interfere with 
the endocrine system. As described above, they have been shown to be responsible for 
vitellogenin production in male fish.10  
 
                                                        
16 a) Westin, J. B.; Richter, E. Trends in Cancer Mortality in Industrial Countries 1990, 609, 269-279. b) Mendez, 
M. A.; Arab, L. Pure Appl. Chem. 2003, 75, 1973-2012. 
17 Shore, L. S.; Shemesh, M. Pure Appl. Chem. 2003, 75, 1859-1871. 
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HO
O
HO
OH
OH
Estrone (E1) Estradiol (E2) Estriol (E3)
HO
OH
 
Figure  II.3: Natural estrogens. 
Many synthetic estrogens have been prepared in search for estrogen pharmaceuticals 
(Figure  II.4). These compounds are designed to have a greater estrogenic potency than 
the natural estrogens by enhancing binding to the receptor or by retarding metabolism. 
The best known example is the use of ethinylestradiol (EE2) in birth control pills. After 
intake in tablet form, the EE2 can be excreted via the urine or the faeces.18 Other 
pharmaceutical compounds include DES that had a past as drug (vide supra) but that is 
also used as an anabolic agent in livestock feedings. Sometimes natural hormones are 
administered as pharmaceutical compounds, such as the use of E2 in the hormone 
replacement therapy with post-menopausal women or in the treatment of breast cancer. 
Another source of estradiol is its use as anabolic agent in feedings for cattle.19  
 
HO
OH
Ethinylestradiol (EE2)
HO
OH
Diethylstilbesterol (DES)  
Figure  II.4: Pharmaceutical estrogens. 
II.2.4.2. Phyto-estrogens 
A more surprising source of EDCs can be found in plants. They produce non-
steroidal phyto-estrogens that encompass two main classes: the isoflavones and the 
                                                        
18 Ingerslev, F.; Vaclavik, E.; Halling-Sorensen, B. Pure Appl. Chem. 2003, 75, 1881-1893. 
19 Katzenellenbogen, J. A.; Muthyala, R. Pure Appl. Chem. 2003, 75, 1797-1817. 
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lignans (Figure  II.5). Humans consume isoflavones via soybeans and other legumes. 
The lignans are consumed by eating grains, fibres and fruits. 
 
O
OH
OH
HO
O
isoflavones: Genistein
O
lignans: (-)-Matairesinol
O
O
O
OH
HO
 
Figure  II.5: Phyto-estrogens. 
Actually, the first endocrine disrupting effect on animals described in 1948 was 
linked to phyto-estrogens.20 Sheep in Western Australia suffered from a decrease in 
fertility by eating red clover. Apparently, the red clover contained high percentages of 
isoflavones that can disturb the endocrine system resulting in infertility.21 The role of 
phyto-estrogens however, is not totally clear. On one hand, they are linked with a lot of 
beneficial effects on human health involving cardiovascular diseases, breast cancer and 
post-menopausal osteoporosis.22 The reduced risk of breast cancer in women in 
Singapore was found to correlate with a daily, high soy intake.23  On the other hand, 
studies on animals have shown that phyto-estrogens can act as endocrine disruptors. 
Probably, the time of exposure is very important and that is why particular attention is 
given to babies who are fed with soy-based infant formulas.24 
                                                        
20 Bennetts H.W., U. E. J., Shier, F.L. Aust. Vet. J. 1948, 22, 2-12. 
21 Adams, N. R. J. Anim. Science 1995, 73, 1509-1515. 
22 Wanibuchi, H.; Kang, J. S.; Salim, E. I.; Morimura, K.; Fukushima, S. Pure Appl. Chem. 2003, 75, 2047-2053. 
23 Lee, H. P.; Gourly, L.; Duffy, S. W.; Esteve, J.; Lee, J.; Day, N. E. Lancet 1991, 331, 1197-1200. 
24 Verger, P.; Leblanc, J. C. Pure Appl. Chem. 2003, 75, 1873-1880. 
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II.2.4.3. Industrial chemicals 
An intriguing variety of men-made compounds, or their metabolites, seem to be 
estrogenically active. Though their potency is rarely high, some are very lipophilic and 
have the tendency to bio-accumulate throughout the food chain. The most important 
estrogenic chemicals are summarised below. 
One class of chemicals that were released intentionally into the environment are the 
chlorinated aromatic insecticides (Figure  II.6) like the notorious DDT. In the 1940’s, it 
was used on a large scale against insect vectors for diseases as typhus and malaria, 
helping to finally eliminate malaria in Europe and Northern America. From 1950 till 
1980 DDT found wide spread use as a general insecticide in agriculture. After the 
publication of Silent Spring, it became clear that the release of large quantities of DDT 
in the environment had it’s consequences on wildlife and humans.1 Thus it was banned 
from world wide agricultural use, but an exception was made for the fight against 
malaria in developing countries. 
 
Cl Cl
Cl
Cl Cl
Cl Cl
Cl
ClCl
Cl Cl
Cl Cl
Cl Cl
Cl Cl
p,p'-DDT o,p'-DDT DDE DDD  
Figure  II.6: Chlorinated aromatic insecticides. 
Commercially available DDT is actually a mixture consisting for the main part out 
of the p,p’- and the o,p’- DDT isomers (Figure  II.6). A minor fraction consists of DDE 
and DDD, which are also the breakdown products of DDT.25 
These chlorinated aromatic insecticides are persistent organic molecules which are 
very hydrophobic. A study in 200226 found detectable levels of DDT or metabolites in 
                                                        
25 WHO/IPCS Environmental Health Criteria 9: DDT and its derivatives, 1979. 
26 CDCP National Report on Exposure to Environmental Chemicals, 2005. 
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the blood samples of more then half of the subjects tested. These values are the direct 
consequence of the past world wide use of the insecticides. This bio-accumulation is the 
reason why they continue to raise much concern, although they are only weak 
estrogenic compounds. In vitro binding assays showed that the highest estrogenic 
activity was displayed by o,p’-DDT.27 Several studies were undertaken to determine a 
relationship between DDT levels in adipose tissue and breast cancer, but failed to find a 
significant link.8 However, concentrations were determined in the patients at the 
moment they already developed the cancers, but maybe the exposure during foetal 
development and childhood plays a more important role. 
Another threat is posed by the substances shown in Figure  II.7. These are 
estrogenically active chemicals that are unintentionally released into the environment. A 
disturbing example is bisphenol-A (BPA) which is a frequently used monomer for the 
preparation of polycarbonates and epoxy resins. These polymers are used in plastic 
water bottles, baby bottles, plastic food containers and dental materials. The monomer 
BPA is known to leach from these products. With baby bottles, leaching occurs during 
heating of the bottle and this exposes infants fed with liquid formula to BPA. A study 
by the European Food Safety Authority showed that daily intake with these infants can 
be as high as 13µg/kg/day.28 Although it was already shown in 1936 that bisphenol-A is 
an estrogenically active compound, only Canada intends to put a ban on the use of 
BPA.29 While Europe and the USA conclude that there is a potential danger, they state 
that current human exposure levels are to low to induce adverse effects. Nevertheless, 
the first bisphenol-A free bottles are on the market, trying to benefit from the growing 
public concern.30 
                                                        
27 Forster, M. S.; Wilder, E. L.; Heinrichs, W. L. Biochem Pharmacol 1975, 24, 1777-80. 
28 EFSA Opinion of the Scientific Panel on food additives, flavourings, processing aids and materials in contact 
with food (AFC) related to 2,2-BIS(4-HYDROXYPHENYL)PROPANE, 2006. 
29 Dodds, C. E.; Lawson, W. Nature 1936, 137, 996-996. 
30 BPA free plastic bottles can be ordered via http://www.babybornfree.co.uk  
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Phthalates in plastics are another source of estrogenic chemicals. These chemicals 
are called plasticizers because they soften hard plastics when added. They are not 
chemically bound to the polymeric framework and can thus migrate to the surface. 
Phthalates are found in soft toys, cosmetics, flooring, medical equipment and colourful 
prints on children’s clothing. In vitro tests showed that they have weak estrogenic 
properties.31 The most potent phthalate, bis(2-ethylhexyl)phthalate (DEHP), used in 
medical tubing, catheters and blood bags, may harm sexual development in male 
infants.32 Based on these and other results, including animal testing, the European 
Commission has banned the use of phthalates in children’s toys. 
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Figure  II.7: Industrial estrogenic chemicals. 
Alkylphenol polyethoxylates (APEs) are non-ionic surfactants, used extensively in 
household detergents. This implies that they are disposed into the sewage system where 
they are broken down by micro-organisms. The remaining alkylphenols are resistant to 
further biological degradation and show up in rivers.33 Although there are many 
different APEs, 80% of them is composed of p-nonylphenol (NP). This compound 
showed in vitro and in vivo estrogenic activity and is not only exposed to aquatic life, 
but also to humans via drinking water and the consumption of fish.8 The use of 
nonylphenol ethoxylates is now restricted by the European Commission. 
                                                        
31 Johnson, A.; Jurgens, M. Pure Appl. Chem. 2003, 75, 1895-1904. 
32 Fisher, J. S. Reproduction 2004, 127, 305-15. 
33 Preziosi, P. Pure Appl. Chem. 1998, 70, 1617-1631. 
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These examples show that we are exposed to EDCs on a daily basis in products that 
are used without suspicion. Careful monitoring of the concentrations and the potencies 
of the EDCs to which we are exposed is thus very important. 
II.2.5. Biological monitoring of estrogenic compounds 
The total estrogenic activity of a solution can be determined using in vitro or in vivo 
assays.  
Biologically based in vitro methods can be categorised as follows: 
Receptor binding assays measure binding of agonists (or antagonists) to the human 
estrogen receptor (hER). These methods rely on the displacement of a high-affinity 
radioligand (3H-labeled estradiol) by a possible estrogenic chemical. Its value is then 
compared to the displacement caused by the unlabeled estradiol and is expressed in 
relative binding affinities (RBA of E2 being 100%). They have the advantage of being 
very sensitive, RBAs of 0,0003% can be detected.19 
Cell proliferation assays depend on the ability of possible estrogens to induce rapid, 
uncontrolled cellular growth in the human breast cancer cell line MCF-7.4 These cells 
have high levels of estrogen receptors and consequently proliferation can be induced 
with very low concentrations of estrogenic substances. 
Receptor-dependent gene expression assays measure the ability of a compound to 
stimulate a receptor dependent response in genes. The most popular assay for the 
determination of estrogenic activity is the Yeast Estrogen Screen (YES assay).34 It 
consists of yeast cells in which the hER is expressed. When an estrogen binds to the 
hER, a reporter gene is transcribed and eventually translated into the enzyme β-
galactosidase. This enzyme catalyses the hydrolysis of o-nitrophenol-β-D-
galactopyranoside after which the concentration of the o-nitrophenol can be determined 
via UV-measurements at 420 nm. 
                                                        
34 Arnold, S. F.; Robinson, M. K.; Notides, A. C.; Guillette, L. J.; McLachlan, J. A. Environ. Health Perspect. 
1996, 104, 544-548. 
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For the in vivo assessment of estrogenic activity, the following tests are frequently 
used: 
With the uterotrophic assay the ovary from mouse is removed, reducing the intrinsic 
female hormone levels to a minimum and thus shrinking the uterus. After 
administrating the test compound, the inflation of the uterus is monitored and the 
estrogenic activity of the compound can be determined.12c 
The induction of vitellogenin production in juvenile male fish is an approach to 
measure the estrogenicity of the aquatic environment. The concentration of this 
biomarker in the blood is measured and can be correlated with the estrogenic potency of 
the mixture.35 
The in vitro and in vivo assays give complementary results and should be used 
together in a battery of tests.36 Although in vitro test are easier in use because of the 
lack of animal testing, they have significant drawbacks. They do not take into account 
the effects of bioaccumulation and metabolism and other possible pathways of 
interaction are neglected. In vivo tests on the other hand, lack standardisation which 
makes it difficult to compare results obtained with the same method. 
Biological methods to measure the concentration of an EDC depend on the 
antibody–antigen interaction and are thus called immunoassays.37 If antibodies are to be 
generated against small molecules like EDCs, they first have to be conjugated with a 
large protein like the bovine serum albumin to render them immunogenic.38 The 
immunoresponse to this ligated molecule or hapten, yields different antibodies. When 
extracted from the serum, these polyclonal antibodies can be used directly or first be 
purified to get only one type of monoclonal antibodies. The latter are much more 
selective and have less cross reactivity then the polyclonal antibodies. 
                                                        
35 Eggen, R. I. L.; Bengtsson, B. E.; Bowmer, C. T.; Gerritsen, A. A. M.; Gibert, M.; Hylland, K.; Johnson, A. C.; 
Leonards, P.; Nakari, T.; Norrgren, L.; Sumpter, J. P.; Suter, M. J. F.; Svenson, A.; Pickering, A. D. Pure Appl. 
Chem. 2003, 75, 2445-2450. 
36 Zacharewski, T. Environ Health Perspect 1998, 106 Suppl 2, 577-82. 
37 Eggen, R. I.; Segner, H. Anal Bioanal Chem 2003, 377, 386-96. 
38 Schneider, C.; Scholer, H. F.; Schneider, R. J. Steroids 2004, 69, 245-253. 
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When using immunoassays, the binding event is usually visualised by an auxiliary 
reaction, in which a second labelled immunoreactant binds to the analyte. With enzyme-
linked immunoassays (ELISAs), this label is an enzyme that can convert a colourless 
substrate into a coloured product, from which the concentration can then be measured 
using UV-spectroscopy.39 
Immunoassays are technically simple and allow a rapid screening of high sample 
numbers. Their production however, is a time consuming, trial and error based process. 
Another big disadvantage is that they are too selective, only one or a few chemicals can 
be quantified and not a whole set of related compounds. 
II.2.6.Chemical monitoring of estrogenic compounds 
To establish a link between a certain EDC and its possible effects on human health, 
quantitative exposure levels should be determined at different stages of life. Because 
most biological tests do not give away the identity and the amount of the chemical that 
is causing the endocrine disruption, these tests need to go hand in hand with chemical 
analysis. 
Quantifying EDCs in environmental matrices is a difficult process not only because 
of the low concentrations at which the EDCs are present but also because of the 
complex constitution of the matrices (e.g. sewage water, serum, urine samples, …).40 
Before the actual measurements take place, the desired compounds have to be extracted 
from the matrix. For liquid samples, this is usually done via solid-phase extraction 
(SPE) techniques.41 The sample is sent over a SPE-cartridge which is packed with an 
adsorbent like C18 silica or styrene based polymers. The analytes are retained on the 
cartridge, depending on their water-octanol partitioning coefficient (log P value). The 
higher this value for a certain chemical, the better it is retained on an apolar phase like 
                                                        
39 Campbell, C. G.; Borglin, S. E.; Green, F. B.; Grayson, A.; Wozei, E.; Stringfellow, W. T. Chemosphere 2006, 
65, 1265-1280. 
40 de Alda, M. J. L.; Barcelo, D. J. Chromatogr. A 2001, 938, 145-153. 
41 Holland, P. T. Pure Appl. Chem. 2003, 75, 1843-1857. 
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C18. After extraction, the chemicals can be washed from the packing material using a 
small amount of organic solvent. This pre-concentration step can be followed by GC-
MS or LC-MS analysis. 
GC separation of the compounds followed by detection with MS has developed into 
a primary technique for the identification and quantification of EDCs. Electron impact 
(EI) is the most common used ionisation technique and yields smaller fragments of the 
molecule. By comparing the retention time and the corresponding fragments of a 
compound with a database, the identity of the compound can be established. If this 
technique is used with an internal standard, an isotope of the analyte, low detection 
limits and high accuracy are possible. However, EDCs with polar functionalities like 
estradiol are more difficult to evaporate due to hydrogen bonding. This can be solved 
via derivatisation reactions (e.g. silylating or capping the alcohols).42 
With LC-MS, the most common used ionisation techniques are electrospray 
ionisation (ESI) or atmospheric pressure chemical ionization (APCI). Both yield the 
hydrogen or sodium adduct of the molecule, giving direct information about the 
molecular weight and identity of the compound. Low detection limits can be reached 
without the need for derivatisation.43 
II.2.7. SPE techniques for the enrichment of EDCs 
The most crucial step in the whole analysis protocol, whether GC- or LC-MS is 
used, is the pre-concentration step. Instead of just extracting apolar compounds, current 
research is focussing on the extraction of specific classes of compounds, like EDCs. A 
lot of progress has been made using biologically based interactions, but a trend towards 
                                                        
42 a) Tan, B. L. L.; Mohd, M. A. Talanta 2003, 61, 385-391. b) Lerch, O.; Zinn, P. J. Chromatogr. A 2003, 991, 77-
97. 
43 a) Giese, R. W. J. Chromatogr. A 2003, 1000, 401-412. b) de Alda, M. J. L.; Diaz-Cruz, S.; Petrovic, M.; 
Barcelo, D. J. Chromatogr. A 2003, 1000, 503-526. 
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synthetic systems like molecular imprinted polymers (MIPs) and synthetic proteins is 
visible.44 
II.2.7.1. SPE based on immuno-affinity sorbents 
The underlying principle of immuno-affinity sorbents, which is outlined in Figure 
 II.8, is basically the same as with immunoassays. The sorbent consists of antibodies 
specific to the target analytes. These antibodies are produced in the same way as 
described before and can thus encompass polyclonal or monoclonal antibodies. 
Monoclonal antibodies are frequently used because they give more reproducible 
results.45 Nevertheless, polyclonal antibodies are preferred since they recognise more 
than one compound. Due to the heterogeneity of the polyclonal antibodies they are able 
to bind structural variants of the analyte.46 
 
 
Figure  II.8: Principle of immuno-affinity sorbents. 
When eluting the analytes from the sorbent, organic solvents have to be applied. 
These can cause irreversible unfolding of the antibodies with loss of activity as a result. 
Another drawback, as with immunoassays, is the high selectivity of the technique, 
making it more attractive for a single residue then for a multiple residue analysis, where 
20 to 30 analytes have to be determined. 
                                                        
44 Tozzi, C.; Anfossi, L.; Giraudi, G. J. Chromatogr. B. 2003, 797, 289-304. 
45 Hennion, M.-C.; Pichon, V. J. Chromatogr. A 2003, 1000, 29-52. 
46 Su, P.; Zhang, X.-X.; Chang, W.-B. J. Chromatogr. B 2005, 816, 7-14. 
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II.2.7.2. SPE based on molecular imprinted polymers (MIPs) 
Molecular imprinting is a technique to create template-shaped cavities in polymeric 
frameworks and has been applied to pre-concentrate several EDCs from aqueous 
samples.47 MIPs are generated by first adding a template to a mixture of functionalised 
monomers (Figure  II.9). These monomers can organise themselves around the template 
creating a non covalent 3D structure that fits around the template. This structure is 
locked by initiating the polymerisation process and thus creating covalent bonds 
between the different monomers. After the template is washed away, a cavity remains in 
the polymer network that has the shape of the template. It is claimed that these 
recognition sites mimic the binding sites of antibodies and receptors.48 
When packed into a SPE cartridge, this polymer can then be used to selectively 
concentrate the template and structural look-a-likes. These MIPs are chemically and 
physically more robust than the biological immuno-affinity sorbents. 
 
Polymerisation Washing
Functional
monomer
Template
Cavity
 
Figure  II.9: Preparation of MIPs. 
Though the principle of MIPs looks nice, there are a lot of practical drawbacks with 
these artificial receptors. A first problem is the leaching of the analyte, resulting in a 
positive error. Due to insufficient washing, some of the template molecules can stay 
                                                        
47 a) Bravo, J. C.; Fernandez, P.; Durand, J. S. Analyst 2005, 130, 1404-1409. b) Meng, Z. H.; Chen, W.; 
Mulchandani, A. Environmental Science & Technology 2005, 39, 8958-8962. c) Bravo, J. C.; Garcinuno, R. M.; 
Fernandez, P.; Durand, J. S. Anal. Bioanal. Chem. 2007, 388, 1039-1045. 
48 Haupt, K. Chem. Commun. 2003, 171-178. 
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behind and leach during the analysis. The washing step is therefore crucial during the 
preparation of MIPs, but complete removal of the template is not always possible. 
Another problem is the solvent based effects. Care must be taken in which solvent 
the organisation and polymerisation of the monomers is carried out. Effects like 
hydrogen bonding are less pronounced in water, while hydrophobic interactions are 
enhanced. This can result in the absence of selectivity between the MIP and the non-
imprinted polymer blank.49 However, selectivity can be enhanced by performing the 
polymerisation in an organic solvent, but this renders the MIP unusable for the analysis 
of aqueous matrices as is the case for EDCs. 
II.2.7.3. SPE based on synthetic peptides 
In the search for more robust systems that work in an aqueous environment, 
combinatorial solid phase techniques are used to develop new materials with 
biomimetic recognition properties.50 Using these synthetic protocols, Tozzi et al 
prepared small polypeptides that could selectively bind estradiol and other similar 
structures in aqueous media.51 
The monomers used for the peptide synthesis were Arg, Ser, Pro, Val, Leu, Gln, Gly 
and Ala. These were chosen because they are part of the HBD of the human steroid 
binding protein, a transport protein present in the serum of humans. With these amino 
acids, a first library was made consisting of dipeptides. By incubating the different 
solid-phase bound members with tritium-labelled estradiol, the dipeptide with the best 
binding characteristics was selected. This dipeptide was then the starting material for a 
second library, now consisting of tetrapeptides. Again the best tetrapeptide was selected 
                                                        
49 a) Tse Sum Bui, B.; Belmont, A. S.; Witters, H.; Haupt, K. Anal. Bioanal. Chem. 2008, 8, 2081-2088. b) Ye, L. 
The Analyst 2001, 126, 760-765. c) Rachkov, A.; McNiven, S.; Cheong, S. H.; El'Skaya, A.; Yano, K.; Karube, I. 
Supramol. Chem. 1998, 9, 317-323. d) Giraudi, G.; Giovannoli, C.; Tozzi, C.; Baggiani, C.; Anfossi, L. Chem. 
Commun. 2000, 1135-1136. 
50 Diaz-Garcia, M. E.; Pina-Luis, G.; Rivero, I. A. TrAC, Trends Anal. Chem. 2006, 25, 112-121. 
51 Tozzi, C.; Anfossi, L.; Giraudi, G.; Giovannoli, C.; Baggiani, C.; Vanni, A. J. Chromatogr. A 2002, 966, 71-79. 
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by measuring the radioactivity of the beads. These steps were repeated until the stage of 
the octapeptide. 
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Figure  II.10: Employed synthetic strategy. 
The peptides were synthesised on Amberlite, an acrylic acid based polymer that was 
cross-linked to a high degree with divinylbenzene. Consequently, it has no swelling 
properties, unlike other frequently used commercial resins for peptide synthesis like 
Tentagel and Merrifield resin.52  
A rather unusual synthetic strategy was adopted for the peptide synthesis (Figure 
 II.10). Instead of synthesising in the conventional C → N direction, the opposite 
direction was chosen. The carboxylic acid functions on bead were first pre-activated as 
their N-hydroxysuccinimide esters. An aqueous basic solution of an amino acid was 
then added to the activated beads to generate an amide bond. 
This manner of coupling seems very odd when compared to standard protocols 
where the N-α-protected amino acid is activated in an organic solution like DMF or 
DCM, and is subsequently added to the amine-functionalised beads. Instead, Tozzi et al 
used unprotected amino acids that were dissolved in a carbonate buffer. The article does 
not give any proof of the identity and purity of the synthesised peptides, only the 
                                                        
52 Adams, J. H.; Cook, R. M.; Hudson, D.; Jammalamadaka, V.; Lyttle, M. H.; Songster, M. F. J. Org. Chem. 1998, 
63, 3706-3716. 
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dissociation constants Kd towards estradiol are displayed. These are shown in Table 
 II.1. 
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Table  II.1: Kd values for estradiol and the ratio (Restradiol/testosterone) of bound estradiol/bound 
testosterone. 
Peptide Kd (µM) R estradiol/testosterone 
Arg-Ser 32 6 
Arg-Ser-Ser-Val 17 10,1 
Arg-Ser-Ser-Val-Gly-Ser 12 5,6 
Arg-Ser-Ser-Val-Gly-Ser-Gln-Ser 15 3,4 
 
A trend in decreasing dissociation constants can be observed until the hexapeptide, 
the octapeptide already has less affinity for estradiol. The selectivity was tested by 
determining how much testosterone was retained on the beads and comparing this with 
the values for estradiol. The higher R, the more selective the peptide is for estradiol 
over testosterone. It seems that after the tetrapeptide, the selectivity declines. 
Because of their good selectivity and affinity properties, the beads containing the 
tetrapeptide were selected to be packed into a pre-concentration column. This was 
tested on a mixture of natural and synthetic hormones and good recoveries were 
obtained. 
To summarise this chapter, it can be said that in search for a new, selective SPE 
material, a trend is visible towards synthetic systems that are more robust and 
furthermore are useful for the simultaneous determination of more than one compound 
(multi residue method). However, a real rational design for a receptor that can 
selectively entrap EDCs is still missing. 
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II.3. Rationally designed artificial receptors 
The solid phase extraction materials like the MIPs and the Tozzi peptides are 
examples of systems synthesised in a random manner. Once the monomers are selected 
to make an MIP, a random equilibrium is generated between the template and the 
functionalised monomers. Although there is a 3D structure formed upon 
polymerisation, this cavity is not designed (nor does anybody know how it looks). 
Randomness also played a great role in the development of the Tozzi peptides. All the 
possible combinations were made and then the best one was selected. No effort was 
made in trying to characterise the nature of the interactions and so, no lessons could be 
learned from it. 
Another approach to make artificial receptors relies more on the rational design of a 
molecule. Such a rationally designed molecule should contain the right functional 
groups that allow binding of the target. When these functionalities are organised in a 
specific orientation, a cavity can be formed in which the target can fit. 
The design of artificial receptors that can bind a target in water still remains quite 
challenging. Although electrostatic interactions, such as ion pairs or H-bonds, are 
important for imposing selectivity in supramolecular complexes, they are weakened in 
water because of competitive solvation by the polar water molecules. 
In the next chapter, the progress that has been made in designing such receptors is 
presented. Some attention is also paid to how the [receptor-target] complex is 
characterised. 
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II.3.1. One-armed receptors 
A lot of pioneering work in the field of one-armed receptors has been carried out by 
Schmuck. 53 His group focuses on the recognition of small peptides in water. As the 
binding site for the tetrapeptide’s carboxylate, a cationic guanidiniocarbonylpyrrole 
moiety was used (Figure  II.11). Additional interaction sites in the form of a linear 
tripeptide unit were attached. The peptidic nature of the receptor allowed the formation 
of a hydrogen bonded antiparallel β-sheet with the backbone of target peptide. Based on 
this receptor design, a combinatorial receptor library was synthesised on Tentagel. 
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Figure  II.11: Schematic representation of complex formation of a library member with the target 
tetrapeptide D-Glu-L-Lys-D-Ala-D-Ala. 
The best receptor of the library was identified by labelling the target compound with 
the fluorescent Dansyl group. The peptide sequence of this receptor was deciphered to 
be Lys-Lys-Phe.  
The binding strength of the complex was determined via UV titrations in water. The 
UV absorbance of the pyrrole ring was monitored while increasing amounts of the 
unlabeled tetrapeptide were added. From these data a Kd of 65 µM was obtained. 
                                                        
53 a) Schmuck, C.; Heil, M. Chem. Eur. J. 2006, 12, 1339-1348. b) Schmuck, C.; Rupprecht, D.; Wienand, W. 
Chem. Eur. J. 2006, 12, 9186-9195. c) Schmuck, C.; Rupprecht, D.; Junkers, M.; Schrader, T. Chem. Eur. J. 2007, 
13, 6864-6873. 
Chapter  II 
 27
Selectivity was tested by determining the Kd for the receptor and the reversed 
tetrapeptide Ala-Ala-Lys-Glu which was only 208 µM. 
With the design of this receptor, two strategies were combined. The first one was the 
rational design of the carboxylate binding motif. This was then combined with the 
random generation of different structures via combinatorial chemistry. Although no 
cavity around the target peptide was formed, a receptor consisting of only one arm was 
obtained that showed some selectivity. 
II.3.2. Tweezers 
In attempt to create receptors with a cavity like structure, two-armed receptors or 
tweezers were designed. The structure of such a dipodal group consists of a scaffold 
which is conformationally restricted and directs, or pre-organises the functionalised 
receptor arms. 
Figure  II.12 shows two frequently used scaffolds. Structure II.1 is based upon the 
cholic acid skeleton which has a very rigid, predefined structure.54 The two built in 
arms are directed in a parallel orientation. The carboxylic acid function was used to 
couple the scaffold to a Tentagel solid support, allowing the generation of a 
combinatorial library.  
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Figure  II.12: Dipodal scaffolds or tweezers. 
                                                        
54 Barry, J. F.; Davis, A. P.; Perez-Payas, M. N.; Elsegood, M. R. J.; Jackson, R. F. W.; Gennari, C.; Piarulli, U.; 
Gude, M. Tetrahedron Lett. 1999, 40, 2849-2852. 
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Using this dipodal scaffold our group has mimicked the cavity of a protease enzyme 
that could hydrolyse an ester bond.55 Because its predefined structure it is currently also 
being used for the synthesis of epitope mimics of the measles virus.56 
Dipodal scaffold II.2 is based on a diketopiperazine skeleton. Though this backbone 
is less rigid then the cholic acid derived scaffold II.1, X-ray analysis showed that the 
two peptide arms were pointing in the same direction, forming a cavity that was able to 
recognise small peptides.57 To determine which small peptide was a suitable target for a 
receptor, the receptor molecules were labelled with a disperse red dye. The labelled 
receptors were then added to a combinatorial library of small peptides. After incubation, 
the beads were washed and those that stayed red, contained a peptide that was a suitable 
target for the tested receptor. 
II.3.3. Tripodal scaffolds 
The next logical step towards a better cavity for the molecular recognition of target 
molecules is the development of a three-armed or tripodal scaffold. In this way, the 
target can be captured by three arms, providing more coverage of the molecular surface 
of the target.  
 
                                                        
55 De Muynck, H.; Madder, A.; Farcy, N.; De Clercq, P. J.; Perez-Payan, M. N.; Ohberg, L. M.; Davis, A. P. 
Angew. Chem. Int. Ed. 2000, 39, 145-148. 
56 Bode, C. A.; Muller, C. P.; Madder, A. J. Pept. Sci. 2007, 13, 702-708. 
57 Wennemers, H.; Nold, M. C.; Conza, M. M.; Kulicke, K. J.; Neuburger, M. Chem. Eur. J. 2003, 9, 442-448. 
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Figure  II.13: Tripodal scaffolds. 
In the recent years, a lot of tripodal scaffolds have been designed of which the most 
important ones are represented in Figure  II.13.58 All three of them allow the 
incorporation of three different peptide chains that are pointing in the same direction. 
The TAC scaffold II.3 has an extra functionality that acts as an anchoring point to the 
solid phase. With II.4 and II.5, the first one of the three peptide arms has to be 
synthesised on solid phase, after which the scaffold can be coupled and the two other 
arms can be constructed. 
Scaffolds II.3 and II.4 have been designed and used by Liskamp in the search for a 
receptor for the dipeptides D-Ala-D-Ala.59 This dipeptide is a precursor for the bacterial 
cell wall. Consequently, receptors that are able to bind the dipeptide, can play an 
important role in the next generation of antibiotics. Based on these two scaffolds, large 
combinatorial libraries were generated and screened for affinity against the D-Ala-D-
Ala sequence. With the TAC backbone, a library of 46656 members was screened by 
adding a labelled peptide to the beads. The CTV based library consisted of 2197 
possible receptors and the most active one was selected by screening with the same 
                                                        
58 Guarise, C.; Zaupa, G.; Prins, L. J.; Scrimin, P. Eur. J. Org. Chem. 2008, 3559-3568. 
59 a) Chamorro, C.; Hofman, J. W.; Liskamp, R. M. J. Tetrahedron 2004, 60, 8691-8697. b) Chamorro, C.; 
Liskamp, R. M. J. Tetrahedron 2004, 60, 11145-11157. 
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labelled target as depicted in Figure  II.14. In both cases, the screening was performed 
in an aqueous buffer which resulted in a few positive hits. By using different fluorescent 
labels, it was shown that the reporter group had a profound, albeit not decisive influence 
on the binding by the receptor. After identification of the active receptors, they were 
tested for inhibition of bacterial growth, but no inhibition was observed. No attempt was 
made to determine Kd values. 
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Figure  II.14: Labelled D-Ala-D-Ala. 
Scaffold II.5 was employed by Schmuck for the synthesis of a receptor for 
carbohydrates in water.60 Carbohydrates represent difficult substrates for recognition in 
water, as their dominant functional group (the OH group) is difficult to distinguish from 
water molecules. Nevertheless, a prototype was synthesised that showed weak affinity 
(Kd~357 µM) towards an adenosine monophosphate (AMP) molecule. Binding 
constants were obtained by adding increasing amounts of AMP to the receptor and 
monitoring the decrease in absorbance. A further improvement of binding capacities 
might be achieved by varying the amino acid substituents. For this purpose, a 
combinatorial approach is currently under research by the group of Schmuck. 
Having some experience with tweezers, our group decided to explore the 
possibilities of tripodal scaffolds and see if the cavity of a protease enzyme could be 
better mimicked in this way.  
 
                                                        
60 Schmuck, C.; Heller, M. Org. Biomol. Chem. 2007, 5, 787-791. 
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Figure  II.15: A tripodal scaffold with a flexible but preorganised geometry. 
The scaffold II.6 in Figure  II.15 was designed starting from a flexible 
pentaerythritol backbone to which three different protected aromatic moieties were 
attached.61 Though the aromatic interactions between these three cores keep the 
attached chains together, the molecule still is flexible enough to be able to cope with 
targets of different sizes. 
After the synthesis, the scaffold was tested by synthesising one member of a library 
of possible protease mimics. During synthesis, however, some problems arose due to 
the instability of the scaffold against certain deprotection conditions. It appeared that 
the benzylic ethers were stable neither against conditions used for the deprotection of 
the alcohol functions nor against conditions to deprotect the side chains of the amino 
acids. The employed acidic conditions also led to the loss of one or more of the arms. 
Although the conditions for the synthesis of one library member were carefully 
optimised, a full library was never made.62 
                                                        
61 Farcy, N.; De Muynck, H.; Madder, A.; Hosten, N.; De Clercq, P. J. Org. Lett. 2001, 3, 4299-4301. 
62 Gea, A.; Farcy, N.; Rossell, N. R. I.; Martins, J. C.; De Clercq, P. J.; Madder, A. Eur. J. Org. Chem. 2006, 4135-
4146. 
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Based upon these literature results and upon previous experience in the lab with 
dipodal and tripodal scaffolds, the notion grew that in order to arrive at an efficient 
receptor for EDCs, a tripodal scaffold could be useful for obtaining a binding cavity for 
EDCs. 
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III. Project aim and objectives 
The main aim of this PhD is the development of a new artificial receptor for 
endocrine disrupting chemicals. Once attached to a solid support, this receptor can be 
used to pre-concentrate EDCs, allowing a more accurate and sensitive determination of 
EDCs in different environmental samples. In this way, this project could help to fill 
some current data gaps about EDCs in our environment, leading to a better 
understanding of the effects of EDCs on human health. 
A biomimetic approach will be used in the construction of EDC receptors. Based on 
the knowledge that most EDCs directly exert their effect through binding with the ER, 
the cavity of the hormone binding domain of the hER will be mimicked. Building the 
key amino acids of the hormone binding domain of the hER into the flexible, but 
preorganised structure III.1 allows to build such a system in a combinatorial way. For 
this purpose, quantities of the scaffold will be required and thus an efficient synthesis 
for tripodal scaffold III.1 has to be developed. Once synthesised, the scaffold has to be 
coupled to a suitable solid phase, and protocols for the independent incorporation of 
three different peptide chains have to be established. 
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Figure  III.1: Library of possible estrogen receptor mimics. 
Molecular diversity will be created by using automated solid-phase peptide synthesis 
(SPPS). In this way a parallel library of 120 possible estrogen receptor mimics will be 
created. These first generation receptors will be screened for affinity towards a few 
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selected estrogenic chemicals. For this screening, a close collaboration with the 
laboratory of separation sciences of Prof. Dr. P. Sandra will be set up. Once the best 
receptor is identified, an attempt will be made to characterise the nature of the [target-
receptor] complex. Lessons learned from these preliminary studies will be used to 
design a second generation of possible receptors with improved binding affinities. 
Finally, the optimised receptor will be coupled to a solid support that will then be 
packed into a SPE cartridge. This cartridge will be evaluated in the analysis protocol of 
aqueous samples and compared with commercially available SPE materials. In this way, 
we hope to obtain an improved enrichment and selectivity. 
 
 
 
 
 
 
 
 
 
receptor 
EDC Other pollutants 
Figure  III.2: Development of EDC selective SPE material.
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IV. Synthesis of hER mimics 
IV.1. Synthesis of the tripodal scaffold 
The design of new artificial receptors requires a suitable scaffold that allows 
incorporation of various chemical functionalities and at the same time pre-organises the 
different incorporated residues. Based on previous experiences, tripodal structure IV.1 
(Scheme  IV.1) was designed. 
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Scheme  IV.1: Retrosynthetic analysis. 
The scaffold consists of a flexible triamine core IV.2 and three differently protected 
p-aminobenzoic acid derivatives IV.3. Pre-organisation of the three arms is possible due 
to the π−π interactions between the three aminobenzoic cores. By starting from a 
flexible backbone, the receptor will be able to recognise different whch may that can 
vary in size. Hence, this flexible but pre-organised scaffold is a suitable starting point 
for the synthesis of receptors that can be used for pre-concentration in a multi residue 
analysis method. 
The parallel orientation of the three arms was indicated by modelling studies using 
Macromodel V.6.0 (force field MM2). To reduce calculation times, the carboxylic acid 
was replaced by a methyl group and the three different amine protecting groups were 
simplified as acetyl groups. Figure IV.1 shows the two most energetically favoured 
conformations in water. Extra stabilisation is achieved via hydrogen bonding, 
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Figure  IV.1: Two most energetically favoured 
conformations of a simplified version of IV.1 in water 
a) 0.0 kJ mol b) 18.8 kJ mol
represented by the dotted lines. From these modelling studies it can be deduced that 
some conformationial freedom is 
possible, but a parallel orientation of 
the three arms is dominant.  
Another feature of the scaffold is 
the carboxylic acid head group that 
will function as an anchoring point, 
allowing attachment to a solid support. 
In this way, solid-phase peptide 
synthesis protocols can be employed in 
a manual or automated fashion. This 
has the advantage that for each reaction, a large excess of reagents can be used, driving 
the reaction to completion and enabling fast reaction kinetics. When the reaction has 
finished, the excess of reagents can simply be washed away. 
IV.1.1. Synthesis of the triamine core 
Thanks to the work of Dr. An Gea, a great deal of the building blocks for the 
triamine core were already available in the lab. Starting from acetaldehyde, she 
prepared multi gram quantities of the alcohol IV.7 via a previously described method.63 
 
                                                        
63 Imbert, D.; Thomas, F.; Baret, P.; Serratrice, G.; Gaude, D.; Pierre, J.L.; Laulhère, J.P. New. J. Chem. 2000, 24, 
281-288.  
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Scheme  IV.2: Synthesis of alcohol IV.7 
After protection of the aldehyde with cyclohexylamine (Scheme  IV.2), the 1,4-
addition on acrylonitrile was performed in an autoclave at a temperature of 170 °C. To 
prevent any radical polymerisation of acrylonitrile, some p-hydroquinone was added to 
trap unintentionally formed radicals. The addition product was subsequently hydrolysed 
and the resulting aldehyde reduced with NaBH4 to give the alcohol IV.7.  
Scheme  IV.3 shows the synthesis of the triamine backbone starting from this 
alcohol. First a t-butyldimethylsilyl (TBS) group was introduced. Next, the nitriles were 
reduced but this reaction did not proceed smoothly. Although according to the 
published procedure, complete nitrile reduction should be achieved using hydrazine in 
the presence of preactivated RaNi-catalyst, TLC-monitoring showed the reduction not 
to be fully complete, with some mono- and di-nitriles still present. Changing the 
reaction variables and the type of catalyst did not result in a significant improvement. 
However, the crude product could be used as such and the impurities could be removed 
on a later stage in the synthesis. 
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Scheme  IV.3: Protection of the alcohol and subsequent reduction of the nitriles. 
IV.1.2. Synthesis of the arms 
The three different aromatic moieties were synthesized starting from 4-
aminobenzoic acid. The aromatic amines were protected as carbamates. An acid labile 
(Boc), Pd° labile (Alloc) and base labile (Fmoc) protecting group were chosen to ensure 
complete orthogonality during later attachment of the three different peptide chains.64 
Protection of the amines proceeded in all cases smoothly, the products were easily 
purified by acidifying the solution and collecting the precipitate (Scheme  IV.4). 
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Scheme  IV.4: Synthesis of the protected arms. 
                                                        
64 Mu, F.; Coffing, S.L.; Riese, D.J.; David, J. J. Med. Chem. 2001, 44, 441-452 
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Before the arms were coupled to the triamine IV.2, they were first pre-activated as 
their pentafluorophenol (PFP) esters. This was achieved via a condensation between 
PFF and the three acids using DCC as a coupling reagent and DMAP as a nucleophilic 
catalyst (Scheme  IV.5). The products were purified from the DMAP and the urea side 
product by column chromatography. The yield for the Fmoc-derivative was a little 
lower due to an extra crystallisation step necessary to remove some remaining urea side 
product. 
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Scheme  IV.5: Mechanism of activation with DCC using DMAP as a catalyst. 
IV.1.3. Coupling of the arms to the triamine backbone 
In general, the synthesis of tripodal structures is a challenging, sometimes frustrating 
quest because differentiation of three equal functionalities requires the use of an excess 
of starting material. Thus, in order to maximize the yield of mono derivatisation in the 
first step of Scheme  IV.6, 3.2 equivalents of triamine IV.2 were used and activated 
IV.9 was added over a period of 8 h. Separation of the monopodal product from the 
excess starting material and the side products was achieved via chromatography using a 
DCM/MeOH/NH3 mixture. The second aromatic residue IV.10 was added over a period 
of 8 h to a solution of 2.2 equivalents of the monopodal IV.12. Also in this case, the 
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desired dipodal product IV.13 was isolated via chromatography with 
DCM/MeOH/NH3. For the coupling of the last Fmoc arm IV.11, only one equivalent of 
dipodal IV.13 was necessary and since all the amines were acylated, the 
chromatographic separation with a DCM/MeOH mixture was much easier.  
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Scheme  IV.6: Coupling of the arms. 
IV.1.4. Establishing the anchor point 
Silyl ethers can be deprotected using either strong nucleophiles or acidic conditions. 
Good nucleophiles in this context are the MeO- and the F- anion. These are however 
also basic enough to cause Fmoc deprotection. Therefore, the deprotection of the silyl 
ether had to be done under acidic conditions, without removing the acid labile Boc 
group (Scheme  IV.7). This was achieved with catalytic amounts of (+)-camphor 
sulphonic acid (CSA)65 and only a very small amount of Boc deprotection (< 1%) was 
observed. 
 
                                                        
65 Garcia-Rubio, S.; Meinwald, J. J. Org. Chem. 2001, 66, 1082-1096. 
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Scheme  IV.7: Deprotection and oxidation. 
Finally, oxidation to the carboxylic acid IV.1 was carried out using Jones reagent. In 
total, an amount of 4.5 g of IV.1 was synthesised, which proved to be sufficient for the 
rest of the PhD. 
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IV.2. Solid phase synthesis of possible EDC receptors 
IV.2.1. Synthetic and analytical strategies 
To create a cavity that can encompass different endocrine chemicals, small peptide 
strands have to be incorporated into scaffold IV.1. This implies the repeated formation 
of amide bonds between amino acids (AAs). The condensation between two amino 
acids is only possible if one of the carboxylic acid functions is activated, enabling 
nucleophilic attack of the amine function of the other amino acid. This means that the 
correct protecting groups have to be employed to avoid undesired side reactions. 
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Scheme  IV.8: Solid phase peptide synthesis. 
Scheme  IV.8 shows the principles of solid phase peptide synthesis or SPPS 
according to the Fmoc strategy. The first AA is attached to the solid phase via its 
carboxylic acid. In this way; the carboxylic acid is protected and no activation can occur 
during the peptide coupling . Moreover, after the condensation, the excess of reagents 
can be filtered away while the product stays behind on the resin, making time-
consuming chromatographic separations unnecessary. The α-amino group of the AA 
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that is built into the peptide chain is protected as a carbamate. Consequently, when 
activating the acid, no homopolymerisation can occur.  
Amino acids are building blocks of nature, which has provided them with a great 
diversity of chemical functions, incorporated in their side chains. When the side chains 
contain nucleophilic or electrophilic groups, these need to be properly protected to 
avoid any side reactions during the coupling of the next AA. With the Fmoc/tBu 
strategy, the N-α group is protected with a base labile Fmoc group and the side chains 
with acid labile groups, ensuring orthogonality during the synthesis. Deprotection of the 
side chains is usually performed with a mixture of trifluoroacetic acid (TFA) and 
various nucleophiles, called scavengers, that neutralise the formed cations. 
The selection of a suitable solid support can have a big influence on the synthesis 
outcome. Crucial properties of the solid phase include good physical and chemical 
stability as well as good swelling of the resin in solvents used for peptide synthesis. Gel 
type resins posses all of these qualities and are the most used in SPPS. The structures of 
some of the frequently used resins are shown in Figure  IV.2. 
The two most known examples are the classic Merrifield resin and Tentagel resin. 
Both consist of a polystyrene framework that is crosslinked with 1 or 2 % 
divinylbenzene. With Tentagel, extra polyethyleneglycol chains are grafted onto this 
network, rendering the resin more compatible with polar solvents like water.66  
Resins that do not consist of a large hydrophobic core are represented by PEGA and 
CLEAR. The first one is based on acrylamide monomers cross linked with polyethylene 
glycol chains, resulting in a very polar resin that has good swelling properties. Due to 
the presence of the amide bonds, a peptide like environment is created which is thought 
to be beneficial for peptide synthesis.67 CLEAR, on the other hand, consists of ester 
linkages with a high degree of cross linking and a high percentage of polyethylene 
                                                        
66 Adams, J. H.; Cook, R. M.; Hudson, D.; Jammalamadaka, V.; Lyttle, M. H.; Songster, M. F. J. Org. Chem. 1998, 
63, 3706-3716. 
67 Atherton, E.; Clive, D. L.; Sheppard, R. C. J. Am. Chem. Soc. 1975, 97, 6584-6585. 
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glycol chains. Consequently, the polar resin shows a high degree of swelling in 
especially polar solvents including water.68 
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Figure  IV.2: Structures of Merrifield, Tentagel, PEGA and CLEAR. 
Based on previous expertise in the lab, Tentagel was chosen as the solid support for 
the synthesis of the receptors. Due to its reported good swelling properties in water,69 an 
on-bead screening of the receptors for the affinity towards EDCs is possible. 
For the synthesis of linear peptide chains, the Merrifield support was chosen. This 
resin has a high loading and moreover, it is available with a variety of linkers that allow 
attachment of the first AA to the resin and cleavage of the final peptide from the resin. 
For this purpose, the acid labile linkers like the 2’-chlorotrityl linker (Figure  IV.3) are 
very popular. With the 2’-chlorotrityl linker, the peptide can be cleaved from the resin 
                                                        
68 Kempe, M.; Barany, G. J. Am. Chem. Soc. 1996, 118, 7083-7093. 
69 Santini, R.; Griffith, M. C.; Qi, M. Tetrahedron Lett. 1998, 39, 8951-8954. 
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as a fully, side chain protected segment,70 or the cleavage of the peptide can be 
combined with the deprotection of the side chains. 
 
Cl
Cl
Cleavage of protected peptides: 
AcOH/TFE/DCM or HFIP/DCM
Cleavage of unprotected peptides:
TFA + scavengers
 
 
Figure  IV.3: 2’-chlorotrityl resin. 
A carboxylic acid can be activated using a plethora of methods and strategies.71 
Usually, an intermediate active oxobenzotriazole ester (OBt ester) is formed by mixing 
the acid with an appropriate activating agent. The reagents routinely used in our lab are 
depicted in Scheme  IV.9. The most reactive agents are PyBOP, a phosphonium based 
coupling reagent, and HBTU, an uronium based agent, and are used in the presence of a 
base like DIEA. The more classical carbodiimide based couplings are somewhat slower 
but represent a useful alternative if base free circumstances are necessary. 
 
                                                        
70 a) Barlos, K.; Gatos, D.; Kallitsis, J.; Papaphoti, G.; Sotiriu, P.; Wenging, Y.; Schäfer, W. Tetrahedron Lett. 
1989, 30, 3943-3945. b) Bollhagen, R.; Schmiedberger, M.; Barlos, K.; Grell, E. J. Chem. Soc., Chem. Commun. 
1994, 2559-2561. 
71 Montalbetti, C.; Falque, V. Tetrahedron 2005, 61, 10827-10852. 
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Scheme  IV.9: Coupling reagents. 
Before further chain elongation can occur, the N-α protecting group has to be 
removed. By adding a secondary amine like piperidine to the resin, the base labile Fmoc 
group is deprotected, giving rise to fulvene and carbamic acid (Scheme  IV.8). While 
the carbamic acid dissociates in CO2 and the free amine, the fulvene undergoes a 1,4-
addition by the excess of piperidine. The concentration of the formed complex can be 
determined by UV measurements and correlated to the amount of product on the resin.  
Another way of monitoring reactions on bead is cleaving the peptide from the resin 
and analysing the cleavage solution via LC/MS. With acid labile linkers this is rather 
difficult, because the scavengers present in the cleavage cocktail can interfere with the 
analysis and each time a fresh cleavage solution should be prepared. In order to 
facilitate monitoring of reactions on solid support, a photocleavable linker (Figure 
 IV.4) was used which releases the product upon irradiation at 365 nm.72 Only small 
amounts of resin are needed (typically 1 mg or less) and the solution obtained upon 
irradiation can be directly analyzed by LC-ES-MS. Using the photocleavable linker, in 
some cases yellow coloration of the solid support was observed, lowering the sensitivity 
of the TNBS-test (vide infra). This problem could be circumvented by using the NF31-
test which has a higher sensitivity.  
 
                                                        
72 Holmes, C.P. J. Org. Chem. 1997, 62, 2370-2380 
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Figure  IV.4: Photocleavable linker. 
For very fast routine assessment of the completeness of a coupling reaction, colour 
tests are used. (Scheme  IV.10). An incomplete coupling results in free amine 
functionalities on the beads. These can be detected with various reagents giving an 
intense colour after reaction with the amines.73 One of these colour tests, NF31,74 was 
developed in our lab. This very efficient reagent is currently available via Bachem. 
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Scheme  IV.10: Colour tests for the detection of amines.  
                                                        
73 a) Hancock, W. S.; Battersby, J. E. Anal. Biochem. 1976, 71, 260-264. b) Sarin, V. K.; Kent, S. B. H.; Tam, J. P.; 
Merrifield, R. B. Anal. Biochem. 1981, 117, 147-157. 
74 Madder, A.; Farcy, N.; Hosten, N.; De Munck, H.; De Clercq, P.J.; Barry, J.; Davis, A.P. Eur. J. Org. Chem. 
1999, 11, 2787-2791. 
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IV.2.1.1.Fast and easy detection of aromatic amines on solid support 
Once scaffold IV.1 is coupled to a solid phase, the protecting groups have to be 
removed to allow the incorporation of different peptide chains. Deprotection of the 
carbamates provides an aromatic amine that is subsequenty acylated with the desired 
amino acid. Monitoring of the completeness of this coupling reaction by colour tests has 
proven to be very difficult. The two most commonly used colour tests, the ninhydrine 
and TNBS test, are not applicable in case of aromatic amines. To date, only the so 
called chloranil test has been reported to monitor the progress of these reactions with 
high sensitivity.75 During this Phd, the NF31 test was established as a reliable method 
for the on bead detection of primary aromatic amines.76 
In order to tackle the sensitivity issue, mixtures of Fmoc-Gly-OH and Boc-Gly-OH 
were coupled in varying ratios to Tentagel (loading 0.21 mmol/g) using the PyBOP 
/DIPEA protocol. After selective Fmoc deprotection with 20 % piperidine in DMF, 
Fmoc-protected p-aminobenzoic acid (Fmoc-p-Abz) was coupled using PyBOP and 
DIPEA. The amount of Fmoc-p-Abz on the resin was determined by the previously 
described method, giving values of 3.4, 13 and 18 µmol g-1. Finally the Fmoc-group 
was deprotected with a 20% piperidine/DMF solution.  
In order to check if the sensitivity of the colorimetric tests is influenced by sterical 
hindrance we further prepared resin loaded with 5.4 and 11 µmol g-1 of o-Abz in the 
same manner.  
The resins were treated with a 0.002 M solution of NF31 in acetonitrile and heated 
at 70°C for 10 min. The results are summarized in Table  IV.1.  
                                                        
75 Marik, J.; Song, A.; Lam, K. S. Tetrahedron Lett. 2003, 44, 4319-4320. 
76 Van der Plas, S. E.; De Clercq, P. J.; Madder, A. Tetrahedron Lett. 2007, 48, 2587-2589. 
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Table  IV.1: Detection of resin bound aromatic amines with NF31. Tentagel resin (loading 0.21 
mmol/g) was used in these experiments. A single plus indicates that it still is possible to observe the 
free amines. The ++ indicates a strong coloration of the beads. 
 
 Resin substitution (µmol g-1) Result 
3.4 (~2%) + 
13 (~5%) ++ N
H
O
NH2
 
18 (~9%) ++ 
5.4 (~3%) + 
N
H
O
H2N  11 (~5%) ++ 
 
In conclusion reagent NF31 offers a simple and sensitive test for the monitoring of 
coupling reactions to free aromatic amines during solid phase synthesis. Previously 
validated for the monitoring of peptide coupling, the use of NF31 is now extended to 
the detection of free aromatic amines, rendering it a versatile and useful tool for the 
solid phase chemist. 
IV.2.2.Coupling of scaffold IV.1 to a solid phase 
The photocleavable linker was coupled to Tentagel (loading: 0.21 mmol/g) by 
activating the acid with PyBOP in the presence of DIEA (Scheme  IV.11). Boc-γ-
aminobutyric acid was used as a spacer to minimize sterical hindrance when performing 
coupling reactions to the secondary amine of IV.15. It was noted that the use of Fmoc-
γ-aminobutyric acid led to undesired alkylation of the spacer upon Fmoc deprotection 
with piperidine. 
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Scheme  IV.11: Coupling of the linker, spacer and scaffold to the resin. 
Following Boc-deprotection, coupling of the scaffold IV.1 to the solid support was 
first tested (entry 1, Table  IV.2) using a five-fold excess of IV.1 in the presence of 
PyBOP (5 eq) and DIEA (10 eq) for 3 h, yielding a loading of 0.077 mmolg-1 (maximal 
theoretical loading is 0.176 mmolg-1). LC control of the reaction mixture (Figure  IV.5) 
showed that a small amount of Fmoc-deprotected compound was present. Taking into 
account the percentage of Fmoc deprotected compound (4 %), the total loading was 
0.080 mmol/g. These experiments were repeated several times and the loading values 
were always between 0.077 and 0.084 mmol/g. 
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Figure  IV.5: HPLC at 214 nm of IV.17 (entry 1, Table  IV.2) after photocleavage in MeCN. 
The efforts undertaken to optimise the coupling of IV.1 are summarised in Table  IV.2. 
In a first attempt to improve the coupling yield (entry 2), the more reactive N, N’-
tetramethylfluoroformamidinium hexafluorophosphate (TFFH) was used as coupling 
reagent (Figure  IV.6). By adding TFFH, the carboxylic acid is transformed to the 
corresponding acylfluoride. This reactive intermediate is known to give good results for 
the coupling of sterically hindered AA.77 In our case however, no improvement was 
observed. 
F
N N
PF6
 
Figure  IV.6: TFFH. 
 
                                                        
77 Carpino, L. A.; Elfaham, A. J. Am. Chem. Soc. 1995, 117, 5401-5402. 
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Table  IV.2: Optimisation of the coupling conditions. 
Entry 
Coupling 
reagent 
IV.1 
(eq) 
DIEA  
(eq) 
Coupling 
time (h) 
T  
Total 
loading 
(mmol/g) 
Remarks 
1 PyBOP 5 10 3 rT 0.077-0.086 
Fmoc-depr.: 3 
to 25% 
2 TFFH 5 10 3 rT 0.084 
Fmoc-depr.: 3 
to 25% 
3 PyBOP 6 12 3 rT 0.085 
Fmoc-depr.: 3 
to 25% 
4 PyBOP 3 6 3 rT 0.100 
Double 
coupling 
5 DIC/HOAt 5 10 18 rT 0.084 
Guanidine 
formation 
6 HBTU 5 10 3 rT 0.082 
Guanidine 
formation 
7 PyBOP 5 15 3 rT 0.95-0.105 
Fmoc-depr.: 3 
to 25% 
8 PyBOP 3 9 18 50 °C 0.085-0.100 
up to 50% 
Fmoc depr. 
9 PyBOP 1.5 4.5 18 50 °C 0.085-0.100 
up to 50% 
Fmoc depr. 
10 PyBOP 1.5 4.5 18 rT 0.085-0.104 
Fmoc-depr.: 3 
to 25% 
11 DIC/HOAt 1.5 4.5 18 rT 0.059 
Guanidine 
formation 
 
Increasing the number of  equivalents of IV.1 (entry 3) did not result in a higher 
loading. A higher loading was observed after a double coupling (entry 4), using 3 
equivalents for each coupling. In total, 6 equivalents are used, which is not very 
economical.  
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The undesired removal of the Fmoc group could be prevented by using DIC in the 
presence of the coupling additive HOAt (entry 5), the more 
active variant of HOBt. By replacing the benzene ring with 
pyridine, reaction kinetics are enhanced by a neighbouring 
group effect.78 After performing the coupling, the TNBS and 
NF31 colour test indicated that all the amines were acylated. 
Loading determination however, did not indicate a significantly 
higher loading. After photocleavage from the resin, the LC-MS analysis showed that the 
uncoupled spacer amines had attacked directly on the DIC resulting in the guanidilation 
of the molecule. A similar side reaction was observed with the coupling reagent HBTU 
(entry 6). 
During one of the coupling experiments, 15 instead of 10 equivalents of DIEA were 
accidentally added. This apparently led to better loading values (entry 7). It was 
decided to use a scaffold/base ratio of 1:3. The amount of Fmoc deprotected compound 
did not seem to increase significantly under these circumstances (entry 8). 
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Figure  IV.8: HPLC at 214 nm of IV.17 (entry 10) after photocleavage in MeCN. 
                                                        
78 Carpino, L. A. J. Am. Chem. Soc. 1993, 115, 4397-4398. 
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It goes without saying that the less scaffold that is used for a coupling, the better it 
is. On the other hand, when lowering the number of equivalents, the overall 
concentrations drop because a minimum volume of solvent has to be used to ensure 
good swelling of the resin. This can be compensated by raising the temperature and 
prolonging the reaction time. Indeed, only 1.5 equivalents were needed to obtain the 
same loadings as with 5 equivalents (entry 9). These conditions were repeated at rT and 
it seemed that this was sufficient to get the same loading (entry 10). These 
circumstances were repeated but now with DIC in the presence of HOAt resulting 
however in a lower loading (entry 11). 
In conclusion, by activating only 1.5 equivalents of scaffold IV.1 with PyBOP in the 
presence of 4.5 equivalents of DIEA, a loading of 0.085-0.104 mmolg-1 was obtained, 
correlating with a coupling yield of 48 to 59%. The only problem associated with this 
reaction was the partial Fmoc removal during the coupling (Figure  IV.8). 
IV.2.3. Capping of the remaining spacer amines 
The Fmoc deprotection occuring during the coupling was rather unexpected. Indeed, 
with standard coupling procedures, 2 equivalents of DIEA with respect to the activated 
AA, are classically added and no Fmoc deprotection is observed. The sterically 
hindered base is known to remove very small amounts of the Fmoc group only after 
prolonged reaction times (> 3 h).79 In our case, it could be that the free amines the resin 
are acting as a base, but this option does not apply when the scaffold was activated with 
DIC in the presence of HOAt. Under these circumstances, no Fmoc deprotection was 
observed, even after a coupling time of 18 h. Therefore, it was concluded that Fmoc-
aminobenzoic acid derivatives are more base labile than their aliphatic counterparts.  
                                                        
79 Chang, C. D.; Waki, M.; Ahmad, M.; Meienhofer, J.; Lundell, E. O.; Haug, J. D. Int. J. Pept. Protein Res. 1980, 
15, 59-66. 
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When looking at the mechanism of the Fmoc deprotection however80 (Scheme 
 IV.12), it is difficult to come up with a rational explanation. The rate determining step 
is the abstraction of the fulvene proton, so the reaction kinetics should not be influenced 
by the better leaving group capacities of the aminobenzoic acid. Probably, the electron 
withdrawing aminobenzoic acid influences the acidity of the fulvene proton but no 
proof of this theory was found in literature. 
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Scheme  IV.12: Fmoc deprotection. 
The attachment of the scaffold did not proceed in a 100 % yield, leaving unreacted 
spacer amino groups free for a subsequent coupling. Consequently, these had to be 
capped before any new amide bond could be formed. Capping had to be selective in 
order not to block one of the arms of the scaffold. This ruled out the use of Ac2O in the 
presence of a base, because as well aliphatic as aniline amino groups are capped under 
these circumstances. 
                                                        
80 Carpino, L. A.; Han, G. Y. J. Org. Chem. 1972, 37, 3404-3409. 
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Scheme  IV.13: Capping of the free spacer amines. 
Selectivity could be obtained by taking into account that aliphatic spacer amines are 
more reactive than anilines. The difference in reactivity could be exploited by capping 
with AcOH that is activated with PyBOP and DIEA. The in situ formed OBt ester is 
less reactive than the usually employed acetic acid anhydride. The reaction was 
monitored with the ninhydrine test and after 1 h, a negative colour test was obtained. 
Analysis after photocleavage showed that less than 2 % of deprotected tripodal 
construct IV.17a was acetylated (Figure  IV.9). 
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Figure  IV.9: HPLC at 214 nm of IV.17b after photocleavage in MeCN. 
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IV.2.4.Attachment of the first amino acids 
After the deprotection of one of the protecting groups of construct IV.17 (Scheme 
 IV.11) an aniline derivative is generated. In addition to being 
conjugated to the aromatic system, this amine can be regarded 
as a vinylogous ureum derivative with very poor nucleophilic 
properties (cfr. the pKa of protonated Abz = 2.38). 
Acetylation with standard coupling reagents as PyBOP, 
HBTU or DIC/HOBt gives incomplete reactions even after repeated couplings.81 A few 
examples of aniline acetylations are described using PyBrOP,82 acid chlorides,83 DIC 
activation,84 symmetrical anhydrides85 and unsymmetrical anhydrides.86 
Activation with PyBrOP yields the acyl bromide, a very reactive intermediate. 
Nevertheless, 10 equivalents of AA and PyBrOP in the presence of 20 equivalents of 
DIEA were needed for 18 h to finish the reaction. Keeping in mind that prolonged 
exposure to tertiary bases can remove the Fmoc group, it was decided not to use this 
method. 
The acyl chlorides of an amino acid can be prepared in advance with thionyl 
chloride (SOCl2) or oxalylchloride. This however, requires an extra synthesis and 
purification step and therefore other alternatives were first explored. 
Unsymmetrical anhydrides are known to be very reactive species. They can be 
generated by reacting the AA with (Boc)2O in the presence of a weak base (Scheme 
 IV.14). After 1 h, the activated species is added to the resin to acylate the free amine. 
Ten equivalents of the activated species for 18 h were not sufficient to drive the reaction 
to completion. Therefore the coupling had to be repeated. In a few cases, the Boc 
                                                        
81 Pascal, R.; Sola, R.; Labeguere, F.; Jouin, P. Eur. J. Org. Chem. 2000, 3755-3761. 
82 a) Neustadt, B. R.; Smith, E. M.; Nechuta, T.; Zhang, Y. Tetrahedron Lett. 1998, 39, 5317-5320. b) Kilburn, J. 
P.; Lau, J.; Jones, R. C. F. Tetrahedron Lett. 2000, 41, 5419-5421. 
83 Spivey, A. C.; McKendrick, J.; Srikaran, R.; Helm, B. A. J. Org. Chem. 2003, 68, 1843-1851. 
84 Kawato, H. C.; Nakayama, K.; Inagaki, H.; Ohta, T. Org. Lett. 2001, 3, 3451-3454. 
85 Franke, R.; Doll, C.; Eichler, J. Tetrahedron Lett. 2005, 46, 4479-4482. 
86 Hamze, A.; Martinez, J.; Hernandez, J. F. J. Org. Chem. 2004, 69, 8394-8402. 
Figure  IV.10: PyBrOP 
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protected scaffold was obtained, probably resulting from insufficient preactivation or 
attack on the wrong carbonyl centre. 
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Scheme  IV.14: Unsymmetrical anhydrides. 
To avoid these problems, activation of an AA with DIC was tried. Here, the reactive 
species is the O-acylureum (Scheme  IV.15). Normally this intermediate is intercepted 
by HOBt to give the OBt ester, but in the absence of this nucleophilic catalyst, the O-
acylureum stays the reactive intermediate. Activation occurs preferably in DCM and by 
lowering the temperature, the formation of the less reactive N-acylureum is avoided. A 
slight excess of AA should be used to prevent guanidylation of the free amine by the 
unreacted DIC. Although the coupling proceeded well using DIC activation, in some 
cases, guanidinylated side product was noticed. 
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Scheme  IV.15: Activation with DIC: formation of N-acylureum at room temperature. 
We then focussed our attention on the symmetrical anhydrides, which possesses a 
reactivity similar to acetyl chlorides. When an acid is activated with DIC, the O-
acylureum intermediate can be intercepted by a second equivalent of acid to yield the 
symmetrical anhydride (Scheme  IV.16). The symmetrical anhydride is formed by 
preactivating the AA with DIC at 0 °C for half an hour. The solvent of choice is DCM, 
Chapter  IV 
 59
because carboxylic acids form a hydrogen bonded stabilised dimer in DCM that then 
rapidly reacts with DIC to give the symmetrical anhydride.87 Depending on the amino 
acid, some DMF can be added to increase the solubility of the anhydride. 
 
RHN
OH
O
R'
N C N
. .
. .
2 eq 1 eq
+
0 °C, 30'
DCM
O
N
H
N
H
RHN
O
O
R'
O
NHR
R'
+
 
Scheme  IV.16: Activation to symmetrical anhydrides. 
Upon activating 12 equivalents of AA with 6 equivalents of DIC, a clean coupling 
of the AA to the scaffold was obtained after overnight reaction. Occasionally, the 
reaction had to be repeated due to incomplete coupling, but more importantly, no side 
reactions were observed. 
Using this protocol, three different AAs were attached to the resin-bound scaffold 
IV.17 and in this manner, proof was delivered for its use in the construction of tripodal 
libraries.88 
One drawback is that this protocol is less suited for automated synthesis. With 
automated synthesis, all necessary solutions are made in advance (AA, coupling 
reagent, base) and then mixed with each other and the resin by the robot arm. Being a 
volatile solvent, DCM easily evaporates and this can cause clogging of the needle of the 
robot arm. Moreover, the necessity to cool at 0 °C is difficult to achieve in the robotic 
setup. 
For this reason, a glycine residue will first be manually incorporated into each chain. 
The starting material for the automated synthesis will now be the tripodal structure 
IV.17 but where the three aromatic units are elongated with a glycine residue (Figure 
 IV.11). In order to keep the orthogonality, glycines with the correct N-protecting groups 
will have to be coupled. 
                                                        
87 DeTar, D. F.; Silverstein, R. J. Am. Chem. Soc. 1965, 88, 1013-1019. 
88 Van der Plas, S. E.; Gea, A.; Figaroli, S.; De Clercq, P. J.; Madder, A. Eur. J. Org. Chem. 2008, 1582-1588. 
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Figure  IV.11: A new starting point for automated synthesis. 
IV.2.5. Reconsidering the orthogonality scheme: synthesis of new glycine 
derivatives 
Now that a protocol was established for attaching the scaffold IV.1 to Tentagel 
resin, and for the coupling of the first AA, peptide chains could be constructed on to 
this backbone. The scaffold is designed in such a way that three different peptide chains 
can be incorporated. In theory, by coupling FmocGlyOH, AllocGlyOH and BocGlyOH, 
the same orthogonality scheme is applicable.  
IV.2.5.1.Replacing the acid labile Boc group 
In the present scheme, the Boc group restricts the use of side chain protected amino 
acids in previous chains. If for example, a glutamic acid residue is introduced in the first 
chain, this side chain will be deprotected when applying 50 % TFA/DCM to access the 
second arm. To increase diversity and flexibility of the synthesis, a new protecting 
group had to be selected and a suitably protected glycine was thus needed. 
Chapter  IV 
 61
hυ spacer HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
IV.17
hυ spacer HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHFmoc
NHPGNHAlloc
PG = ?
 
Figure  IV.12: New orthogonality scheme. 
The possibilities for protecting an α-amino group of an AA are truly enormous89 and 
even today, new protecting groups are designed and tested.90 In the search for a new, 
compatible group, the ortho-nitrobenzenesulfonyl (oNBS) group caught our attention. It 
offers a number of features justifying its use as a temporary amino protecting group.91 A 
first advantage is that upon deprotection with a thiolate via SNAr, a yellow coloured 
chromophore is released allowing simple visual confirmation of deprotection (Scheme 
 IV.17). 
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Scheme  IV.17: Deprotection of oNBS protected amines. 
The second advantage is that the reagent necessary for the synthesis of oNBS amino 
acids, is commercially available and considerably cheaper than e.g. Fmoc-Cl. This 
protecting group has also been used by Liskamp in the synthesis of the earlier 
mentioned tripodal TAC scaffold.59a 
                                                        
89 Albericio, F. Biopolymers 2000, 55, 123-139. 
90 Pothukanuri, S.; Pianowski, Z.; Winssinger, N. Eur. J. Org. Chem. 2008, 3141-3148. 
91 Miller, S. C.; Scanlan, T. S. J. Am. Chem. Soc. 1998, 120, 2690-2691. 
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Scheme  IV.18: Preparation of oNBSGlyOH. 
The glycine derivative IV.18 was easily prepared following previously published 
procedures concerning the preparation of benzenesulfonyl amino acids (Scheme 
 IV.18).92 It was incorporated into construct IV.17 together with AllocGlyOH and 
FmocGlyOH (as later described in more detail in Chapter  IV.2.6) and its orthogonality 
was tested by attaching BocAlaOH after Fmoc deprotection (Scheme  IV.19). 
 
                                                        
92 Milne, H. J. Am. Chem. Soc. 1957, 79, 639-644. 
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Scheme  IV.19: Testing of the oNBS group. 
After the photocleavage of a small sample, the product was analysed by LC-MS. 
From Figure  IV.13 it can be seen that the main peak had a mass corresponding to the 
desired product plus an extra BocAlaOH residue. 
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Figure  IV.13: LC-ESI-MS of IV.20 after photocleavage in EtOH. The ESI- spectrum of the main peak 
is included, indicating that a double acetylation had occurred. 
The formation of this product could be explained by assuming that during the 
coupling of the BocAlaOH (step ii in Scheme  IV.19) the DIEA deprotonated the 
sulphonamide, generating a reactive nucleophile capable of attacking a second 
equivalent of activated amino acid. Indeed, it is for this reason that the oNBS group is 
sometimes used for the selective alkylation of amines.93 However, the oNBS has also 
been used as a replacement for the Fmoc group in the synthesis of small peptides 
without any problems.91 Nevertheless, this side reaction showed the oNBS group to be 
unsuitable for our purposes and a new protecting group had to be found. 
 
                                                        
93 Fukuyama, T.; Cheung, M.; Kan, T. Synlett 1999, 1301-1303. 
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Scheme  IV.20: Synthesis of ivDdeGlyOH. 
Another potentially useful group is the 2-iso-valerydimedone (ivDde) group. This 
group has become a valuable tool in the synthesis of branched or side chain modified 
protected peptides by the Fmoc/tBu solid phase approach.94 The group can be 
introduced in good yield by a condensation reaction (Scheme  IV.20). Deprotection can 
be carried out using a 2 % hydrazine solution in DMF (Scheme  IV.21). After 
incorporation, the group was tested for orthogonality towards Fmoc and Alloc 
deprotection conditions and no side reactions were observed. 
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Scheme  IV.21: Deprotection of the ivDde group. 
IV.2.5.2. Orthogonality of the Alloc group 
The allyloxycarbonyl (Alloc) group is widely used in combination with a Fmoc/tBu 
strategy95 and is also used in different dipodal56 and tripodal scaffolds.57 Cleavage is 
achieved by catalytic amounts of (PPh3)4Pd in the presence of an appropriate 
nucleophile, a so called scavenger. Moreover, the Alloc group is stable under Boc, 
Fmoc and ivDde deprotecting conditions. 
                                                        
94 Chhabra, S. R.; Hothi, B.; Evans, D. J.; White, P. D.; Bycroft, B. W.; Chan, W. C. Tetrahedron Lett. 1998, 39, 
1603-1606. 
95 Brase, S.; Kirchhoff, J. H.; Kobberling, J. Tetrahedron 2003, 59, 885-939. 
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Scheme  IV.22: Mechanism of Alloc deprotection and undesired alkylation. 
The scavenger plays an important role in trapping the cationic π-allyl-Pd-complex, 
thus preventing attack of the liberated amine on this cation which would lead to 
undesired alkylation (Scheme  IV.22). For this reason, 10 equivalents of scavenger or 
more are usually added to the reaction mixture. In literature, a range of scavengers are 
described96 and some of them were tested for their effectiveness (Table  IV.3). 
                                                        
96 Guibe, F. Tetrahedron 1998, 54, 2967-3042. 
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Table  IV.3: Scavengers tested for the Alloc deprotection. 
Entry Scavenger Equivalents Time Solvent Remarks 
1 Morpholine 180 18 h DMF 
- Concurrent Fmoc 
deprotection. 
- Incomplete Alloc 
deprotection. 
2 Bu3SnH 10 1 h DCM 
- Concurrent Fmoc 
deprotection. 
- Incomplete Alloc 
deprotection. 
- Undesired 
alkylation. 
3 Bu3SnH 20 2 x 30' DCM 
- Concurrent Fmoc 
deprotection. 
- Complete Alloc 
deprotection.. 
4 
Anilinium p-
toluenesulfinate 
70 1 h DMF 
- Incomplete Alloc 
deprotection 
5 
Bu3SnH + 
anilinium p-
toluenesulfinate 
20 + 10 2 x 60' DCM 
- Complete Alloc 
deprotection. 
6 PhSiH3 25 2 x 10' DCM 
- Incomplete Alloc 
deprotection.. 
7 PhSiH3 25 2 x 60' DCM 
- Complete Alloc 
deprotection 
- Irreproducible 
results 
8 TIS 75 45' DCM 
- Incomplete Alloc 
deprotection. 
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Test reactions were performed on derivatives of construct IV.22 (Figure  IV.14) and 
conditions were optimised for the removal of an Alloc group attached to an aromatic 
amine. 
The scavenger previously used in our lab was morpholine which was applied in a 
very large excess for 18 h (entry 1). Besides causing Fmoc deprotection, this secondary 
amine was apparently not performant enough as incomplete deprotection was observed 
using this reagent. 
The first explored alternative was Bu3SnH (entry 2).97 This Sn derivative, though 
effective, is less used nowadays due to its toxicity. In a first experiment it was noticed 
that 10 equivalents were not sufficient for complete deprotection of the Alloc group. 
Moreover, some alkylation was observed. Increasing the equivalents (entry 3) gave a 
complete deprotection without alkylation. However, the hydride appeared basic enough 
to cause undesired Fmoc deprotection.  
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Figure  IV.14: Tested scavengers for the Alloc deprotection. 
Sulfenic acids are also known to be able to scavenge the cationic π-allyl-Pd-complex 
generated during the Alloc deprotection.98 Using the salt of p-toluenesulfinic acid and 
aniline did not lead to a complete deprotection (entry 4), even when a very large excess 
                                                        
97 Dangles, O.; Guibe, F.; Balavoine, G.; Lavielle, S.; Marquet, A. J. Org. Chem. 1987, 52, 4984-4993. 
98 Honda, M.; Morita, H.; Nagakura, I. J. Org. Chem. 1997, 62, 8932-8936.  
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was applied. The advantage is that the Fmoc group is not deprotected and no alkylation 
is observed. 
When combining the sulfenic acid with Bu3SnH in a 1:2 ratio, a complete 
deprotection was observed without removal of the Fmoc group (entry 5). This is 
probably due to a decrease in pH of the solution when the acidic salt is added. The 
combined scavengers also prevented alkylation of the liberated amine. 
Another, commonly used scavenger is phenylsilane. The allyl group is transferred 
under neutral conditions using PhSiH3 and consequently, no Fmoc deprotection is 
observed.99 Additionally, no trace of the alkylated side product was observed using this 
scavenger. The reported reaction time of 10 min seemed insufficient to completely 
deprotect the Alloc group (entry 6). Prolonging the reaction time until 60 min led to a 
complete removal in most cases. However, the deprotection showed to be irreproducible 
(entry 7). Sometimes only one hour was sufficient but in other cases, the deprotection 
had to be repeated for three times. Interestingly, triisopropylsilane, a known hydride 
donor routinely used in our lab during the side chain deprotection of peptides (vide 
infra), was unable to give good results (entry 8). 
In conclusion, two systems (PhSiH3 and anilinium p-toluenesulfinate/Bu3SnH) were 
found to be effective in the deprotection of the Alloc group. The silyl reagent was 
preferred due to the lower toxicity but each time the deprotection was carefully 
monitored via LC(-MS) to make sure that all the starting material had disappeared. 
According to literature, when using PhSiH3 as a scavenger, the liberated amine should 
be rapidly and quantitatively acylated in the presence of a suitably activated carboxylic 
acid.100 When performing the deprotection in the presence of pre-activated FmocGlyOH 
(Figure  IV.15), it appeared that not only was the Alloc removal incomplete but also 
only 20 % of the liberated amine was acylated. In a second experiment, the symmetrical 
anhydride was only added to the deprotection mixture after 30 min but no improvement 
                                                        
99 Thieriet, N.; Alsina, J.; Giralt, E.; Guibe, F.; Albericio, F. Tetrahedron Lett. 1997, 38, 7275-7278. 
100 Thieriet, N.; Gomez-Martinez, P.; Guibe, F. Tetrahedron Lett. 1999, 40, 2505-2508. 
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was seen. Therefore, the deprotection and subsequent coupling were carried out 
separately. 
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Figure  IV.15: Tandem deprotection-coupling. 
Once the Alloc group was removed, AllocGlyOH had to be coupled to ensure 
complete orthogonality. 
Not being commercially available, AllocGlyOH first had to be synthesised. The 
Alloc group can be introduced using allyl chloroformate (Scheme  IV.23). However, 
this reagent is reactive enough to be attacked by the carboxylate anion, generating a 
mixed anhydride that in turn can be attacked by another glycine, resulting in a 
dipeptide. 
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Scheme  IV.23: Formation of AllocGlyGlyOH. 
This can be prevented by in situ transforming the chloroformate into the less reactive 
acylazide (Scheme  IV.24).101 In our hands, the desired compound was obtained using 
this protocol, but 13C-NMR analysis showed the presence of another glycine derivative. 
Coupling of this Alloc-glycine to the tripodal scaffold however, gave only one 
detectable compound with the right mass. 
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Scheme  IV.24: Alloc protection of glycine. 
To illustrate the problems that were still encountered with the Alloc group, we 
focussed is on the synthesis of 24 library members. The choice of amino acids and the 
details of the synthesis are explained stage in this chapter. The starting point is construct 
IV.26 (Scheme  IV.25) to which three different peptide strands are attached. To clarify 
the encountered problems, a specific sequence IV.27 is chosen as example. 
The synthesis was started by first deprotecting the Fmoc group of IV.26 and thus 
generating a free glycine amino group which was subsequently acetylated with a Glu 
                                                        
101 Cruz, L. J.; Beteta, N. G.; Ewenson, A.; Albericio, F. Org. Process Res. Dev. 2004, 8, 920-924. 
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residue. The second incorporated AA was Leu and the first peptide strand was capped 
with Ac2O. For the Alloc deprotection, PhSiH3 was manually added to each reaction 
vessel followed by the addition of catalytic amounts of Pd° in DCM. The reaction was 
vortexed by the synthesiser for 60 min and the sequence was repeated once. After the 
Alloc deprotection, no more manual steps had to be included. The coupling of Leu and 
His and subsequent capping was automatically followed by ivDde removal. The third 
strand consisted of Arg and Phe and was capped with Ac2O. 
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Scheme  IV.25: Automated synthesis of 24 library members. 
The identity of the obtained compound was checked via analysis of the product after 
photocleavage. Because the polar side chains of His, Arg and Glu were still protected, 
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resulting in a mass of the photocleaved product of 2315.9 Da, analysis was only 
possible via MALDI-TOF.102  
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Figure  IV.16: MALDI analysis of IV.27 after photocleavage. 
The obtained MALDI spectrum (Figure  IV.16) was at start a little bit puzzling. The 
correct mass of the compound (2317.1 [M+H]+) was observed, but it was not the main 
peak. Clearly, a product that was heavier than the target compound had been 
synthesised (2380.2, 2402.3). Besides the loss of side chain protecting groups, which is 
due to the acidic sample preparation for MALDI analysis, other peaks with a lower 
mass were observed. 
The key to solving this spectrum was found in the mass difference between 2226.2 
and 2339.3 [M+Na]+ which corresponded with a missing Leu residue. This deletion 
could come from the first Fmoc strand or from the second Alloc strand. Taking into 
account the previous problems encountered with the Alloc group, it was assumed that 
the Leu was missing in the second strand. In this way, the peak at 1847.0 could be 
explained as a double deletion: no Leu and His were present. The higher masses of 
                                                        
102 For ESI, current equipment does not allow the analysis of masses higher than 2000 Da. 
Synthesis of hER mimics 
 74 
2380.2 and 2402.3 could eventually be correlated to a double insertion of the third 
strand, implying that instead of the insertion of a Leu and His, an Arg and a Phe were 
incorporated. 
Similar spectra were obtained when other samples were analysed and the same trend 
was observed after the side chain protecting groups were removed. 
One way for explaining this was by assuming that after the Alloc deprotection, the 
free glycine amine was reversibly blocked. Indeed, only a fraction of the unprotected 
product was coupled to the first AA (Leu) after Alloc deprotection. This compound 
would eventually lead to the desired product with the observed masses of 2317.1 
[M+H]+ and 2339.3 [M+Na]+.  
Nevertheless, the peak of 2226.2 [M-Leu+Na]+ suggests that after the Leu coupling, 
the glycine amine was partially unblocked and able to react in the subsequent His 
coupling forming IV.29 (Figure  IV.16). Moreover, this also explains the existence of 
IV.30 and IV.28. It seems that after every treatment with a nitrogen base like piperidine 
for the Fmoc deprotection, DIEA during the AA coupling or pyridine during the 
capping step, the temporarily blocked glycine generated during the Alloc deprotection, 
is partially deprotected. 
What can be the nature of this blocked glycine amine? The following possibilities 
are suggested (Figure  IV.17):  
a) The formed carbamic acid is silylated and does not decompose (IV.26a). When 
using silyl or tin based scavengers, it is thought that the intermediate carbamic acid 
binds with the Lewis acid. The formed adduct readily decomposes in the presence of 
traces water.100 In this context, it should be noted that when working in an automated 
fashion, it is impossible to work under dry circumstances, so there is always some water 
present in the reaction mixture. 
b) The liberated amine forms a complex with Pd (IV.26b). Though Pd° was only 
added in catalytic amounts (20 mol %), the deprotection was repeated once and so 
partial blocking of the glycine can result from a glycine-Pd complex formation. This 
complex could then be dissociated by adding another N-ligand like piperidine or 
pyridine. 
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Figure  IV.17: The two suggested possibilities for the partial blocking of Gly. 
Whatever the chemical answer to these questions may be, one fact is sure from these 
and previous experiments: the Alloc group is an unreliable protecting group lacking the 
robustness needed for the synthesis of a library of tripodal receptors. 
IV.2.5.3. In search of a new protecting group: azidoglycine 
Faced with the practical drawbacks of the Alloc group, a new literature search was 
started to find a new protecting group for α-amines which is compatible with the Fmoc 
and ivDde group. Luckily, at that time click chemistry had become a chemical hype and 
azides were in the spotlight. The idea grew of using the azido derivative of glycine in 
our synthesic scheme. 
Using the azide as a protective group in peptide synthesis is surprisingly enough 
discarded in most reviews about protecting group strategies.89 A few examples are 
known were azido derivatives of amino acids are used.103 Probably the inherent 
instability of azides has prevented widespread use of the azido derivatives of amino 
                                                        
103 a) Debaene, F.; Winssinger, N. Org. Lett. 2003, 5, 4445-4447. b) Zhang, Z. S.; Carter, T.; Fan, E. K. 
Tetrahedron Lett. 2003, 44, 3063-3066. c) Yan, R. B.; Yang, F.; Wu, Y. F.; Zhang, L. H.; Ye, X. S. Tetrahedron 
Lett. 2005, 46, 8993-8995. 
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acids. When working with a specific azide, the following equation should be kept in 
mind:104 
 
Nc + NO
NN
> 3
Equation I
O
HO
N3
Azidoglycine IV.31
2 + 2
3
= 1.33
 
Figure  IV.18: Safety aspects of azidoglycine. Equation I gives the ratio of the number of C and O 
atoms to the number of N atoms. 
Only azides with a ratio larger than 3 can be handled like a normal non-explosive 
organic compound. If the calculation is done for azidoglycine IV.31, a value of 1.33 is 
found. Nevertheless, several articles report about the synthesis and applications of this 
small, energy rich molecule.105 All the articles mention that care must be taken in 
handling this compound but no accidents have ever been reported using azidoglycine. 
One article even discusses the thermal decomposition of azidoglycine and the 
characterisation of the formed products.106 In light of these examples, it was decided to 
synthesise azidoglycine and to incorporate it into the synthesic strategy.  
The azide group could be easily introduced via an SN2 reaction in DMSO (Scheme 
 IV.26).  
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Scheme  IV.26: Synthesis of azidoglycine IV.31. 
                                                        
104 Kolb, H. C.; Finn, M. G.; Sharpless, K. B. Angew. Chem. Int. Ed. 2001, 40, 2004-2021. 
105 a) Cai, J. F.; Li, X. X.; Yue, X.; Taylor, J. S. J. Am. Chem. Soc. 2004, 126, 16324-16325. b) Banaszynski, L. A.; 
Liu, C. W.; Wandless, T. J. J. Am. Chem. Soc. 2006, 128, 15928-15928. 
106 Dyke, J. M.; Groves, A. P.; Morris, A.; Ogden, J. S.; Dias, A. A.; Oliveira, A. M. S.; Costa, M. L.; Barros, M. 
T.; Cabral, M. H.; Moutinho, A. M. C. J. Am. Chem. Soc. 1997, 119, 6883-6887. 
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The deprotection was optimised on construct IV.32 (Scheme  IV.27). Though 
reduction of the azide is possible via SnCl2/ArSH/base107 it was decided to use the more 
classical Staudinger conditions to avoid reduction of the nitro group of the 
photolinker.108 
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Scheme  IV.27: Staudinger reduction of azide IV.32. 
The first step of the Staudinger reduction consists of the nucleophilic attack of the 
phosphine nucleophile on the azide. The kinetics of this first step are dependent on the 
donating properties of the phosphine substituents and the electron deficiency of the 
azide.109 In the second step, both steric and electronic properties play a role. The 
kinetics for the second step are presumably in favour for phosphines with little sterical 
hindrance like Me3P rather than bulkier nucleophiles like Ph3P. After nitrogen loss, an 
iminophosphorane or [N-P]-ylide is obtained which can subsequently be hydrolysed. 
                                                        
107 Zhang, Z. S.; Carter, T.; Fan, E. K. Tetrahedron Lett. 2003, 44, 3063-3066. 
108 Wu, Z.; Rea, P.; Wickham, G. Tetrahedron Lett. 2000, 41, 9871-9874. 
109 Nyffeler, P. T.; Liang, C. H.; Koeller, K. M.; Wong, C. H. J. Am. Chem. Soc. 2002, 124, 10773-10778. 
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The iminophosphoranes of Ph3P are more stable than those of Me3P and thus more 
difficult to hydrolyse. 
From these considerations Me3P can be considered to posses the best properties for 
reducing the azide. Nevertheless, both Me3P and Ph3P were tested because the former is 
more readily oxidised and has the practical disadvantage of an irritant, persistent smell.  
Looking at the results depicted in Table  IV.4 it is clear that the more hindered and 
less nucleophilic Ph3P is not suited for a fast reduction of the azide (entry 1 & 2). First 
results obtained with Me3P however (entry 3 & 4), did not give a complete reduction 
but this was due to the low viscosity of the organic solvent system. It appeared that after 
10 min, the solution containing the reagent had leaked through the filter, explaining the 
bad results. It must be noted that this approach is not compatible with a Fmoc group in 
the molecule, so the azide cannot be deprotected as the first protecting group. The 
viscosity was increased by using a 1:1 mixture of THF/H2O (entry 5) and indeed, after 
two times 1 h the reduction was complete. In a final experiment, reaction times could be 
reduced to two times 10 min, establishing the azide as a robust protecting group, ideally 
suited for the current orthogonality scheme. 
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Table  IV.4: Optimising the Staudinger reduction. 
Entry Nucleophile Conc. Solvent Time Remarks 
1 Ph3P 1 M dioxane 2 h 
- Incomplete azide reduction.  
- Stable [N-P]-ylide present. 
2 Ph3P 1 M 
dioxane/H2O 
(4:1) 
2 h 
- Incomplete azide reduction. 
-  Stable [N-P]-ylide present. 
3 Me3P 1 M THF 2 h 
- Solvent leaks through filter. 
- Incomplete azide reduction.  
- Concurrent Fmoc deprotection.  
4 Me3P 0.8 M 
THF/H2O 
(4:1) 
2 h 
- Solvent leaks through filter. 
- Incomplete azide reduction. 
- Concurrent Fmoc deprotection. 
5 Me3P 0.5 M 
THF/H2O 
(1:1) 
2x 1 h - Complete azide reduction. 
6 Me3P 0.5 M 
THF/H2O 
(1:1) 
2x 10' - Complete azide reduction. 
 
IV.2.6. Incorporation of the new glycine derivatives 
Starting from construct IV.17, the three differently protected glycine derivatives 
were attached via their symmetrical anhydrides (Scheme  IV.28). First the Fmoc group 
was deprotected and the corresponding amine was acylated with ivDdeGlyOH. Then 
the Boc group was removed and subsequent coupling of FmocGlyOH was followed by 
the Alloc deprotection. Finally, azidoglycine was attached to yield construct IV.32. 
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Scheme  IV.28: Construction of the starting material for automated synthesis. 
Each coupling was carefully monitored via LC-MS after photocleavage of a small 
sample. Sometimes, a double coupling had to be performed to make sure that all the 
starting material had reacted. The azide derivative was coupled last to prevent any 
undesired reduction by the phosphine ligands of the Pd° catalyst during the Alloc 
deprotection. IV.32 was obtained in a good purity (Figure  IV.19) and will serve as the 
starting point for the synthesis of the receptor library. 
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Figure  IV.19: LC-MS of IV.32 after photocleavage in EtOH (exact mass = 1297.6) 
IV.2.7. Selection of the key amino acids 
Now that the protocols for the solid phase synthesis of a library based on the tripodal 
scaffold IV.1 are established, the right AAs have to be chosen in order to efficiently 
mimic the HBD of the hER. The choice was made based on X-ray structures of the HD 
of the hER with different ligands.110 A schematic representation of the HBD of hERα in 
complex with estradiol is depicted in Figure  IV.20.111 
 
                                                        
110 The X-ray structures downloaded from The Protein Data Bank consist of the HBD of hER in complex with 
Genistein (PDB ID: 1QKM), estradiol (PDB ID: 1ERE and 1A52) and bisphenol-A (PDB ID: 2P7G). 
111 a) Tanenbaum, D. M.; Wang, Y.; Williams, S. P.; Sigler, P. B. PNAS 1998, 95, 5998-6003. b) Pike, A. C.; 
Brzozowski, A. M.; Hubbard, R. E.; Bonn, T.; Thorsell, A. G.; Engstrom, O.; Ljunggren, J.; Gustafsson, J. A.; 
Carlquist, M. EMBO J 1999, 18, 4608-18. 
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Figure  IV.20: Schematic representation of A) hydrogen bonding network and B) hydrophobic 
interactions between the AAs of the HBD of the hER and its natural ligand estradiol. 
The hormone is orientated by two types of contacts: hydrogen bonding at the two 
ends (A) and van der Waals contacts along the body of the hormone (B). 
The hydroxyl group of the phenol is H-bonded to a Glu residue while the aliphatic 
hydroxyl interacts with the imidazole ring of His524. The glutamate is oriented and 
positioned through a hydrogen bonding network involving a highly polarised water 
molecule and an Arg side chain. This Arg is braced by a hydrogen bond to the carbonyl 
of the residue preceding a Phe which in its turn is fixed by an aromatic interaction with 
the phenolic ring of the ligand. 
The body of estradiol interacts with various apolar side chains. The flat A ring is 
caught in a pincer like environment created by the bulky side chains of different Leu 
residues. 
From these data, six AA were selected to be incorporated into the tripodal backbone. 
For mimicking the hydrogen bond network, His, Arg and Glu were chosen. The apolar 
environment of the receptor would be mimicked by choosing Leu, Phe and Met as 
building blocks. 
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IV.2.8. Size of the parallel library 
When applying a split-and-mix or combinatorial approach (Figure  IV.21), all the 
possible combinations with the six selected AA on the six different positions of the 
scaffold would be made. The number of synthesised molecules would be 66 or 46656, a 
very big number indeed. The disadvantage of these combinatorial libraries is that while 
generating a very large diversity, it is practically impossible to make 10 or even 1 mg of 
resin for each member. Generally, the libraries contain only 10 beads carrying the same 
peptide. This of course has its implications on the screening for activity. Usually, a 
marked ligand, coloured or fluorescent, is added and after incubation of the whole 
library, the beads that are coloured or fluorescent are selected and analysed to find out 
the identity of the peptides.59 The identity of the active compound can be determined 
using techniques such as radio frequency tagging,112 chemical tagging, Edman 
degradation or other available methods.113 In view of the small amounts available, it 
remains difficult to identify the active members.114  Moreover, it is impossible to check 
the purity of the synthesised compounds which implies that one is never sure whether 
the whole spectrum of desired molecules has actually been made.  
To avoid these problems, a larger amount of the different compounds should be 
synthesised. This is possible via parallel libraries, where the identity of the compound is 
determined by the fixed position of the reaction vessel. Though molecular diversity can 
be generated with automated synthesis, it is practically impossible to synthesise a 
library of more then 46000 members. For example, if it takes 1 working day to make 24 
members, then 1944 days are needed to make 46656 members in a parallel fashion. 
                                                        
112 Nicolaou, K. C.; Xiao, X. Y.; Parandoosh, Z.; Senyei, A.; Nova, M. P. Angew. Chem. Int. Ed. 1995, 34, 2289-
2291. 
113 Czarnik, A. W. PNAS 1997, 94, 12738-12739. 
114 Schmuck, C.; Wich, P. New J. Chem. 2006, 30, 1377-1385. 
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Figure  IV.21: Combinatorial vs parallel libraries. 
The size of the theoretically possible library was substantially decreased by applying 
some preconditions. A first simplification was made by leaving out the combinations 
where it seems that one strand is traded in place with another strand (Figure  IV.22). In 
other words, the tripodal structure is treated like a D3-symmetrical structure. 
Consequently, the size of the original library (66 = 46656) was reduced to a number of 
8436 (according to (x^(3n)+2x^n)/3 where x is the total number of AAs that can be 
incorporated and where n is the number of AAs per arm). A second restriction was 
made by inserting each AA only once into the tripodal structure. In this way, a small 
sized library of 120 members was designed.115 
 
                                                        
115 The possible sequences of the library of 8436 members were listed in an Excel File by the Sequence V1.5 
software developed by James E. Redman (Redman, J.E., Wilcoxen, K.M and Ghadiri M.R, J. Comb. Chem. 2003, 
5, 33-40). The 120 compounds with 6 different AAs where selected by a specially written Visual Basic Application 
(VBA) protocol. 
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Figure  IV.22: Simplifying the library composition. 
IV.2.9. Automated solid phase synthesis of 120 receptors 
For the automated synthesis, a SYRO I robot setup was used. This device consists of 
a pipetting arm that simply adds different mixtures to the reaction vessel containing the 
resin. Via the software, the sequence of the desired peptide is inserted and in this way 
the robot arm knows when a specific AAx has to be coupled. 
The solutions used for peptide coupling are a 0.5 M HBTU/DMF solution, a 0.5 M 
AAx/DMF solution and a 2 M DIEA/NMP solution. In total, 5 equivalents of AAx and 
HBTU are added next to 10 equivalents of DIEA. Next to these solutions, also a 40 % 
piperidine/DMF mixture, and a capping solution (Ac2O/pyridine/NMP (1:3:10) are 
prepared. For the ivDde deprotection a 2 % H2NNH2.H2O/DMF is made and for the 
azide reduction a solution of 0.5 M Me3P in THF/H2O is prepared. 
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Scheme  IV.29: Automated synthesis of the library. 
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Once the different solutions are prepared and the correct sequence is inserted in the 
software, the resin has to be weighed in the different reaction vessels. After pressing the 
start button, everything proceeds automatically. Coupling times are typically 40 min 
and the Fmoc deprotection takes 15 min. Since there are 24 reaction vessels and it takes 
20 h to finish the synthesis of 24 members, the whole library was prepared in only 5 
days. 
For each member, 1-3 mg of resin bound IV.32 (Scheme  IV.29) was weighed in a 
reaction vessel. The purity and identity were checked by randomly picking 20 members 
throughout the library and analysing the compounds after photocleavage via MALDI 
and LC. 
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Figure  IV.23: MALDI analysis of a library member. 
The MALDI spectrum (Figure  IV.23) looked very nice at first sight, but when the 
purity was checked (Figure  IV.24), two main peaks were observed. A more careful 
analysis of the mass spectrum revealed a small peak of 2350.7 (not shown) 
corresponding to the desired product + an extra oxygen. In this view, the peak of 2373.4 
could now also be seen as the Na+ adduct of [M + O], what would explain the relative 
large intensity of this peak (normally K+ adducts are observed in lower intensity). 
An explanation was found by assuming that the incorporated Met was oxidised 
during synthesis, causing a hydrophilic shift in the HPLC chromatogram. Normally, this 
oxidation only happens under acid catalysed conditions. The purity of the starting 
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compound FmocMetOH was checked via HPLC and only one peak was observed, so 
this showed that the oxidation happened during the automated synthesis. This is 
probably due to the fact that the suspension of the beads and the reaction mixture are 
vortexed intensely during synthesis. No inert atmosphere is applied, so oxygen is really 
mixed into the solution.  
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Figure  IV.24: HPLC chromatogram at 214 nm of a library member. 
The oxidised Met can be regarded as a protected amino acid. Indeed, sometimes Met 
is fully oxidised before using it as a building block for peptide synthesis. This extra 
protecting group should now be taken into account when the other side chains are 
deprotected. 
IV.2.10. Side chain deprotection 
The side chain protecting groups of His, Glu and Arg can be removed using TFA. 
During the deprotection, several carbocations are generated and these can cause 
undesired alkylations of the synthesised molecule. Generally, the cations are trapped by 
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adding scavengers to the reaction mixture. Based on previous experience in the lab, 
thioanisole, triisopropylsilane (TIS), 3,6-dioxa-1,8-octanedithiol (DODT)116 and water 
ared added as scavengers. For the reduction of the sulfoxide, NH4I (1.5 w/w%) and 
Me2S (2 %) are added to the cleavage cocktail.117 In Scheme  IV.30 library member 
IV.33 is taken as an example. 
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Scheme  IV.30: Deprotection of the side chain protecting groups. 
Because a lot of scavengers are added, the amount of TFA and thus the acidity or 
reactivity of the mixture is lowered. The acidity of the cleavage mixture is also lowered 
by using Tentagel as a solid phase. The polyethylene glycol chains tend to be 
                                                        
116 Teixeira, A.; Benckhuijsen, W. E.; de Koning, P. E.; Valentijn, A.; Drijfhout, J. W. Protein and Peptide Letters 
2002, 9, 379-385. 
117 Hackenberger, C. P. R. Org. Biomol. Chem. 2006, 4, 2291-2295. 
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protonated by the acid, hence lowering the effective [H+]. By prolonging the standard 
reaction time of 1 h to 3 h these effects can be compensated. 
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Figure  IV.25: HPLC of IV.34 after photocleavage in H2O. 
The HPLC chromatogram looked very clean (Figure  IV.25) and this result was 
confirmed by ESI. No trace of oxidised product was observed anymore. The analysis 
was repeated for the 18 other randomly picked members and besides having the right 
mass, all of them displayed a purity similar to IV.34 (for the LC chromatograms of the 
18 members, see Chapter  VIII.3.5). 
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Figure  IV.26: ESI (+ mode) of IV.34 after photocleavage in H2O. 
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IV.3. Conclusion 
In this chapter a synthetic protocol for small sized libraries of possible EDC 
receptors was established. Starting from simple commercial building blocks the tripodal 
scaffold IV.1 was synthesised (Scheme  IV.31). After optimisation of the coupling of 
IV.1 to Tentagel the weak nucleophilicity of the aromatic amines was bypassed and at 
the same time the whole orthogonality scheme was reconsidered. Starting from IV.32, 
this new strategy enabled the synthesis of 120 library members in a short period of time. 
Moreover, after analysis, it was proven that the overall quality of the synthesised library 
was very good. 
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Scheme  IV.31: Summary of chapter IV. 
The next chapter will discuss the screening of the library and the different problems 
encountered will be addressed. 
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V. Screening of the library 
Synthesising a lot of molecules is one thing, finding out which one has the desired 
properties is a completely different story. With combinatorial and parallel libraries, 
screening for affinity has generally been achieved by incubating the library with a 
labelled ligand. The ligand can be marked with a coloured substrate118, a fluorescent 
label53a,59 or a radioactive marker.51 
The first two options inherently possess some drawbacks. The main problem is that 
the ligand used for screening is very different from the unlabelled substrate. Usually, 
the possible interactions with the label itself are then further investigated either by 
incubating the unligated label with the library or by screening the library with the same 
substrate but differently labelled.  
Considering the estradiol-hER interaction, it is clear that besides hydrogen bonding 
at both sides of the molecule, hydrophobic interactions, and more specifically aromatic 
interactions, will play a key role in molecular recognition. Hence, this recognition can 
be influenced by coupling an aromatic coloured or fluorescent label to the substrate. 
These problems can be solved by using a radioactive ligand like [3H]-labelled 
estradiol in the work of Tozzi et al.51 With this approach, the changes to the ligand are 
minor but the molecule still is detectable at very low concentrations. The only drawback 
is that neither the equipment nor the experience needed for the successful 
implementation of this method is present in our lab.  
For this reason, alternative screening methods were explored during this PhD that 
focussed on using unmodified ligands and on a direct multi-residue screening of the 
library. This was only possible thanks to the strong collaboration with the Laboratory of 
Separation Sciences of Prof. Dr. P. Sandra, and more specifically the scientific aid of 
Dr. F. Lynen and Drs. E. Van Hoeck. Also a significant contribution was made in 
                                                        
118 Shepherd, J.; Gale, T.; Jensen, K. B.; Kilburn, J. D. Chem. Eur. J. 2006, 12, 713-720. 
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solving this problem by Drs. S. Figaroli, who had joined our team in the context of the 
European Marie Curie sEnDiChem project.119 
V.1. SPE tests 
V.1.1. Tentagel based SPE material 
In first instance, it was decided to use an approach similar to the one described by 
Tozzi et al.51 In the work of Tozzi, a radioactive ligand was incubated with the different 
resin-bound library members. By analysing the amount of ligand remaining on the 
beads after draining the solution, the most active member could be selected.  
In our case, the concentration of the ligand before and after incubation was checked 
via LC-MS, making the use of radioactive ligands unnecessary. The concentration of a 
ligand could be determined by adding an internal standard, estradiol-d3, to the 
incubation mixture. Another big advantage of this method was that the library members 
could be screened for affinity towards different EDCs in one and the same experiment. 
Surely, the different compounds were first separated on a C18 column before the 
intensity of the mass signal was correlated to the concentration of the specific 
compounds.  
Before screening the actual library, the affinity of Tentagel towards the EDC 
mixture was examined. Certainly, the data obtained from screening of the library can 
only be interpreted if suitable blank data are available. These blank data were obtained 
by adding a mixture of bisphenol-A (BPA), diethylstilbestrol (DES), estrone, estradiol 
(E2), ethinylestradiol (EE2) and testosterone (Tes) in water to the unmodified Tentagel 
beads. Testosterone, a non-estrogenic compound, was added to test for possible 
selectivity of the beads towards estrogenic compounds.  
                                                        
119 For more info about the sEnDiChem project please visit http://www.sendichem.ugent.be.  
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Figure  V.1: Testing of Tentagel (  ) for affinity towards EDCs. 
From Figure  V.1 it is clear that Tentagel is not a good solid support for affinity SPE 
testing. The Y-axis represents the percentage of EDCs that sticking to the beads. In the 
case of bisphenol-A, everything seems to be absorbed by the Tentagel. In general, 88 % 
to 100 % of the selected EDCs are trapped on the beads. Consequently, it will be 
difficult to see whether a receptor attached to Tentagel is able to bind EDCs because of 
this high background absorbance. 
In order to tackle this problem, a way had to be found to wash away the non specific 
interactions without disturbing the specific [receptor-ligand] interactions. The 
difference between specific and non-specific interactions could only be seen if the data 
obtained with unmodified Tentagel were compared to Tentagel modified with a known 
EDC receptor. For this reason, the protected Tozzi-tetrapeptide H2N-GABA-Arg-Ser-
Ser-Val-OH V.2 (Chapter  II.2.7.3) was synthesised and attached to Tentagel. This 
linear peptide was described by Tozzi to have a Kd of 17 µM for estradiol in water 
(Table  II.1). 
 
Screening of the library 
 94 
spacerNH hυ N
H
O
O
Arg Ser Ser Val OH
V.4
Cl
i) FmocValOH,
   DIEA, DCM, 85 %
   
ii) 20 % piperidine,
O
O
NH2
iii) automated
    synthesis
HO
H
N
N
H
H
N
NH3
O
O
O
O
O
O
HN
NH
H
NPbf
iv) AcOH/TFE/DCM
    (1:1:3), 60 %
O
O
2'-Chlorotrityl
NH hυ spacer
v) Succinic anhydride
    DIEA, DCM
vi) PyBOP, DIEA, DMF
vii) DIEA, DMF
viii) TFA/TIS/thioanisole/DODT/H2O
Protected Tozzi-Tetrapeptide V.2
TentagelV.1 IV.16
V.3
spacerNH hυ NH
O
O
OBt
NH2
 
Scheme  V.1: Preparation of resin bound construct V.4. 
Because Tozzi et al used a rather unusual N → C build up for their peptides and no 
experience with this synthesis approach was present in our lab, the Tozzi-tetrapeptide 
was first synthesised on 2’-chlorotritylresin via the standard C → N build up (Scheme 
 V.1). Cleavage with AcOH/TFE/DCM generated the protected peptide segment that 
could be coupled to the pre-activated construct V.3. Finally, the side chains were 
deprotected and the product was characterised by ESI and HPLC. 
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Figure  V.2: Washing away the non specific interactions with 60 % MeCN in H2O. 
The results for Tentagel (  ) and construct V.4 (  ) are shown. 
As can be seen from Figure  V.2, a washing step would be unsuccessful. The amount 
of EDCs that stay on construct V.4 after washing with 60 % MeCN/H2O, are not 
significantly higher than the amount of EDCs left on Tentagel. Hence, it was not 
possible to selectively wash away the non-specific interactions from the specific ones. 
V.1.2. Alternatives for Tentagel 
In order to circumvent the high background adsorption caused by the Tentagel 
matrix, a new resin was needed for these affinity SPE tests. A lot of well and less well 
known resins were tested for affinity towards EDCs (Figure  V.3). Among them, the 
classical Merrifield resin, the polar polyacrylamide PEGA beads, a polyester CLEAR 
support (Figure  V.4) and an amine-functionalised silica material. It appeared that 
Merrifield, silica and, in a lesser extent, CLEAR did not retain the EDCs too much. 
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Figure  V.3: Testing of the affinity towards EDCs of Merrifield (  ), 
CLEAR (  ), PEGA (  ), Tentagel (  ) and aminopropylsilica (  ). 
For the Merrifield resin, an explanation can probably be found in the fact that this 
apolar resin does not swell in aqueous media. Hence, the EDCs cannot penetrate the 
core and interact with the bulk of the polymer. 
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Figure  V.4: Structures of different solid supports. 
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CLEAR is a resin constituted of polyethylene glycol chains linked via ester bonds 
resulting in a highly polar polymer swelling in a broad range of solvents, including 
water.120 Though it has been described as a useful alternative to Tentagel, it was found 
that the synthesis on this CLEAR resin was more difficult. Certain acetylations failed to 
proceed quantitatively and for this reason no further effort was put in optimising the use 
of this resin. 
Besides the fact that the tested EDCs already stick to a high degree to PEGA, this 
resin was not used due to its tendency to become statically charged. PEGA is provided 
as a suspension in MeOH but upon drying, the resin becomes impossible to handle and 
basic actions like weighing are very difficult. 
Via this elimination process, aminopropylsilica remained the only suitable solid 
support. In a test sequence, the tripodal scaffold was coupled to photolinker-modified 
silica and one member of the library was synthesised (Scheme  V.2). Not only was the 
overall purity of the protected member less than on Tentagel (due to a major deletion of 
Leu and Met sequences) but more importantly, deprotection of the side chains was 
unsuccessful (Figure  V.5). Even after a second treatment with a higher percentage of 
TFA, the deprotection was not complete. This is probably due to the oxygen rich 
backbone of silica. These oxygens can be protonated by TFA lowering the effective 
[H+]. 
 
                                                        
120 Kempe, M.; Barany, G. J. Am. Chem. Soc. 1996, 118, 7083-7093. 
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Scheme  V.2: Testing silica as a suitable solid phase. 
In view of these results, it became clear that there was no solid support available that 
combines good synthetic properties with a low background absorbance of EDCs. 
Consequently, a completely different approach was needed to screen the library for 
affinity towards EDCs. 
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Figure  V.5: HPLC of protected V.8 after photocleavage in EtOH (A). HPLC of 2x deprotected V.8 
after photocleavage in EtOH (B). MALDI-TOF of 2x deprotected V.8 after photocleavage in EtOH 
(C). 
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V.2.Affinity LC 
V.2.1. Development of a new estradiol column 
In the previous experiments, the receptor was immobilised on the solid support 
while the ligands were present in solution. It was decided to reverse this order by 
binding a ligand to a solid support. More specifically, if silica is used as a solid phase, a 
column can be packed using this silica-bound substrate. Consequently, when the 
receptors are sent over the column, the one that shows the highest retention time should 
have the strongest affinity towards the ligand. This principle is called affinity LC. 
For the development of a new column material, a suitable ligation reaction had to be 
developed to couple a ligand to the silica material. The copper(I)-catalyzed azide-
alkyne cycloaddition seemed very interesting for this purpose (Scheme  V.3). This CuI 
catalysed addition received considerable attention during the past 7 years as it is one of 
the click reactions described by Sharpless et al.104 In this paper, the CuI catalysed azide-
alkyne cycloaddition is described as the ‘cream of the crop’ of a class of reactions 
giving high yields, are very specific an can proceed in benign solvents like H2O. 
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R1 N
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R2
1,4 triazole
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Scheme  V.3: CuI catalysed addition of an azide to an alkyne. 
Applied to our specific situation, it was decided to attach the alkyne-bearing 
ethinylestradiol (EE2) to an azido-functionalised silica material via the CuI catalysed 
addition (Scheme  V.4). The azido-functionalised silica was obtained after acetylation of 
aminopropylsilica with 6-azido-hexanoic acid V.9. This azide was prepared via a SN2 
substitution of 6-bromo-hexanoic acid with NaN3 in good yields.121 
                                                        
121 Grandjean. J. Org. Chem. 2005, 70, 7123-7132. 
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The click reaction itself was performed in a 1:1 iPrOH/H2O mixture at 40 °C using 
catalytic amounts of CuII that was reduced in situ to CuI by an excess of sodium 
ascorbate. After overnight reaction, the addition was finished as witnessed by the 
disappearance of the azide peak (~ 2100 cm-1) in the corresponding IR spectrum.  
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Scheme  V.4: Preparation of an estradiol column. 
By packing the silica material V.11 into a column (2.1 x 150 mm), an estradiol 
affinity column was obtained that could be used for the screening of the library. 
V.2.2. Evaluation of the estradiol column 
Because this approach was quite new, no real literature precedents existed and it was 
decided to first validate this column. This could be achieved by testing the peptides 
described by Tozzi et al.51 For this reason, they were synthesised on the 2’-chlorotrityl 
resin via automated synthesis (Figure  IV.3). Serving as a ‘blank peptide’, the 
tetraglycine derivative V.13 was synthesised in a similar fashion. 
The retention times of the peptides were monitored via LC-MS. A flow of 0.2 
mL/min was applied under isocratic conditions. Buffered H2O at pH 7.4 was used as 
eluent. 
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Scheme  V.5: Synthesis of the different Tozzi peptides. 
It was expected from Table  II.1 that the Tozzi-hexapeptide V.16 should elute first 
followed by the Tozzi-octapeptide V.17 and then the Tozzi-tetrapeptide V.14. It must 
be noted that the differences in Kd values of the different peptides are small and the 
error margins were not taken into account.  
Figure  V.6 clearly shows that an increase in retention times is observed when the 
data of the Tozzi peptides are compared to the retention of the ‘blank’ tetraglycine 
derivative V.13. 
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The reversed order of elution (V.14 < V.16 < V.17 instead of V.16 < V.17 < V.14) 
probably can be ascribed to the poor difference in Kd values of the three peptides. 
Nevertheless, based on these results, it should be possible to recognise compounds with 
a certain affinity for estradiol. 
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Figure  V.6: Retention times of the different Tozzi peptides compared with the blank tetraglycine 
peptide. The retention times were monitored via LC-MS. 
V.2.3. Testing of the library via affinity LC 
The 120 members could easily be tested using the developed affinity method. For 
each member, a small sample (1 mg resin or less) was suspended in 100 µL H2O and 
irradiated at 360 nm for 3 h. After the photocleavage, the resin was washed with water 
and the resulting 400 µL was diluted 10 times before transferring it into a HPLC vial. 
These vials were collected in the rack of an auto sampler allowing a rapid screening of 
the 120 members. 
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Figure  V.7: Optimisation of the elution conditions for one library member. Retention time was 
monitored via LC-MS. 
 
Before the whole library was screened, the elution and detection parameters were 
optimised by injecting one member (Figure  V.7). Using the same isocratic conditions 
as for the screening of the Tozzi peptides, no signal was observed. The receptor 
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seemed-to be sticking to the estradiol column. In an attempt to disturb the hydrogen 
bonding, the pH was lowered to 3 but still no signal was observed. More drastic elution 
conditions were then applied by a gradient to 100 % MeOH. Changing the solvent from 
H2O to MeOH implied that the hydrophobic interactions were disturbed. This 
eventually led to the elution of the receptor. 
Excited by these preliminary results, a big increase in affinity compared to the Tozzi 
peptides was observed, the next step was taken by screening the whole library. Another 
‘blank’ molecule was prepared by attaching six glycine residues to construct IV.17 via 
automated synthesis to evaluate the effect of the scaffold.  
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Figure  V.8: Screening of the library. Retention times were monitored via LC-MS. 
The results obtained from these screening are shown in Figure  V.8. The first 
surprising fact is that blank peptide V.18 has a higher retention time than the Tozzi-
tetrapeptide V.14. This would mean that the tripodal scaffold, substituted with six 
glycines is a better receptor than the Tozzi peptide? In addition, there is no member of 
the library that really jumps out, all the receptors have a similar retention time and elute 
between 24.61 min and 25.53 min. 
When looking at these data, the excitement disappeared and made place for doubt. 
Questions rose about what really was happening on the column. The initial thought was 
that the receptors would form a complex with the silica-bound estradiol and depending 
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on the strength of this complex, a shift in retention time would be observed. However, it 
should be taken into account that a separation based on polarity is also possible. 
Certainly, a new stationary phase is formed when clicking the EE2 to the azido-
functionalised silica particles. According to our results, instead of an estradiol affinity 
column, this new phase can best be compared with a standard C18 phase but with 
different properties.  
These indecisive results made it necessary to design a new set of experiments to 
determine if the separation is based on polarity and/or affinity. 
V.2.4. Development of a norethindrone column 
The first alternative experiment that crossed our mind was the preparation of a new 
type of column, to which the receptors should have no or weak affinity. By clicking the 
progestron 19-norethindrone to azido-functionalised silica material (Scheme  V.6), a 
new non-estrogenic column was prepared. 
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Scheme  V.6: Preparation of a norethindrone column. 
The library was designed to show no or weak affinity towards non-estrogenic 
compounds, so low retention times should be obtained when injected over the 
norethindrone column. However, the same window in retention times was observed. In 
Figure  V.9 the example is shown for one library member. Of course, this could be due 
to a lack of selectivity. But when the Tozzi-tetrapeptide V.14 was injected, a similar 
retention time as on the estradiol column was observed. 
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Figure  V.9: Screening on the norethindrone column. Retention times were monitored via LC-MS. 
 
Confused by the fact that even the Tozzi-tetrapeptide V.14 failed to show any 
selectivity, alternative methods were explored to determine the exact nature of this 
chromatographic experiment. 
V.2.5. Competition experiments 
Assuming that the retention time of a library member is the consequence of a 
complex formation between the silica-bound-estradiol and the receptor, then this 
retention time should be influenced when there is less [estradiolsilica-receptor] complex. 
This can be achieved in the same experimental set up but now some estradiol has to be 
added to the eluent. Indeed, then a [estradiolsolution-receptor]-complex can be formed, 
complexing the receptor up in the eluent and consequently causing a decrease in 
retention time. 
No shift was however observed upon adding estradiol to the aqueous buffer. The 
poor solubility of estradiol in H2O limited the amount that could be added. Maby there 
was just not enough estradiol present in the eluent to be able to compete with the large 
amount of silica-bound-estradiol (loading ~ 0.6-0.7 mmol/g). These problems could be 
tackled if a new column was developed with a lower loading. 
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Scheme  V.7: Development of a new estradiol column with a lower loading. 
Next to lowering the loading of the new column, it was also decided to insert a 
spacer between estradiol and the triazole function to minimise possible effects of the 
triazole on complex formation. This was done by first deprotonating 1,7-octadiyne with 
nBuLi (Scheme  V.7).122 An excess of this carbon nucleophile was added to estrone 
yielding 53 % of the desired derivative V.20. It seemed impossible to separate the 
estradiol derivative V.20 from the starting compound, however, since estrone does not 
possess an alkyne function, separation between the two compounds was unnecessary. 
The loading of the aminopropylsilica was lowered by first coupling FmocGlyOH in 
the presence of 5 equivalents of AcOH, yielding a loading of only 0.066 mmol/g. After 
deprotection of the Fmoc group, the azido-hexanoic acid was coupled using PyBOP.  
Clicking again proceeded very smoothly as monitored by IR spectroscopy. After 
washing the silica thoroughly, the material was packed into an HPLC column. 
                                                        
122 Ali, H.; Ahmed, N.; Tessier, G.; van Lier, J. E. Bioorg. Med. Chem. Lett. 2006, 16, 317-319. 
Screening of the library 
 108 
Sadly enough, the new material appeared to possess too little estradiol to be able to 
retain our library members. A few compounds were tested and they all eluted with the 
solvent peak, showing little or no retention. Hence, further competition experiments 
were made impossible. 
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V.3. Reconsidering the SPE test 
Though the developed affinity LC method allowed a fast screening of the 
synthesised library while only a small sample of each compound was needed, it failed to 
deliver decisive results. It was not clear whether the obtained retention times could be 
related to a certain affinity for estradiol. In search of a second screening method that 
could evaluate these results, we looked back at the initial experiments in Chapter  V.1. 
There the problem was the high background EDC adsorbance by Tentagel. On the other 
hand, materials that showed less retention of the EDCs, could not be used due to 
practical drawbacks concerning the synthesis of the library on these materials. 
One way of dealing with this situation is by performing the synthesis on Tentagel 
and then transferring the members to an inert solid phase, like silica. In this way, the 
library members could be synthesised via the already established protocols on Tentagel, 
but their activity in an SPE cartridge could be tested on silica, bypassing any 
background absorption by the solid phase. 
V.3.1. General strategy 
Until now, a photocleavable linker was used to cleave the synthesised compounds 
from the beads. Photocleavage, however, yields a carboxamide that offers few 
possibilities for recoupling to another solid support (Figure  V.10). Consequently, 
recoupling to another solid phase like silica is impossible unless a new chemical 
functionality is introduced. This anchor moiety should not only ensure a smooth 
coupling but at the same time it has to be inert to the applied protocols for synthesising 
a library member. An extra requirement is that the ligation reaction has to be compatible 
with the unprotected side chain functionalities of the library members. 
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Figure  V.10: Photocleavage yields an unreactive carboxamide. 
All these stringent conditions are fulfilled when the CuI-catalysed cycloaddition 
between an azide and an alkyne is used. Since a protocol for the synthesis of azide-
functionalised silica was already established, the library members had to be equipped 
with an alkyne functionality. 
To test if the affinity LC method was able to identify the best receptor, two members 
of the library were scaled up for subsequent coupling to silica. From the affinity LC 
experiments, the member with the lowest and the member with the highest retention 
time were chosen (Figure  V.11). In this way, the data obtained from the affinity LC 
could be correlated to the SPE behaviour of our two compounds. In other words, library 
member V.25 should retain less EDCs than member V.24 when coupled to silica. 
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Figure  V.11: The ‘best’ and the ‘worst’ receptor as determined via affinity LC. 
To determine the effect of the tripodal scaffold on the efficiency of the receptors, a 
derivative of the ‘best’ receptor V.24 should be synthesised. In derivative V.26, the 
three benzylic cores are replaced by the side chains of a Lys residue. Any aromatic 
interaction is thus excluded, resulting in three peptide chains that are not spatially 
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constrained. By comparing the SPE results obtained with V.24 and V.26, the influence 
of the scaffold should become clear. 
To correctly interpret the data obtained with the SPE tests, an alkyne derivative of 
the Tozzi-tetrapeptide (V.27) should be synthesised. After clicking it to silica, the 
construct can serve as a calibration point for the SPE tests. 
V.3.1.1. Synthesis of V.24 and V.25: incorporating an alkyne via the Lys approach 
One way of incorporating an alkyne is by replacing the current spacer with a Lys 
residue. Indeed, the side chain of Lys can be regarded as a distancing arm while the α-
amine group can be used to couple pentynoic acid. 
Starting from Tentagel equipped with the photocleavable linker, first a 
FmocLys(Boc)OH residue was coupled (Scheme  V.8). After Fmoc deprotection of the 
α-amine, the alkyne moiety was introduced via coupling of pentynoic acid. This was 
followed by removing the Boc group with TFA, yielding a free ε-amine that could be 
used as anchoring point for the tripodal scaffold IV.1. 
After selectively capping the remaining free Lys- ε-amines with AcOH and PyBOP, 
the orthogonality scheme was adapted by coupling the Gly derivatives as their 
symmetrical anhydrides. Construct V.31 was then used as the starting point for the 
automated synthesis. Only the ‘best’ and the ‘worst’ members (as determined via 
affinity LC, vide supra) were synthesised. 
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Scheme  V.8: Synthesis of the alkyne modified receptors. 
Once the two receptors were prepared on bead, they still had to be cleaved from the 
resin. For this purpose, the resin was suspended in DCM and irradiated with light at λ = 
360 nm for 18 h. This was repeated five times in order to obtain yields as high as 
possible. After pooling the organic fractions, the solvent was removed in vacuo. 
Subsequently, the side chain protecting groups, including the oxidised Met, were 
deprotected with TFA and scavengers. 
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Figure  V.12: HPLC chromatogram of V.24 and V.25 after prep. HPLC. 
Finally the two receptors were purified by preparative reversed phase HPLC. At the 
end 4.2 mg (20 % yield) of the ‘best’ receptor V.24 and 3.5 mg (16 % yield) of the 
‘worst’ receptor V.25 were obtained in good purity (Figure  V.12) and their identity was 
confirmed by MALDI-TOF (Figure  V.13). 
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Figure  V.13: MALDI-TOF spectrum of V.24 and V.25 after prep. HPLC. 
V.3.1.2. Synthesis of V.26: the hydrazine linker approach 
A little bit disappointed by the yields obtained in Scheme  V.8, it was decided to 
develop a new route for the synthesis of the non-constrained V.26. Though the 
photocleavable linker is an excellent tool for monitoring reactions on solid phase, it 
becomes less efficient when an up-scaling is necessary, in view of the lower cleavage 
yields. 
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Figure  V.14: Hydrazine linker: principle of cleavage. 
To overcome this problem, a hydrazine linker was tested for the synthesis of V.36. 
As shown in Figure  V.14, the synthesised peptide can be cleaved from the resin after 
oxidation of the hydrazine.123 The obtained activated carbonyl reacts readily with a 
great variety of nucleophiles.124 In this way, not only can good cleavage yields be 
obtained but at the same time the desired alkyne moiety can be introduced if 
propargylamine is used as the nucleophile. 
 
                                                        
123 a) Millington, C. R.; Quarrell, R.; Lowe, G. Tetrahedron Lett. 1998, 39, 7201-7204. b) Stieber, F.; Grether, U.; 
Waldmann, H. Angew. Chem. Int. Ed. 1999, 38, 1073-1077. 
124 Woo, Y. H.; Mitchell, A. R.; Camarero, J. A. Int. .J. Pept. Res. Therap. 2007, 13, 181-190. 
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Scheme  V.9: Preparation of the non-constrained construct V.36. 
For the solid phase synthesis of V.36, a dual linker strategy was used (Scheme  V.9). 
Though the hydrazine linker was used for the quantitative cleavage from the resin, the 
photocleavable linker still was incorporated to allow fast reaction monitoring. 
Starting from construct IV.15, the hydrazine linker was introduced by coupling 
Fmoc-hydrazinobenzoic acid with PyBOP. Subsequently, a spacer arm was attached 
and next the first FmocLys(Boc)OH was coupled. After deprotection of the side chain, 
azidoglycine IV.31 could be coupled. Another FmocLys(Boc)OH was then coupled and 
when the Boc group of this side chain was removed, ivDdeGlyOH (IV.21) was coupled. 
The incorporation of the final FmocLys(Boc)OH was followed by Fmoc deprotection of 
the α-amine. This was first capped before the side chain was removed with TFA and 
FmocGlyOH could be finally coupled to give Tentagel-bound V.35. 
By implementing the photocleavable linker, a side reaction that occurred during the 
capping step (xv in Scheme  V.9) could be characterised. Indeed, MALDI-TOF analysis 
showed that mono- and especially di-acetylation of the hydrazine linker itself had 
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occurred during the capping step. This side reaction is mentioned in literature and future 
capping should proceed with the more sterically hindered pivalic anhydride.125 
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Scheme  V.10: Acetylation of the hydrazine linker. 
The oxidative cleavage can be carried out by using a one-step process with 
Cu(OAc)2 in the presence of a suitable nucleophile (method A), or in a two-step process 
with N-bromosuccinimide and subsequent addition of the nucleophile (method B). In 
both cases, the reactions are performed open to the air. Both procedures were examined 
(Scheme  V.11) and it was found that in the two cases, the hydrolysed side product 
V.26b was present. However, the two step process gave rise to a much more substantial 
amount of free carboxylic acid V.26b than the CuII mediated cleavage. This is probably 
due to the intermediate washing steps needed to remove the excess of NBS. 
 
                                                        
125 Peters, C.; Waldmann, H. J. Org. Chem. 2003, 68, 6053-6055. 
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Scheme  V.11: Optimising the cleavage conditions. 
Based on these results, method A was chosen for the cleavage of V.36. Though it is 
possible that the thioether of Met is oxidised during the cleavage and consequently 
consumes some of the CuII needed for the cleavage, this does not cause a problem 
because the CuI is re-oxidised by oxygen from the air. 
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Scheme  V.12: Cleavage, side chain deprotection and purification. 
After side chain deprotection and reduction of the Met(O), the peptide was purified 
by preparative reversed phase HPLC to give 0.9 mg (11 %) of the desired compound 
(Scheme  V.12). The identity of the compound was confirmed via MALDI-TOF 
analysis (Figure  V.15) but due to the low amount of obtained product, no HPLC 
analysis was performed to evaluate the purity. 
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Figure  V.15: MALDI-TOF spectrum of compound V.26. 
In conclusion, the at first sight promising hydrazine linker did not give a significant 
improvement in yield. Certain factors can be invoked for this ineffectiveness: a) 
capping and thus deactivation of the linker by Ac2O and b) hydrolysis of the oxidised 
linker during the cleavage. Nevertheless, the desired compound V.26 was obtained in a 
sufficient amount and purity for further ligation experiments. 
V.3.1.3. Synthesis of the Tozzi-tetrapeptide V.27 
The alkyne containing tetrapeptide V.27 could be synthesised via standard 
automated synthesis. The alkyne group was introduced in the final step by a manual 
capping of the sequence with pentynoic acid (Scheme  V.13). Cleavage with TFA and 
scavengers yielded peptide V.27 in a very good yield (92 %). 
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Scheme  V.13: Synthesis of tetrapeptide V.27. 
V.3.2. ‘Clicking’ of the alkyne derivatives to silica 
Scheme  V.14 shows the preparation of four different SPE materials based on a silica 
framework. Starting from azido-functionalised silica with a controlled loading of 0.110 
mmol/g, the four alkyne components were attached via the CuI-catalysed cycloaddition. 
The difficulty resided in the determination of the loading of the obtained materials, 
which is necessary for the correct interpretation of the results. 
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Scheme  V.14: ‘Clicking’ of the alkyne derivatives to silica. 
Only in the case of the alkyne Tozzi-tetrapeptide V.27 sufficient material was 
available to use an excess of alkyne. This resulted in a quantitative reaction as proved 
by a complete disappearance of the azide absorption in the IR spectrum. Consequently, 
a loading of 110 µmol/g was obtained. 
Because there was not enough material to use an excess of V.24 and V.25 in the 
‘click’ reaction, the corresponding loading values were determined with UV-
spectroscopy. First a UV calibration curve was determined at λ = 265 nm. Using this 
calibration curve, the concentration of the two receptors in the remaining solution could 
be determined after the reaction. In this way, an estimate of the amount of compound 
that was covalently linked to the silica material could be made. This resulted in a 
loading of ~ 40 µmol/g for V.40 and ~ 52 µmol/g for V.41.  
This approach could not be applied when V.26 was coupled to the silica material. 
Due to the presence of only one aromatic moiety (Phe), the absorbance at 254 nm was 
too weak to give accurate UV measurements. The calibration curve was thus recorded 
at 214 nm. However, the CuII and sodium ascorbate matrix of the reaction resulted in a 
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high background at this wavelength, making concentration determination via UV 
impossible. 
In an attempt to tackle this problem, the amount of catalyst added was raised (20 eq 
instead of 0.2 eq) and the mixture was shaken for 4 days. The reaction was followed by 
ESI and after 4 days, no signal of V.26 was observed anymore. From this, the 
conclusion was drawn that all of the starting alkyne component had reacted leading to a 
loading of ~ 24 µmol/g. 
V.4. Results of the SPE tests 
The different materials (V.40 → V.43) were tested by incubating them with an 
aqueous solution containing bisphenol-A (BPA), diethylstilbestrol (DES), estrone, 
estradiol (E2), ethinylestradiol (EE2) and testosterone (Tes). Testosterone, a non-
estrogenic compound, was added to test for possible selectivity of the SPE materials 
towards estrogenic compounds. After incubation, the concentrations of the different 
compounds in the solution were determined by LC-UV. From these values, the amount 
that was trapped on the SPE materials was calculated. For each material, the loading 
and the amount of tested material were taken into account. 
The properties of the synthesised materials were compared with OASIS. This 
commercial SPE cartridge is used universally in the clean-up of samples containing 
EDCs.126 
 
                                                        
126 Lopez de Alda, M. J.; Barcelo, D. J. Chromatogr. A 2001, 938, 145-153. 
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Figure  V.16: SPE results: silica (  ), V.40 (  ), 
V.41 (  ), V.42 (  ), V.43 (  ) and OASIS (  ). 
From Figure  V.16 it is clear that the materials loaded with the two receptors (V.40 
and V.41) show an increased affinity towards estrogenic compounds when compared to 
the unmodified silica. More surprising is that the receptors withhold the various EDCs 
better than the Tozzi-tetrapeptide compound V.43, which does not trap any compound 
what so ever. 
However, it is more likely that these effects are the result of non-specific 
interactions (Figure  V.17) and that there is no real complex formation between the 
receptors and the various ligands. Indeed, when looking at compound V.42 that lacks 
the scaffold but has the same amino acid build up as V.40, it is clear that there is no 
significant difference between the two materials. This is probably due to a combined 
effect of non-specific hydrogen and Van der Waals bonding between the estrogenic 
compounds and the amino acids of the compounds. 
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EDC
Solid-phase bound receptor  
Figure  V.17: non-specific interactions between EDCs and the solid-phase bound receptor. 
The fact that there is no selective complex formation between the receptors and the 
estrogenic compounds is confirmed by the amount of testosterone which is trapped. 
Though lower amounts of Tes are being retained, there is no big discrepancy between 
these values and those from BPA. 
From these data, it can be confirmed that the results obtained from the screening 
with the estradiol column (Paragraph  V.2) cannot be correlated with affinity properties 
of the tested library members. Whereas compound V.41 should retain the compounds to 
a lesser extent than compound V.40, Figure  V.16 shows that no significant difference, 
but rather a reversed trend is visible. 
Figure  V.16 above all raises questions about the effectiveness of the Tozzi-
tetrapeptide. Compound V.43 does not show any affinity towards the tested compounds, 
although with the published Kd of 17 µM a different trend was expected. In retrospect, 
until now the published Tozzi peptides have served as a calibration point to assess the 
observed affinities towards estrogenic compounds, but the data for V.43, indicate that 
properties of the Tozzi peptides are not reproducible.  
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Figure  V.18: SPE of hospital water spiked with EDCs. 
Tested materials: V.41 (  ) and OASIS (  ). 
 In a last experiment, the potential of V.41 to extract EDCs from a more complex 
matrix was compared to OASIS. In this experiment, a sample from the waste water of 
the UZ hospital in Ghent was spiked with the EDC mixture and then sent over the two 
SPE materials. Maybe now an increased efficiency towards OASIS could be obtained, 
but it is clear from Figure  V.18 that OASIS is still performing better. Nevertheless, the 
ability of V.41 to extract EDCs from a more complicated matrix remain unchanged 
when compared to data of Figure  V.16 obtained in deionised water. 
 
V.5. Conclusion 
This chapter dealt with the difficult task of screening the synthesised library of 120 
members towards affinity for various estrogenic compounds. 
In a first attempt, the solid-phase bound members were treated as small SPE 
cartridges but the high background absorption of Tentagel made this approach not 
meaningful. A different material was sought that was compatible with the developed 
synthesis protocols and at the same time showed no affinity towards EDCs. However, it 
appeared that a suitable solid support combining these two properties could not be 
found. 
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Figure  V.19: Affinity LC approach. 
A completely different approach was then investegated by using an affinity LC 
based method (Figure  V.19). For this purpose, ethinylestradiol was ‘clicked’ to silica 
and from this material a HPLC column was packed. Though first results looked 
promising, screening of the library did not yield decisive results. 
The selectivity of the library was tested by screening it via a second, non estrogenic 
norethindron column. The data obtained however, were similar as with the EE2 column 
indicating that the difference in retention times may not be due to a difference in 
affinity but to a difference in polarity. In other words, instead of an affinity column, a 
new type of reversed phase material was developed. 
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Figure  V.20: SPE approach. 
These preliminary conclusions were confirmed by another set of experiments where 
two receptors, V.24 and V.25 were scaled up and ‘clicked’ to silica. These materials 
could now be used as SPE cartridges (Figure  V.20). Incubation with a mixture of EDCs 
showed that there was no significant difference between the two members, on the 
contrary, a slight opposite trend was observed. 
To conclude, it can be said that though materials have been made which can retain 
EDCs from an aqueous mixture, a comparison with known SPE cartridges like OASIS 
shows that the amounts trapped are not sufficient to justify their use as a clean-up 
procedure before actual chemical analysis. 
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VI. Considering the chirality of the scaffold 
The skeleton of the tripodal scaffold IV.1 inherently possesses a chiral quaternary 
centre at the foot of the carboxylic acid (Figure  VI.1). This implies that at the stage of 
IV.1, a racemic mixture is generated. Consequently, two diastereomers are formed by 
building in a chiral amino acid. As a result, the generated library consists of 240 
members instead of 120 members. 
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Figure  VI.1: Chirality issues. 
The impact of the chiral quaternary centre on the 3D structure of the overall 
molecule was assessed via modelling. The modelling was performed by ir. J. Goeman 
in the Laboratorium of Organic and Bio-organic synthesis of Prof. Dr. J. Vandereycken. 
The conformations of the two diastereomers of VI.1 were optimised in water via the 
OPLS-AA force field, part of the Macro Model V.6 software. 
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Figure  VI.2: Conformational analysis of VI.1 in water. 
The structures of the two epimers in Figure  VI.2 clearly show that the chirality of 
the quaternary centre has a significant impact on the conformational behaviour of the 
chains. With VI.1-S, the three aromatic cores are in close contact with each other, 
leaving no free space in between them. With VI.1-R on the other hand, the three 
aromatic moieties create a space that is filled by an amino acid (Glu) from the peptide 
chains. In the structure of the S epimer, this Glu is floating next to the aromatic cores. 
The fact that the two epimers have a distinct different conformation can have the 
following consequences: 
- Only one of the two diastereomers shows affinity. 
- The two both show affinity resulting in a synergetic effect. 
- None of the two epimers show any affinity. 
When the affinity is tested with the SPE approach, no differentiation between the 
two epimers can be seen. The observed affinity is the overall affinity. With the affinity 
LC approach however, it should be possible to separate the two epimers if there is a 
difference in affinity. This effect was not observed. 
Chapter  VI 
 131
When designing a tripodal scaffold, it is difficult to bypass the chirality problem and 
make an enantiomerically pure compound. Designing an enantiomerically pure version 
of the scaffold would require quite some extra effort. Therefore, the obtained data and 
results should be looked at with great care, keeping in mind that two different sets of 
compounds are made and that this can (or cannot) have a significant effect on the 
obtained results. 
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VII. General conclusions 
The first goal of this PhD to find a protocol to synthesise possible hER mimics, was 
accomplished by starting with the synthesis of tripodal scaffold IV.1. Derived from 
simple commercial building blocks, the tripodal scaffold IV.1 was synthesised in gram 
quantities (Scheme  VII.1). Acetaldehyde and acrylonitrile were used to generate the 
triamine backbone IV.2. The differently protected arms were synthesised from p-
aminobenzoic acid and subsequently activated as their PFF-esters. After coupling the 
active esters to the triamine backbone, the silyl ether was deprotected and the resulting 
alcohol oxidised to give the desired tripodal scaffold IV.1. 
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Scheme  VII.1: Synthesis of tripodal scaffold IV.1. 
Once IV.1 was synthesised, the synthetic protocols for the solid-phase synthesis of 
the library had to be established (Scheme  VII.2). First, coupling of IV.1 to Tentagel 
was optimised to such an extent that only 1.5 equivalents of scaffold were consumed. 
Next, the weak nucleophilicity of the aromatic amines was bypassed by coupling 
glycines as their symmetrical anhydrides. In the same time the whole orthogonality 
scheme was reconsidered by replacing the Boc and the Alloc group with the ivDde and 
azide group respectively. This new strategy enabled the fully automated synthesis of 
120 library members in a short period of time. The incorporated amino acids were 
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chosen based upon the X-ray structures of the hER complexed with various ligands. 
During the synthesis however, the thioether of Met was oxidised, but this problem could 
be solved during the acidic side chain deprotection. After analysis, it was proven by LC 
and MS techniques that the overall quality of the synthesised library was very good. 
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Scheme  VII.2: Solid-phase synthesis of the library. 
The second goal of selecting the most active receptor proved to be more difficult. 
Due to the high background adsorbance of Tentagel, it was impossible to use the resin-
bound members directly as a SPE cartridge. An alternative was investigated by 
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‘clicking’ EE2 to azido functionalised silica material. This material was used to pack an 
HPLC column. By passing the different members separately over this column, the 
retention times were monitored (Scheme  VII.3). These retention times were compared 
with the ones obtained in a similar experiment but with a non-estrogenic compound, 
norethindrone, ‘clicked’ to silica. However, from these experiments, no clear 
connection between the retention behaviour of the different library members and the 
possible affinity towards estradiol could be established. 
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Scheme  VII.3: Affinity LC approach. 
In order to evaluate the results from the affinity LC, the ‘best’ and the ‘worst’ 
receptor as determined by affinity LC were provided with an alkyne moiety and scaled 
up. In the same manner, a compound with the same AA content but without the scaffold 
and a derivative of the Tozzi-tetrapeptide were prepared. Though the scaling-up process 
was hindered by the low yield obtained with the photocleavable and the hydrazine 
linker, the different alkyne substituted compounds were obtained in sufficient amount 
and purity to be ‘clicked’ to silica (Scheme  VII.4).  
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Scheme  VII.4: SPE approach. 
The obtained SPE materials were subsequently tested by incubating them with an 
aqueous mixture of EDCs. From the results depicted in Figure  VII.1, it can be seen that 
the results obtained with the affinity LC method do not correlate with any kind of 
affinity towards EDCs. The ‘best’ and the ‘worst’ receptor V.40 and V.41 show a 
similar affinity towards most EDCs and it even can be said that a reversed trend is 
visible. 
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Figure  VII.1: SPE results: silica (  ), V.40 (  ), 
V.41 (  ), V.42 (  ), V.43 (  ) and OASIS (  ). 
Nevertheless, an increase in affinity towards EDCs is obtained when compared with 
unmodified silica and even when compared with Tozzi-tetrapeptide modified silica 
V.43. 
However, the observed affinity does probably not stem from a complex formation 
between the receptors and the estrogenic compounds and is more likely the result of 
non-specific interactions. Indeed, when looking at compound V.42 that lacks the 
scaffold but has the same amino acid build up than V.40, it is clear that there is no 
significant difference between the two materials. Also the fact that the amount of 
trapped testosterone is similar to the amounts of trapped BPA, indicate that the different 
receptor mimics do not entangle the compounds. The compounds rather stick randomly 
to the modified silica surfaces (Figure  VII.2). 
Finally, the new materials were compared to commercial SPE systems, like OASIS, 
which are known to possess good enrichment qualities for various EDCs. This material 
withholds more than 90 % of all the EDCs making it a valuable tool in solid-phase 
extraction. The newly developed materials V.40 and V.41 clearly do not possess the 
same qualities as the OASIS cartridge as only up to 35 % is retained in the case of DES.  
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EDC
Solid-phase bound receptor  
Figure  VII.2: non-specific interactions between EDCs and the solid-phase bound receptor. 
To conclude, it can be said that though materials have been made that can withhold 
EDCs from an aqueous mixture, a comparison with known SPE cartridges like OASIS 
show that the amounts trapped are not sufficient to justify their use as a clean-up 
procedure before actual chemical analysis. 
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VIII. Experimental part 
VIII.1. Methods and materials 
Methods: All solution phase reactions were conducted under an inert atmosphere of 
argon gas in oven dried glassware. The reactions were monitored by thin layer 
chromatography (TLC) using SIL G-25 UV254 pre-coated silicagel plates (0.25 mm 
thickness). The TLC plates were visualized using an anisaldehyde (5% anisaldehyde in 
ethanol with 1% sulfuric acid) or a PMA (5% phosphomolybdic acid in ethanol) 
solution. Flash column chromatography was performed using BIOSOLVE silica gel 
(0.063-0.200 mm particle size).  
Peptide synthesis: All solid phase reactions on 20 mg resin or less were performed 
in polypropylene Chromabond columns of 1 mL with a polyethylene frit, closed at the 
bottom with a B7 septum from Aldrich. Solid phase reactions on a bigger scale were 
performed in a peptide vessel protected against light with aluminium foil and 
comprising a sintered glass funnel and a 3-way stopcock for easy filtration and washing. 
The solid phase reactions were performed on a shaker (Selecta Vibromatic) or on a 
Yellow Line TTS 2 vortexer. Automated peptide syntheses were performed on a 24 
reactor block SYRO Multiple Peptide Synthesiser equipped with a vortexing unit (from 
Multisyntech, Witten, Germany). Aqueous peptide solutions were lyophilised using a 
Heto Drywinner lyophiliser connected to a Thermoelectron corporation Savant 
SPD111V Speedvac concentrator (Milford, MA, USA). 
Analysis: NMR spectra were recorded at 500 MHz or 300 MHz for proton and at 
125 MHz or 75 MHz for carbon nuclei in chloroform-d, DMSO-d6, MeOD-d4 or 
aceton-d6. Chemical shifts are reported in units of parts per million (ppm), referenced 
relative to the residual 1H or 13C peaks of the used solvent as internal standards 
(chloroform-d: 1H 7.26 and 13C 77.16; DMSO-d6: 1H 2.50 and 13C 39.52; MeOD-d4: 1H 
3.31 and 13C 49.00; aceton-d6: 1H 2.05 and 13C 29.84 and 206.26). The following 
abbreviations were used to explain the multiplicities: s, singlet; d, doublet; t, triplet; q, 
quadruplet; m, multiplet; br, broadened. 
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Infrared spectra (IR) were recorded on a PERKIN-ELMER 1600 series FTIR 
spectrometer and reported in wave numbers (cm-1). Samples were prepared as a thin 
film (neat) on KBr plate or used directly with the Horizontal Attenuated Total 
Reflection (HATR) adaptor. 
Elemental analyses were performed by SIARE at the Université Pierre & Marie 
Curie, Paris, France.  
High-Resolution Mass Spectra (HRMS) were recorded by Amberlab at Ghent 
University on a Thermo Finnigan MAT95XP-Trap tandem mass spectrometer or by the 
Rega institute at the University of Leuven on a ThermoFinnigan LCQ MSn ion trap. 
Low Resolution Mass Spectra Mass Spectra were recorded with LCQ MS (Thermo 
Finnigan, San Jose, CA, USA) equipped with an electrospray ionisation source.   
MALDI-TOF spectra were recorded on an Applied Biosystems Voyager-DE STR 
Biospectrometry Workstation. For the sample preparation, a mixture of 2,5-
dihydrobenzoic acid and TFA was used as the matrix. 
LC-MS data were obtained on an Agilent 1100 series instrument with a Phenomenex 
Luna C18(2) column (250x 4.6 mm, 5 µm at 35 °C) and an ES-MSD type VL mass 
detector using the following systems: 5 mM NH4OAc in H2O (A) and MeCN (B). 
Unless otherwise stated the column was flushed for 2 min with 100% A, then a gradient 
from 0 to 100% B over 15 min was used, followed by 5 min of flushing with 100% B. 
HPLC analyses were performed on an Agilent 1100 Series instrument with a 
Phenomenex Luna C18(2) column (250 x 4.6 mm, 5µ at 35 °C) using a flow rate of 1 
ml/min and with the following solvent systems: 0.1% TFA in H2O (A) and MeCN (B). 
Unless otherwise stated the column was flushed for 3 min with 100% A, then a gradient 
from 0 to 100% B over 15 min was used, followed by 5 min of flushing with 100% B. 
UV-spectra were recorded on a Varian Cary 300 Bio UV-VIS spectrophotometer. 
Photolyses were carried out with a 4W Bioblock Scientific compact UV lamp set at 
365 nm.  
Melting point ranges were determined with an Electrothermal 9100 melting point 
apparatus. 
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Materials. All chemicals were purchased from Sigma Aldrich or Acros except the 
amino acids that were bought at IRIS Biotech GmbH. Tentagel-S-NH2 was purchased 
from NovaBiochem. Extra dry DMF was purchased from Acros. DMF peptide grade 
was purchased from Biosolve. All chemicals were purchased and used without any 
further purification, except tetrahydrofuran (THF), which was distilled from 
Na/benzophenone prior to use and dichloromethane, which was distilled from CaH2. 
VIII.2. Synthesis of the Tripodal Scaffold IV.1 
VIII.2.1. Synthesis of the triamine core IV.2 
VIII.2.1.1. Protection of the alcohol IV.7 
 
i) TBSCl 
DMAP, Et3N
    
CH2Cl2, 84%
N
N
N
OH
IV.7
N
N
N
OTBMS
IV.8
 
 
In a dry flask of 25 ml, 865 mg (4.21 mmol, 1eq.) of IV.7 is dissolved in dry 
dichloromethane. To this solution tert-butyldimethylsilyl chloride (0.699 g, 4.64 mmol, 
1.1 eq.), 4-dimethylaminopyridine (0.514 g, 4.21 mmol, 1 eq.) and triethylamine (587 
µl, 4.21 mmol, 1 eq.) are added. The solution is refluxed overnight. Afterwards, the 
solution is poured into a separating funnel and washed three times with a saturated 
sodium chloride solution and further three times with a 1M hydrochloric acid solution. 
The organic phase is dried on magnesium sulfate, filtered off and evaporated under 
reduced pressure providing 1.130 g (80%) of IV.8 as white crystals. 
 
Molecular Formula: C17H29N3OSi  MW.: 319.52 g/mol  
RF. (DCM:MeOH 9:1): 0.28           Melting Point: 72-73 °C 
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IR. (KBr-plate): 2952 (m), 2927 (m), 2882 (m), 2857 (m), 2248 (m), 1466 (m), 1450 
(m), 1424 (m), 1374 (w), 1297 (w), 1262 (m), 1132 (m), 1102 (s), 1084 (s), 1006 (w), 
940 (w), 858 (s), 840 (s), 782 (m), 748 (w), 674 (m) cm-1. 
ES. (m/z): 337.2 [M+NH4]+ 
1H-NMR (500 MHz, CDCl3): δ 3.40 (2H, s), 2.36 (6H, t, J = 7.9 Hz), 1.73 (6H, t, J = 
7.9 Hz), 0.90 (9H, s), 0.08 (6H, s) ppm. 
13C-NMR + APT (75 MHz, CDCl3): δ 119.06 (C), 65.87 (CH2), 39.84 (C), 29.50 
(CH2), 25.73 (CH3), 18.01 (C), 11.81 (CH2), -5.73 (CH3) ppm. 
 
VIII.2.1.2. Reduction of the nitriles 
 
ii) H4N2.H2O
preact. RaNi, NaOH
EtOH/H2O, 
86%
N
N
N
OTBMS
IV.8
H2N
NH2
NH2
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In a two necked flask of 500 ml, 4 (22.0 g, 68.9 mmol) was dissolved in 250 ml of 
pure ethanol and 13.2 ml of water. To this mixture, NaOH (10.6 g, 26.0 mmol) was 
added, after which the mixture was cooled down to 0°C. After stirring for half an hour, 
hydrazine monohydrate (26.4 ml, 544 mmol) was added. In the meantime a Raney 
Nickel-slurry (6.2 g, 53 mmol, Merck, 50% active catalyst in water) was washed 
thoroughly with water and pure ethanol in a little flask. This suspension was added to 
the reaction mixture over a period of 2 h, after which the solution was allowed to warm 
up to rT. After 1 h of stirring, the reaction mixture was refluxed during 2 h. The 
reaction mixture was filtered off over celite and the filtrate was concentrated under 
reduced pressure. Toluene was added to the residue to precipitate the NaOH. The base 
was filltered off and the filtrate was evaporated under reduced pressure. This action was 
repeated until no more precipitation was formed. A light yellow oil was obtained (19.6 
g, 59.2 mmol, 86%). 
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Molecular Formula: C17H41N3OSi MW.: 331.61 g/mol 
RF. (MeOH/NH3): 0.30   Melting Point: 72-73 °C 
IR. (KBr-plate): 3358 (s), 2929 (s), 28571568 (m), 1472 (m), 1386 (w), 1328 (m), 1252 
(w), 1098 (m), 1006 (w), 836 (m), 774 (m), 739 (w), 668 (w) cm-1. 
ES. (m/z): 332.3 [M+H]+ 
1H-NMR (300 MHz, CDCl3): δ 3.12 (s, 2H), 3.10 (br. s, 6H), 2.64 (t, J = 6.8 Hz, 6H), 
1.34 (m, 6H), 1.15 (m, 6H), 0.84 (s, 9H), 0.03 (s, 6H) ppm. 
13C-NMR + APT (75 MHz, CDCl3): δ 66.4 (CH2), 43.0 (CH2), 39.3 (C), 31.1 (CH2), 
27.4 (CH2), 25.8 (CH3), 18.1 (C), -5.7 (CH3) ppm. 
VIII.2.2. Synthesis of the arms 
VIII.2.2.1. Boc-protection of p-aminobenzoic acid 
 
O
OH
H2N
(Boc)2O, Et3N
THF/H2O, 94%
IV.9a
O
OH
NH
O
O
 
 
In a flask of 1 L, 4-aminobenzoïc acid (17.5 g, 0.128 mol, 1eq) was dissolved in 153 
mL water and 306 mL dioxane. The Et3N (36 mL, 0.256 mol, 2 eq) was then added 
followed by the addition of di-tert-butyl dicarbonate (56.0 g, 0.256 mol, 2 eq). After 
stirring for 24 h the solution was evaporated under reduced pressure. Subsequently, a 3 
N HCl solution was added drop wise until there was no more precipitate formed. 
Finally, the white powder was filtered off and dried over P2O5 under vacuum (28.5 g, 
94 %) 
 
Molecular Formula: C12H15NO4 MW.: 237.25 g/mol 
RF. (DCM:MeOH 1:1): 0.45  Melting point: 198–200 °C 
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IR. (KBr-plate): 3366 (m), 1705 (s), 1678(s), 1609 (m), 1524 (s), 1506 (m), 1409 (w), 
1366 (w), 1311 (w), 1285 (w), 1234 (m), 1160 (s), 1056 (w), 941 (w), 839 (w), 801 (w), 
774 (w), 694 (w), 644 (w) cm-1. 
ES. (m/z): 236.2 [M-H]- 
1H-NMR (500 MHz, DMSO-d6): δ 9.71 (1H, br. s), 7.84 (2H, ddd, J = 9.5/2.3/1.9 Hz), 
7.75 (2H, ddd, J = 9.5/2.4/2.0 Hz), 1.49 (9H, s) ppm. 
13C-APT  (75 MHz, DMSO-d6): δ 167.0 (C), 125.5 (C), 143.7 (C), 130.3 (CH), 124.0 
(C), 117.2 (CH), 79.6 (C), 28.0 (CH3 ) ppm. 
VIII.2.2.2. Activation of IV.9a 
 
BocHN
O
OH
BocHN
O
OPFF
PFF, DCC, DMAP
THF, molcular sieves
0°C    rt, 18 h, 82%IV.9a IV.9  
 
To a solution of IV.9a (10.0 g, 42.0 mmol) in THF (65 mL) was added 
pentafluorophenol (9.37 g, 50.4 mmol), DMAP (260 mg, 2.11 mmol) and molecular 
sieves. After stirring the solution for 10 min at 0 °C the coupling reagent DCC (10.5 g, 
50.4 mmol) was added and the ice-bath was allowed to warm up at rT. After 18 h the 
reaction mixture was filtered off and the filtrate was concentrated under reduced 
pressure. The resulting orange precipitate was chromatographed with pentane/ DCM 
(1:1) to give IV.9 (13.9 g, 82%) as a white powder. 
 
Molecular Formula: C18H14F5NO4 MW.: 403.30 g/mol 
RF. (DCM): 0.64   Melting Point: 124-126°C 
IR. (KBr-plaatjes): 3355 (w), 2983 (w), 2936 (w), 1758 (m), 1736 (m), 1607 (m), 1592 
(m), 1521 (s), 1414 (m), 1370 (w), 1320 (w), 1256 (s), 1236 (s), 1145 (s), 1046 (s), 
1011 (s), 996 (m), 901 (w), 853 (w), 758 (w), 615 (w) cm-1 
E.S. (m/z): 402.7 [M-H]- 
CH-Analysis: calculated: C (53.61%), H (3.50%), N (3.47%) 
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       found:  C (53.71%), H (3.67%), N (3.30%) 
1H-NMR (500 MHz, CDCl3): δ 8.12 (2H, ddd, J = 8.4/2.4/1.8 Hz), 7.54 (2H, ddd, J = 
9.3/2.3/1.9 Hz), 6.77 (1H, br. s), 1.52 (9H, s) ppm. 
13C-APT  (75 MHz, CDCl3): δ 162.1 (C), 151.9 (C), 144.4 (C), 132.2 (CH), 120.7 (C), 
117.6 (CH), 81.7 (C), 28.2 (CH3) ppm. 
VIII.2.2.3. Alloc protection of p-aminobenzoic acid 
 
IV.10a
dioxane, H2O, rT, 24 h, 83%
H2N
O
OH
AllocHN
O
OH
DIEA, NaHCO3
O O
Cl
 
 
In a 2 L flask, 4-aminobenzoic acid (1 g, 7.29 mmol) was dissolved in 10 mL of 
dioxane and 10 mL of water. DIEA (2.6 mL, 14.9 mmol) and NaHCO3 (1.8 g, 21.8 
mmol) were added. Finally, allyl chloroformate (0.78 mL, 7.33 mmol) was added and 
the reaction is stirred overnight. A 1N HCl solution was added drop wise until there was 
no more precipitate forming. The white powder was filtered off and dried over P2O5 
under reduced pressure to provide IV.10a (1.35 g, 83%). 
 
Molecular Formula: C11H11NO4 MW.: 221.21 g/mol 
RF. (DCM:MeOH 1:1): 0.45  Melting Point: 199-201 °C 
IR. (KBr-plate): 3334 (w), 1702 (w), 1685 (m), 1600 (m), 1532 (m), 1425 (w), 1411 
(w),1315 (m), 1230 (s), 1175 (m), 1132 (w), 1055 (m), 985 (w), 938 (w), 856 (w), 771 
(w), 694 (w), 590 (w) cm-1. 
E.S. (m/z): 220.2 [M-H]- 
CH analysis:  calculated:  C (59.73%), H (5.01%), N (6.33%) 
  found:   C (59.43%), H (4.95%), N (6.58%) 
1H-NMR (500 MHz, DMSO-d6): δ 10.07 (1H, br. s), 7.83 (2H, ddd, J = 9.3/2.3/1.8 Hz), 
7.74 (2H, ddd, J = 9.3/2.3/1.9 Hz), 5.95 (1H, ddt, J = 17.3/10.5/5.5 Hz), 5.35 (1H, ddd, 
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J = 17.3/3.3/1.6), 5.21 (1H, ddd, J = 10.4/2.9/1.3 Hz), 4.58 (2H, ddd, J = 5.5/1.3/1.3 
Hz) ppm. 
13C-APT  (50 MHz, aceton-d6): δ 167.3 (C), 153.9 (C), 144.5 (C), 133.9 (CH), 131.6 
(CH), 125.3 (C), 118.3 (CH), 117.9 (CH2), 66.0 (CH2) ppm. 
VIII.2.2.4. Activation of IV.10a 
 
IV.10a
AllocHN
O
OH
AllocHN
O
OPFF
PFF, DCC, DMAP
THF, molecular sieves, 0°C    rt, 
18 h, 83% IV.10  
 
To a solution of IV.10a (19.2 g, 83.6 mmol) in THF (225 mL) was added 
pentafluorophenol (19.2 g, 104.5 mmol), DMAP (480 mg, 3.93 mmol) and molecular 
sieves. After stirring the solution for 10 min at 0 °C the coupling reagent DCC (21.6 g, 
104.5 mmol) was added and the ice-bath is allowed to melt. After 18 h the reaction 
mixture was filtered off and the filtrate was concentrated under reduced pressure. The 
resulting powder was chromatographed with pentane/EtOAc (9:1) to give 7 (26.8 g, 
83%) as a white powder. 
 
Molecular Formula: C17H10F5NO4 MW.: 387.26 g/mol 
RF. (DCM): 0.64   Melting Point: 138°C 
IR. (KBr-plate): 1759 (w), 1596 (w), 1522 (s), 1414 (s), 1314 (w), 1255 (m), 1214 (m), 
1178 (m), 1143 (w), 1046 (s), 1002 (m), 850 (w), 806 (m), 702 (s), 573 (w), 503 (w) 
cm-1 
E.S. (m/z): 386.1 [M-H]- 
C.H. Analysis: calculated: C (52.73%), H (2.60%), N (3.62%) 
    found:  C (52.65%), H (2.78%), N (3.45%) 
1H-NMR (500 MHz, CDCl3) δ 8.17 (2H, ddd, J = 9.4/2.4/2.0 Hz), 7.75 (2H, ddd, J = 
9.4/2.4/2.0 Hz), 5.97 (1H, ddt, J = 17.3/10.5/5.7 Hz), 5.40 (2H, ddd, J = 17.1/2.9/1.5), 
5.30 (2H, ddd, J = 10.4/2.4/1.2 Hz), 4.70 (2H, ddd, J = 5.9/1.3/1.3 Hz) ppm. 
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13C-APT (75 MHz, CDCl3): δ 162.1 (C), 152.6 (C), 143.9 (C), 132.3 (CH), 131.9 (CH), 
121.3 (C), 118.3 (CH2), 117.9 (CH), 66.4 (CH2) ppm. 
VIII.2.2.5. Fmoc protection of p-aminobenzoic acid 
 
IV.11a
dioxane, H2O, rT, 48 h, 96%
H2N
O
OH
O O N
O
O
O
, NaHCO3
FmocHN
O
OH
 
 
In a 5 L flask, 4-aminobenzoic acid (40.7 g, 0.297 mol) was dissolved in 810 mL 
water. NaHCO3 (68.0 g, 0.809 mol) was then added, followed by the addition of 810 
mL of dioxane and FmocOSu (100 g, 0.297 mol). After stirring for 4 h, 400 mL water 
was added. The solution was stirred for another 44 h and was then acidified with 1N 
HCl solution until pH 3 was reached. The white precipitate was filtered off an dried 
over P2O5 under vacuum (102.9 g, 96%). 
 
Molecular Formula: C22H17NO4 MW.: 359.37 g/mol 
RF. (DCM): 0.43   Melting Point: 276-278 °C 
I.R. (KBr-plate): 3342 (w), 1711 (s), 1678 (m), 1608 (w), 1590 (w), 1529 (s), 1443 (w), 
1408 (w), 1378 (w), 1308 (m), 1279 (m), 1238 (s),1179 (w), 1108 (w), 1085 (w), 1054 
(m), 979 (w), 850 (w), 812 (w), 739 (s), 691 (w), 544 (w), 450 (w) cm-1. 
ES. (m/z): 358.5 [M-H]-, 717 [2M-H]- 
CH analysis:  calculated:  C (73.53%), H (4.77%), N (3.90%) 
  found:   C (73.40%), H (4.93%), N (3.93%) 
1H-NMR + COSY (500 MHz, DMSO-d6): δ 10.0 (1H, br. s), 7.91 (2H, d, J = 7.5 Hz), 
7.84 (2H, d, J = 8.1 Hz), 7.75 (2H, d, J = 7.5 Hz), 7.54 (2H, br. s), 7.43 (2H, dd, J = 
7.4/7.4 Hz)), 7.35 (2H, ddd, J = 7.4/7.4/0.9 Hz), 4.53 (2H, d, J = 6.4 Hz), 4.33 (1H, t, J 
= 6.4 Hz) ppm. 
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13C-APT + HSQC + HMBC (75 MHz, DMSO-d6): δ 166.9 (C), 153.2 (C), 143.7 (C), 
143.2 (C), 140.8 (C), 130.4 (CH), 127.7 (CH), 127.2 (CH), 125.2 (CH), 125.1 (C), 
120.2 (CH), 117.4 (CH), 65.8 (CH2), 46.5 (CH) ppm. 
VIII.2.2.6. Activation of IV.11a 
 
IV.11a
FmocHN
O
OH
FmocHN
O
OPFF
PFF, DCC, DMAP
THF, molecular sieves
0°C    rt, 18 h, 74% IV.11
 
 
To a solution of IV.11a (10.0 g, 27.8 mmol, 1 eq) in THF (45 mL) was added 
pentafluorophenol (7.23 g, 38.9 mmol), DMAP (173 mg, 1.40 mmol) and molecular 
sieves. After stirring the solution for 10 min at 0 °C, the coupling reagent DCC (8.11 g, 
38.9 mmol) was added and the ice-bath was allowed warm until rT. After 18 h the 
reaction mixture was filtered off and the filtrate was concentrated under reduced 
pressure. The resulting light-yellow precipitate was recrystallised in EtOAc. Then the 
precipitate was taken into THF and refluxed. When everything was dissolved, the 
solution was slowly cooled in an ice-bath. The white precipitate was filtered off and the 
filtrate was evaporated to give IV.11 (10.8 g, 74%) as a white powder. 
 
Molecular Formula: C28H16F5NO4 MW.: 525.42 g/mol 
R.F. (DCM): 0.59   Melting Point: 195 °C 
IR. (KBr-plate): 3343 (w), 1755 (m), 1708 (m), 1593 (w), 1525 (s), 1451 (w), 1414 (w), 
1310 (w), 1265 (w), 1242 (w), 1223 (m), 1178 (w), 1090 (w), 1062 (m), 995 (m), 848 
(w), 757 (w), 737 (m), 702 (w), 645 (w), 507 (w) cm-1 
E.S. (m/z): 590.4 [M+MeCN+Na]+ 
1H-NMR (500 MHz, CDCl3): δ 8.14 (2H, ddd, J = 8.8/2.4/1.8 Hz), 7.80 (2H, d, J = 7.5 
Hz), 7.63 (2H, d, J = 7.5 Hz), 7.55 (2H, d, J = 8.6), 7.44 (2H, dd, J = 7.2/7.2 Hz), 7.35 
(2H, ddd, J = 7.5/7.5/1.1 Hz), 6.90 (1H, s), 4.62 (2H, d, J = 6.4 Hz), 4.28 (1H, t, J = 6.4 
Hz) ppm. 
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13C-APT + HSQC + HMBC (75 MHz, CDCl3): δ 162.1 (C), 152.8 (C), 143.7 (C), 
143.5 (C), 141.4 (C), 132.3 (CH), 128.0 (CH), 127.2 (CH), 124.8 (CH), 121.3 (C), 
120.2 (CH), 117.9 (CH), 67.2 (CH2), 47.0 (CH) ppm. 
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VIII.2.3. Coupling of the arms to the triamine core 
VIII.2.3.1. Attachment of the first Boc protected arm 
 
NH
H2N
O NH2
OTBS
NHBoc
 IV.9, Et3N
IV.123.2 eq IV.2
NH2
H2N
NH2
OTBS
DCM, Et3N, mol.sieves
18 h, 55%
 
 
To a solution of IV.2 (11.182 g, 33.7, 3.2 eq mmol) in DCM (70 mL) was added 
Et3N (1.475 mL, 10.5 mmol, 1 eq) and molecular sieves. To the resulting mixture, a 
solution of the activated ester 6 (4.247 g, 10.5 mmol, 1 eq) in DCM (60 mL) was slowly 
added via the syringe pump over a period of 8 h. The solution was then stirred overnight 
and afterwards concentrated under reduced pressure. The residual oil was 
chromatographed with gradiënt elution where the amount of MeOH(NH3) in DCM was 
varied from 5% to 25%. The desired diamine IV.12 was obtained as a light-yellow 
foam (3.182 g, 55%). At the end the column was washed with pure MeOH(NH3) to 
recover the excess starting material (6.512 g or 55%). 
 
Molecular Formula: C29H54N4O4Si MW.: 550.85 g/mol 
RF. (DCM:MeOH/NH3 9:1): 0.28 Melting Point: 67-68 °C 
IR. (KBr-plaatjes): 3304 (N-H stretch, br s), 2924 (s), 2854 (s), 1728 (m), 1662 (m), 
1634 (m), 1607 (m), 1538 (m), 1506 (m), 1463 (m), 1367 (m), 1317 (m), 1249 (m), 
1161 (m), 1097 (m), 1053 (m), 855 (m), 836 (m), 774 (m), 668 (w) cm-1. 
ES. (m/z): 551.3 [M+H+] 
1H-NMR+COSY (300 MHz, CDCl3): δ 8.26 (1H, br. s), 7.63 (2H, d, J = 8.8 Hz), 7.36 
(2H, d, J = 8.6 Hz), 6.77 (1H, t, J = 5.6 Hz), 3.25 (2H, m), 3.16 (2H, s), 2.53 (4H, t, J = 
6.6 Hz), 1.43-1.36 (11H, m), 1.28-1.05 (10H, m), 0.77 (9H, s), -0.10 (6H, s) ppm. 
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13C-NMR + APT + DEPT (75 MHz, CDCl3):δ 167.1 (C), 152.9 (C), 142.0 (C), 128.5 
(C), 128.0 (CH), 117.6 (CH), 80.3 (C), 66.4 (CH2), 42.9 (CH2), 40.7 (CH2), 39.2 (C), 
31.1 (CH2), 28.3 (CH3), 27.1 (CH2), 25.8 (CH3), 23.4 (CH2), 18.1 (C), -5.6 (CH3) ppm. 
VIII.2.3.2. Attachment of the second Alloc arm 
 
NH
NH2
O NH2
OTBS
NHBoc
2.2 eq IV.12
ONH
H2N
O
NHAlloc
NH
OTBS
NHBoc
IV.13
DCM/THF, mol.sieves,
18 h, 55%
IV.10, Et3N
 
 
To a solution of the diamine IV.12 (6.176 g, 11.2 mmol, 2.2 eq) in DCM (60 mL) 
was added Et3N (0.72 mL, 5.1 mmol, 1 eq) and molecular sieves. To the resulting 
mixture, a solution of activated ester 7 (1.974 g, 5.1 mmol, 1 eq) in THF (14 mL) was 
slowly added via the syringe pump over a period of 8 h. The solution was then stirred 
overnight and afterwards concentrated under reduced pressure. The residual oil was 
chromatographed with gradiënt elution where the amount of MeOH(NH3) in DCM was 
varied from 3% to 10%. The desired mono-amine was obtained as a light-yellow foam 
with a 54% (2.091 g). 
 
Molecular Formula: C40H63N5O7Si MW.: 754.04 g/mol 
RF. (DCM:MeOH/NH3 97:3): 0.18 Melting Point: 114-116 °C 
IR. (KBr-plate): 3304 (br s), 3179 (m), 3099 (m), 3039 (m), 2930 (s), 2856 (s), 1729 
(s), 1639 (s), 1609 (s), 1460 (m), 1408 (m), 1391 (w), 1368 (m), 1317 (s), 1232 (s), 
1160 (s), 1100 (m), 1054 (m), 936 (m), 851 (w), 771 (s), 668 (w) cm-1. 
ES.. (m/z): 755.0 [MH]+ 
1H-NMR+COSY (500 MHz, CDCl3): δ 7.78 (1H, br. s) 7.73 (2H, d, J = 8.6 Hz), 7.70 
(2H, d, J = 8.6 Hz), 7.42 (2H, d, J = 8.3 Hz), 7.38 (2H, d, J = 8.6 Hz), 7.15 (1H, br. s), 
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6.64 (1H, br. s), 6.57 (1H, br. s), 5.96 (1H, ddt, J = 17.2/10.5/5.7 Hz), 5.36 (1H, ddd, J 
= 17.2/2.9/1.5 Hz), 5.26 (1H, ddd, J = 10.3/2.4/1.3 Hz), 4.66 (2H, ddd, J = 5.6/1.3/1.3 
Hz), 3.38-3.31 (4H, m), 3.22 (2H, s), 2.62 (2H, t, J = 6.8 Hz), 1.53-1.43 (13H, m), 1.35-
1.18 (8H, m), 0.84 (9H, s), -0.03 (6H, s) ppm. 
13C-NMR + APT (75 MHz, CDCl3): δ 167.2 (C), 167.1 (C), 153.2 (C), 152.6 (C), 
141.5 (C), 141.0 (C), 132.3 (CH), 129.3 (C), 128.8 (C), 128.1 (CH), 128.0 (CH), 118.4 
(CH2),118.2 (CH), 118.0 (CH), 80.9 (C), 66.6 (CH2), 66.0 (CH2), 42.9 (CH2), 40.8 
(CH2), 39.4 (C), 31.5 (CH2), 30.8 (CH2 or C), 28.3 (CH3), 27.1 (CH2), 25.8 (CH3), 23.3 
(CH2), 18.1 (C), -5.6 (CH3) ppm. 
VIII.2.3.3. Attachment of the third Fmoc arm 
 
ONH
H2N
O
NHAlloc
NH
OTBS
NHBoc
IV.13
THF,18 h, 89%
IV.11, DIEA
O
O
NHFmoc
NH
NH
O
NHAlloc
NH
OTBS
NHBoc
IV.14  
 
To a solution of the mono-amine IV.13 (2.09 g, 2.77, 1eq mmol) in THF (34 mL) 
was added DIEA (0.48 mL, 2.76 mmol, 1eq) and IV.11 (2.90 g, 5.52 mmo,2 eq). The 
solution was then stirred overnight and afterwards concentrated under reduced pressure. 
The residual yellow foam was chromatographed using gradiënt elution where the 
amount of MeOH in DCM was varied from 2 % to 4 %. In this way the product IV.14 
was collected as a white powder (2.70 g, 89 %). 
 
Molecular Formula:C62H78N6O10Si MW.: 1095.40 g/mol 
RF. (DCM:MeOH 97:3): 0.18  Melting Point: 135-136 °C 
Chapter  VIII 
 153
IR. (KBr-plaatjes): 3296 (w), 2930 (w), 2846 (w), 1714 (m), 1634 (m), 1609 (m), 1530 
(s), 1447 (w), 1408 (w), 1365 (w), 1317 (m), 1223 (s), 1183 (w), 1158 (m), 1101 (w), 
1056 (w), 851 (w), 770 (w) cm-1. 
ES. (m/z):  1095.5 [M+H]+ 
1H-NMR+COSY (500 MHz, CDCl3): δ 7.81 (1H, br. s), 7.74 (2H, d, J = 7.7 Hz), 7.72-
7.65 (6H, m), 7.63 (1H, br. s), 7.59 (2H, d, J = 7.5 Hz), 7.45-7.30 (8H, m), 7.26 (2H, 
ddd, J = 7.4/7.4/0.9 Hz), 7.15 (1H, br. s), 6.95 (2H, br. s), 6.86 (1H, t, J = 5.5 Hz), 5.86 
(1H, ddt, J = 17.2/10.6/5.7 Hz), 5.28 (1H, ddd, J = 17.2/3.0/1.5 Hz), 5.18 (1H, J = 
10.4/2.5/1.2 Hz), 4.58 (2H, ddd, J = 5.7/1.4/1.4 Hz), 4.46 (2H, d, J = 6.6 Hz), 4.21 (1H, 
t, J = 6.9 Hz), 3.26 (6H, br. s), 3.13 (2H, s), 1.46 (9H, s), 1.36 (6H, br. s), 1.09 (6H, br. 
s), 0.77 (9H, s), -0.08 (6H, s) ppm. 
13C-NMR + APT + HSCQ (75 MHz, CDCl3): δ 167.4 (C), 153.5 (C), 152.6 (C), 143.7 
(C), 141.5 (C), 141.3 (C), 141.0 (C), 132.3 (CH), 129.1 (C), 128.6 (C), 128.1 (CH), 
127.9 (CH), 127.2 (CH), 125.0 (CH), 120.1 (CH), 118.4 (C), 118.4 (CH), 118.3 (CH), 
118.1 (CH), 81.0 (C), 67.1 (CH2), 66.6 (CH2), 65.6 (CH2), 47.0 (CH), 40.8 (CH2), 39.3 
(C), 30.8 (CH2), 28.3 (CH3), 25.8 (CH3), 23.1 (CH2), 18.1 (C), -5.63 (CH3) ppm. 
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VIII.2.4. Establishing the anchor point 
VIII.2.4.1. Deprotection of the silyl ether 
 
CSA (20 mol %)
DCM/MeOH, 18 h, 88%O
O
NHFmoc
NH
NH
O
NHAlloc
NH
OTBS
NHBoc
IV.14
O
O
NHFmoc
NH
NH
O
NHAlloc
NH
OH
NHBoc
IV.14b  
 
The silyl ether IV.14 (2.95 g, 2.70 mmol, 1 eq) was dissolved in a 1:1 mixture of 
DCM (45 mL) and MeOH (45 mL). Then (+)-CSA (125 mg, 0.539 mmol, 20 mol %) 
was added and the reaction mixture is stirred overnight. The reaction was monitored by 
reversed-phase HPLC at 262 nm and if there was more than 6 % starting material, then 
an extra portion (+)-CSA (31 mg, 0.13 mmol, 5 mol %) was added. After another 4h the 
mixture is concentrated under reduced pressure in the presence of silica gel. The light-
yellow powder is chromatographed with a gradiënt elution where the amount of MeOH 
is varied from 5 to 6 % to give the alcohol (2.33 g, 88%). 
 
Molecular Formula: C56H64N6O10 MW.: 981.14g/mol 
RF. (DCM:MeOH 94:6): 0.28  Melting Point: 154-155 °C 
IR. (KBr-plaatjes): 3367 (w), 2932 (w), 2867 (w), 2474 (w), 2355 (w), 1714 (m), 1608 
(s), 1567 (w), 1523 (w), 1446 (s), 1393 (w), 1356 (m), 1316 (w), 1243 (m), 186 (w), 
1072 (m), 848 (w), 767 (w) cm-1. 
ES. (m/z):  981.4 [M+H]+ 
1H-NMR+COSY (500 MHz, MeOD): δ 7.81 (2H, d, J = 7.5 Hz), 7.75-7.65 (8H, m), 
7.56-7.42 (6H, m), 7.38 (2H, dd, J = 7.4/7.4 Hz), 7.29 (2H, ddd, J = 7.4/7.4/0.9 Hz), 
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5.96 (1H, ddt, J = 17.2/10.6/5.5 Hz), 5.34 (1H, ddd, J = 17.2/3.1/1.6 Hz), 5.20 (1H, ddd, 
J = 10.5/2.6/1.5Hz), 4.60 (2H, ddd, J = 5.7/1.4/1.4 Hz), 4.48 (2H, d, 6.4 Hz), 4.27 (1H, 
t, 6.6 Hz), 3.30 (8H, m), 1.59-1.50 (6H, m), 1.48 (9H, s), 1.33-1.22 (6H, m) ppm. 
13C-APT+DEPT+HSQC+HMBC: δ 169.8 (C), 155.5 (C), 155.3 (C), 154.8 (C), 145.2 
(C), 143.9 (C), 143.5 (C), 143.4 (C), 142.7 (C), 134.1 (CH), 129.8 (C), 129.3 (C), 129.2 
(CH), 129.1 (CH), 128.9 (CH), 128.2 (CH), 126.2 (CH), 121.0 (CH), 119.1 (CH), 119.0 
(CH), 118.9 (CH), 118.0 (C), 81.7 (C), 67.9 (CH2), 66.6 (CH2), 48.4 (CH), 41.7 (CH2), 
40.3 (C), 32.0 (CH2), 28.7 (CH3)  24.2 (CH2) ppm. 
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VIII.2.4.2. Oxidation of the alcohol 
 
Jones
O
O
NHFmoc
NH
NH
O
NHAlloc
NH
OH
NHBoc
IV.1
O
O
NHFmoc
NH
NH
O
NHAlloc
NH
OH
NHBoc
IV.14b
O
Aceton, 0 °C, 3 h, 77 %
 
 
The alcohol IV.14b (4.35 g, 4.43 mmol, 1 eq) was dissolved in acetone (28 mL) and 
the solution was cooled in an ice bath. Jones reagent was prepared by dissolving CrO3 
(4.01 g, 40.1 mmol) in a mixture of acetone (3.4 mL), H2SO4 (4 mL) and water (11.6 
mL). The freshly prepared Jones reagent (6.7 mL, 2.67 M) was added slowly to the 
reagent mixture in two portions. After one hour another 1.7 mL Jones reagent (1eq) was 
added. The reaction was stirred for another 2 h and then isopropanol (10 mL) was 
added. The mixture was extracted twice with diethyl ether and 6 times with EtOAc, 
where after the organic phase was concentrated under reduced pressure in the presence 
of silicagel. The yellow powder was chromatographed with gradient elution where the 
percentage of MeOH in DCM was varied from 5 to 15%) to give carboxylic acid IV.1 
(3.39 g, 77%). 
 
Molcular Formula: C56H62N6O11 MW.: 995.13 g/mol 
RF. (DCM:MeOH 9:1): 0.26  Melting Point: 156 °C  
IR. (KBr-plaatjes): 3317 (m), 2945 (m), 1736 (s), 1720 (s), 1709 (s), 1676 (m), 1652 
(s), 1638 (s), 1626 (s), 1611 (s), 1560 (m), 1546 (s), 1528 (s), 1501 (s), 1467 (m), 1450 
(m), 1407 (m), 1390 (w), 1369 (m), 1315 (m), 1221 (s), 1186 (m), 1155 (m), 1052 (m), 
850 (m), 760 (m), 740 (m) cm-1. 
ES. (m/z): 992.9 [M-H]- 
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1H-NMR+COSY (300 MHz, DMSO-d6): δ 12.17 (1H, br. s), 9.96 (1H, s), 9.91 (1H, s), 
9.56 (1H, s), 8.33 (3H, br. s), 7.96 (2H, d, J = 7.4 Hz), 7.80-7.68 (8H, m), 7.55-7.45 
(6H, m), 7.41 (2H, dd, J = 7.4/7.4 Hz), 7.33 (2H, ddd, J = 7.4/7.4/1.1 Hz), 5.97 (1H, 
ddt, J = 17.0/10.4/5.5 Hz), 5.36 (1H, ddd, J = 17.2/3.3/1.7 Hz), 5.23 (1H, ddd, J = 
10.4/2.8/1.4Hz), 4.61 (2H, ddd, J = 5.4/1.3/1.3 Hz), 4.49 (2H, d, 6.9 Hz), 4.31 (1H, t, 
6.9 Hz), 3.15 (6H, s), 1.51-1.41 (6H, m), 1.40-1.28 (15H, s), 1.40-1.28 (6H, s) ppm. 
13C-APT+DEPT (75 MHz, MeOD): δ 180.4 (C), 169.7 (C), 155.5 (C), 154.8 (C), 145.2 
(C), 144.0 (C), 143.5 (C), 143.4 (C), 142.7 (C), 134.1 (CH), 129.7 (C), 129.2 (CH), 
128.9 (CH), 128.2 (CH), 126.2 (CH), 121.0 (CH), 119.1 (CH), 119.0 (CH), 118.8 (CH), 
118.0 (C), 81.2 (C), 67.9 (CH2), 66.6 (CH2), 48.4 (CH), 41.2 (CH2), 32.9 (CH2), 28.7 
(CH3), 25.5 (CH2) ppm. 
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VIII.3. Solid phase synthesis 
VIII.3.1. Standard operating protocols 
Swelling: The resin is swollen by adding a solvent (10 mL/g) of choice (usually 
DMF or DCM) to the beads and shaking the suspension for 5 min. To remove the 
solvent, the resin is filtered at the end. 
Washing: Unless stated other wise, the resin is washed with DMF (3x), MeOH (3 x) 
and DCM (3 x). Finally, the resin can be dried by washing it with ether (3 x) or pentane 
(3 x). 
Fmoc deprotection: A 20 % piperidine/DMF solution is added to the resin (10 
mL/g resin). The suspension is shaken for 1 min after which the suspension is filtered. 
This step is repeated for 5 min and 10 min. Finally, the resin is washed with DMF (3 x), 
MeOH (3 x) and DCM (3 x). 
Boc deprotection: The resin is treated with a 50 % TFA/DCM solution for 5 min. 
After filtration; the same solution is applied and the suspension is shaken for 25 min. 
Finally, the beads are washed with DCM (3 x), MeOH (3 x), 10 % DIEA/DCM (3 x), 
DCM (3 x). 
Capping: The free amines are capped by adding a mixture of Ac2O/pyridine/DCM 
(1:3:16) to the beads. After 1 h, the resin is filtered and washed. 
Loading determination: A known amount (typically ~10 mg) of the resin is treated 
with a 20 % piperidine/DMF solution for 30 min. After occasional swirling, the resin 
was left to settle. Subsequently, an amount of the solution was transferred to two UV 
cuvettes (~3 mL). By measuring the absorbance value at λ = 300 nm, the concentration 
of the piperidine-fulvene adduct could be determined by applying the following 
formula: “Abs = 8.0618 x conc.- 0.047”. This concentration could be correlated to the 
loading by taken into account the amount of resin used for the loading test. 
Automated synthesis: The automated synthesis is performed on a Syro I automated 
peptide synthesiser from MultiSyntech (Witten, Germany). All reactions are performed 
at ambient temperature and without protective atmosphere. First, the resin is weighed 
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into 2, 5or 10 mL synringes, depending on the amount of resin. The syringes are placed 
in a reaction block that has 24 positions. This reaction block ensures vortexing of the 
suspensions and subsequent filtration. 
Fmoc deprotection is done in two steps. First a 40 % piperidine solution is added to 
the resin for 3 min. After filtration and washing with DMF, a second volume of 40 % 
piperidine/DMF solution is added, which is immediately diluted until 20 % by adding 
the same amount of DMF. This time, the suspension is vortexed for 12 min after which 
the solution is drained and the resin is washed 6 times with DMF. 
The ivDde group is deprotected by adding a 2 % H2NNH2.H2O/DMF solution to the 
resin for 2 times 10 min. 
The azide group is reduced by adding a solution of 0.5 M Me3P in THF/H2O (1:1) to 
the resin. After vortexing the suspension for 10 min, the solution is drained and the step 
is repeated once. 
Amino acids are coupled by adding a 0.5 M solution of AAx/DMF127 to the resin, 
followed by the addition of a 0.5 M solution of HBTU/DMF. Finally, a 2 M 
DIEA/NMP solution is added in such a manner that the ratio AAx/HBTU/DIEA is 
1:1:2. In total, 5 equivalents of AAx are added. The resulting suspension is vortexed for 
40 min after which the solution is drained and the resin is washed 6 times with DMF. 
Capping is performed by adding a solution of Ac2O/pyridine/NMP (1:3:10) to the 
resin. An equal amount of DMF is subsequently added and the resulting suspension is 
vortexed for 40 min, after which the solution is drained and the beads are washed. 
 
                                                        
127 Except in the case of FmocPheOH which is dissolved in NMP for solubility reasons. 
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VIII.3.2. Coupling of the scaffold IV.1 to Tentagel 
VIII.3.2.1. Coupling of the photocleavable linker to Tentagel 
 
+NH2
Tentagel-NH2
HO
O
NO2
NHFmoc
OMe
3
O
i) PyBOP, DIEA
DMF, 3 h, quant.
ii) 20 % piperidine
DMF
NH hυ NH2
IV.15
Photocleavable linker  
 
The photocleavable linker (210 mg, 404 µmol, 3 eq) was dissolved in 4 mL DMF 
and the solution was added to the pre-swollen resin (650 mg, 0.21 mmol/g). The 
coupling reagent PyBOP (520 mg, 404 µmol, 3 eq) and the base DIEA (145 µL, 808 
µmol, 6 eq) were added. The suspension was shaken for 3 h. After draining, the resin 
was washed. The NF31 test was used to monitor the completeness of the reaction. The 
loading was determined to be 0.21 mmolg-1 (quantitatively). 
For the next reaction, the resin was Fmoc deprotected. 
VIII.3.2.2. Coupling of the spacer Boc-GABA to construct IV.15 
 
HO NHBoc
O
PyBOP, DIEA, DMF
ii) 50% TFA/DCM
i)
NH spacerhυ NH2 NH hυ
IV.15 IV.16
NH2
 
 
The spacer Boc-GABA (475 mg, 2.25 mmol, 5 eq) and the coupling reagent PyBOP 
(1.17 g, 2.25 µmol, 5 eq) were added to the pre-swollen resin (2 g, 0.45 mmol, 1 eq). 
DMF was added and the suspension was shaken until the reagents were dissolved. The 
base DIEA (785 µL, 4.5 mmol, 10 eq) was added whereafter the reaction vessel was 
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shaken for 3 h. After draining and washing the resin, approximately 1 mg of the beads 
were subjected to a NF31 test which was negative. 
Finally, the Boc group was deprotected. 
VIII.3.2.3. Coupling of scaffold IV.1 and subsequent capping 
 
hυ spacer HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
spacerNH hυ
IV.16
IV.17
NH2
IV.1, PyBOP,
DIEA
DMF, 18 h,
48 - 59 %
 
 
A solution of IV.1 (4.5 mg, 4.5 µmol) and PyBOP (2.3 mg, 4.5 µmol) in 0.15 mL 
DMF was prepared. When homogeneous, the solution was transferred to the pre-
swollen resin and after adding DIEA (2.4 µL, 13.5 µmol) the suspension was shaken for 
18 h. The resin was drained and washed thoroughly. The TNBS test turned the beads 
dark-yellow and with NF31 we got red beads. The remaining free spacer-amino groups 
were capped for 1 h with a 0.1 M solution of AcOH and PyBOP in the presence of 2 eq 
DIEA. The ninhydrin test was negative. The loading was 0.075 mmol/g and the amount 
of Fmoc-deprotection was 12%. Thus the total loading was 0.085 mmol/g which 
correlated (maximal theoretical loading is 0.173 mmolg-1) to a yield of 49%.  
 
Molecular Formula: C60H70N8O11  
MW.: 1079.2 g/mol   Exact mass: 1078.5 Da 
ES. (after photocleavage in MeCN): 857.4 [M-Fmoc+H]+, 879.6 [M-Fmoc+Na]+, 
1023.5 [M-tBu+H]+, 1079.4 [M+H]+; 1101.6 [M+Na]+.  
HR-ES (after photocleavage in MeCN, calculated for the Fmoc deprotected IV.17): 
[C45H60N8O9 + H]+: 857.45556, found: 857.45427. 
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VIII.3.3. Synthesis of new glycine derivatives 
VIII.3.3.1. Synthesis of oNBSGlyOH 
 
IV.18
H2N
OH
O
S
O2N
O
O
Cl
H2O, 0°C      rT
, NaOH
18h, 74%
N
H
OH
O
S
NO2
OO
 
 
Glycine (1 g, 13 mmol) was dissolved in a 100 mL aqueous NaOH (0.640 g) 
solution. After putting the flask in an ice bath, oNBSCl (0.754 g, 16 mmol, 1.2 eq) and 
NaOH (0.150 g) were added. This step was repeated 4 times over a period of 4h. Then 
the reaction was stirred overnight. Upon acidifying with NaHSO3H, a white precipitate 
was formed. This precipitate was filtered and dissolved in a mixture of water and 
methanol. The solution was then lyophilised to give a white powder (2.51 g, 74 %) 
 
Molecular Formula: C8H8N2O6S   MW.: 260.22 g/mol 
RF. (DCM:MeOH 95:5 + drop AcOH): 0.36  
Melting Point: 154-156 °C 
IR.: 3472 (br.), 3319 (m), 3096 (m), 2874 (m), 1712 (s), 1534 (s), 1434 (s), 1384 (s), 
1347 (s), 1313 (s), 1260 (s), 1166 (s), 1107 (s), 887 (s) cm-1. 
E.S. (m/z): 259.3 [M-H]- 
1H-NMR (500 MHz, DMSO-d6): δ 12.55 (1H, br. s), 8.37 (1H, 7, J = 5.4 Hz), 8.04-8.00 
(1H, m), 7.97-7.92 (1H, m), 7.86-7.80 (2H, m), 3.75 (2H, d, J = 5.4 Hz) ppm. 
APT (75 MHz, DMSO-d6): δ 170.3 (C), 147.3 (C), 133.9 (CH), 133.5 (C), 132.6 (CH), 
129.7 (CH), 124.3 (CH), 43.9 (CH2) ppm. 
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VIII.3.3.2. Synthesis of ivDdeGlyOH 
 
OH
O
H2N
EtOH, reflux, 18 h
80 %
OH
OH
N
O
O
Et3N
OH
O
O
IV.21
 
 
Et3N (1.74 mL, 12.5 mmol, 1.5 eq) and ivDdeOH (2.36 mL, 10.8 mmol, 1.3 eq) 
were added to a suspension of glycine (623 mg, 8.30 mmol, 1 eq) in EtOH (16 mL). 
The suspension was refluxed overnight under inert atmosphere. After 18 h the clear, 
yellow solution was evaporated under reduced pressure to give a yellow residue. After 
redissolving the residue in a 1:1 dioxane/water mixture, a 4N HCl solution was added 
drop wise until no more precipitation occurred. The white precipitate was dissolved in 
water/MeOH and was subsequently lyophilised to give a white powder (1.86 g, 80 %). 
 
Molecular Formula C15H23NO4  MW.: 281.35 g/mol 
RF. (DCM:MeOH 8:2 + drop AcOH): 0.57   
Melting Point: 234-237 °C 
I.R.: 2959 (m), 2866 (m), 1834 (w), 1725 (s), 1642 (s), 1578 (s), 1534 (s), 1455 (m), 
1429 (m), 1414 (m), 1218 (s), 1181 (m), 1146 (m), 918 (m) cm-1. 
ESI-MS. (m/z):  280.3 [M-H]- 
1H-NMR (500 MHz, DMSO-d6): δ 13.63 (1H, t, J = 4.8 Hz), 13.24 (1H, br.s.), 4.33 
(2H, d, J = 5.0 Hz), 2.94 (2H, s), 2.28 (4H, s), 1.81 (1H, sep, J = 6.8 Hz), 0.93 (6H, s), 
0.89 (6H, d, J = 6.9 Hz) ppm. 
APT + HSQC + HMBC (75 MHz, DMSO-d6): δ 175.0 (C), 169.8 (C), 106.7 (C), 52.6 
(CH2), 45.0 (CH2), 36.7 (CH2), 29.5 (C), 28.2 (CH), 27.8 (CH3), 22.0 (CH3) ppm. 
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VIII.3.3.3. Synthesis of AllocGlyOH 
 
HO
NH2
O OCl
O
, NaN3
dioxane/H2O/NaHCO3
rT, 48h, 74%
HO
H
N
O
O
OIV.25  
 
An aqueous solution (3 mL) of NaN3 (1.04 g, 16 mmol, 1.2 eq) was added to a 
solution of AllocCl (1.2 mL, 11 mmol, 0.8 eq) in dioxane (3 mL). The resulting mixture 
was stirred for 1 h. Meanwhile, glycine (1 g, 13 mmol, 1 eq) was dissolved in a 1% 
Na2CO3 solution (38 mL). When this solution was added to the in situ activated 
allylchloroformate, the pH was kept between 8 and 10 by adding some extra Na2CO3. 
After 48 h, the mixture was extracted 3 times with MTBE, acidified until pH 1 and 
subsequently extracted with EtOAc (3X). This organic phase was dried on MgSO4 and 
evaporated to give a yellow oil (2.86 g, 74%). 
 
Molecular Formula: C6H9NO4  MW.: 159.14 g/mol 
RF. (DCM:MeOH 9:1 + drop AcOH): 0.34 
Melting Point: 28-30 °C 
IR.: 3375 (br.), 2942 (w), 1713 (m), 1523 (m), 1412 (m), 1221 (m), 1055 (m), 991 (m), 
905 (s), 725 (s)  
ES. (m/z): 158.1 [M-H]- 
1H-NMR (500 MHz, CDCl3): δ 9.99 (1H, br. s), 6.67 (1H, br. s), 5.87 (1H, m), 5.62  
(1H, s), 5.27  (1H, d, J = 17.0 Hz), 5.18 (1H, d, J = 10.1Hz), 4.56 (2H, d, J = 4.7 Hz), 
3.96 (2H, s) ppm. 
APT (75 MHz, CDCl3): δ 174.1 (C), 156.7 (C), 132.3 (CH), 118.0 (CH2), 66.1 (CH2), 
42.4 (CH2) ppm. 
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VIII.3.3.4. Synthesis of azidoglycine 
 
HO
Br
O NaN3
DMSO, rT,
64%, 18 h
HO
N3
O
IV.31  
 
NaN3 (5.13 g, 78.9 mmol, 2 eq) was dissolved in DMSO (210 mL) and stirred for 90 
min. Bromoacetic acid (5.17 g, 37.4 mmol, 1 eq) was then added in a solution of DMSO 
(2 mL). After stirring for another 18 h, the solution was diluted with H2O (170 mL) and 
acidified with 6 N HCl (33 mL). The aqeous phase was then 3 times extracted with 
MTBE. The organic phases were pooled and extracted with a 0.1 N HCl solution 
satured with NaCl. After drying and subsequent evaporation of the organic phase, an oil 
(2.40 g, 64%) was obtained. 
 
Molecular Formula C2H3N3O2   M.W.: 101.02 g/mol 
I.R.: 3452 (br.), 2927 (w), 2111 (s), 1726 (m), 1623 (w), 1420 (m), 1282 (m), 1217 (m) 
cm-1. 
EI (m/z): 101 [M.+], 45 [CHO2.+] 
1H-NMR (300 MHz, CDCl3): δ 9.62 (1H, br.s), 3.97 (1H, br.s.) ppm. 
APT (75 MHz, CDCl3): δ 174.2 (C), 50.1 (CH2) ppm. 
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VIII.3.4. Incorporation of the glycine derivatives 
VIII.3.4.1. Attachment of ivDdeGlyOH 
 
hυ spacer HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
IV.17
i) 20 % piperidine/DMF
ii) ivDdeGlyOH IV.21
DIC (2:1), DCM, 0 °C, 30'
then DMF, 18 h
hυ spacer HN O
O
O
HN
HN
HN
O
NHAlloc
NH
NHBoc
O
NHivDde
IV.32a
 
 
First the resin IV.17 (1.6 g, 0.100 mmol/g, 0.19 mmol, 1 eq) was Fmoc deprotected. 
During the Fmoc deprotection, ivDdeGlyOH (646 mg, 2.3 mmol, 12 eq) was dissolved 
in DCM (4 mL) and the solution was cooled down until 0 °C. After adding DIC (170 
µL, 1.1 mmol, 6 eq), the mixture was stirred for 30 min and subsequently added to the 
Fmoc deprotected IV.17. To ensure complete solubility of the symmetrical anhydride, 
DMF (4 mL) was added. The resulting suspension was shaken for 18 h and after 
filtering the resin, the beads were thoroughly washed.  
A small sample was photocleaved in EtOH and analysed via LC which show the 
presence of a small amount of starting material. The coupling was thus repeated once 
and no more starting material was observed. 
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VIII.3.4.2. Coupling of FmocGlyOH 
 
i) 50 % TFA/DCM
ii) FmocGlyOH, DIC (2:1)
DCM, 0 °C, 30'
then DMF, 18 h
hυ spacer HN O
O
O
HN
HN
HN
O
NHAlloc
NH
NH
O
NHivDde
IV.32b
hυ spacer HN O
O
O
HN
HN
HN
O
NHAlloc
NH
NHBoc
O
NHivDde
IV.32a O
NHFmoc
 
First, the Boc group was deprotected. In the mean while, FmocGlyOH (683 mg, 2.3 
mmol, 12 eq) was dissolved in DCM (4 mL) and cooled down until 0 °C. After adding 
DIC (170 µL, 1.1 mmol, 6 eq), the mixture was stirred for 30 min and subsequently 
added to the Boc deprotected IV.32a. To ensure complete solubility of the symmetrical 
anhydride, DMF (4 mL) was added. The resulting suspension was shaken for 18 h and 
after filtering the resin, the beads were thoroughly washed.  
A small sample was photocleaved in EtOH and analysed via LC which show the 
presence of a small amount of starting material. The coupling was thus repeated once 
and no more starting material was observed. 
VIII.3.4.3. Coupling of azidoglycine 
 
hυ spacer HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
NHivDde
IV.32
O
NHFmoc
i) (PPh3)4Pd, PhSiH3, DCM
ii) N3GlyOH IV.31
DIC (2:1), DCM, 0 °C, 30'
hυ spacer HN O
O
O
HN
HN
HN
O
NHAlloc
NH
NH
O
NHivDde
IV.32b
O
NHFmoc
O
N3
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The resin was suspended in DCM. First, the scavenger PhSiH3 (585 µL, 4.75 mmol, 
25 eq) was added to this suspension followed the Pd° catalyst (22 mg, 19 µmol, 10 mol 
%). The resulting brown mixture was shaken for 1 h and subsequently filtered and 
washed 3 times with DCM. After repeating this procedure once, the Alloc group was 
fully removed as monitored by HPLC after photocleavage in EtOH. 
Next, azidoglycine IV.31 (230 mg, 2.3 mmol, 12 eq) was dissolved in DCM (8 mL) 
and cooled down until 0 °C. After adding DIC (170 µL, 1.1 mmol, 6 eq), the mixture 
was stirred for 30 min and subsequently added to the Alloc deprotected IV.32b. The 
resulting suspension was shaken for 18 h and after filtering the resin, the beads were 
thoroughly washed.  
A small sample was photocleaved in EtOH and analysed via LC which show the 
presence of a small quantity of starting material. The coupling was thus repeated once 
and no more starting material was observed. 
 
Molecular Formula: C70H83N13O12 
MW.: 1298.5 g/mol   Exact mass: 1297.6 Da 
LC-MS. (after photocleavage in EtOH): 650 [M+2H]2+, 1298.6 [M+H]+ 
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VIII.3.5. Automated synthesis of 120 members 
 
hυ spacer scaffold
G
lyN
H
Fm
oc
G
lyN
3
G
l yN
H
i vD
de
IV.32
1st2nd3rd
Automated Synthesis
5 days
hυ spacer scaffold
GlyGly Gly
AA5 AA3 AA1
AA2AA4AA6
AcAcAc
120 members
 
 
In 24 plastic syringes of 2 mL, a small amount of resin IV.32 (1 to 3 mg, 0.09 µmol 
to 0.27 µmol) was weighed. These syringes were placed into the reaction block of the 
Syro I. 
After inserting the correct sequences in the software program and preparing the AAx, 
HBTU, DIEA, piperidine and capping solutions, the sequence was started.  
First the Fmoc group was deprotected. The first AA was coupled by adding a 0.5 M 
solution of AAx (60 µL) to the resin. Then, each syringe was filled with a 0.5 M HBTU 
solution (60 µL) and a 2 M DIEA solution (30 µL). The suspension was vortexed for 40 
min, after which it was drained and washed. This procedure was repeated once. The 
first strand was terminated by adding the capping mixture (120 µL) and DMF (120 µL) 
to the resin. 
The ivDde group was removed by adding a 2 % H2N.NH2.H2O/DMF (180 µL) to the 
syringes. After vortexing for 10 min, the resin was shortly washed with DMF and the 
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deprotection was repeated once. Then the subsequent AAx were coupled as already 
described. The second strand was terminated by capping the free amine with A2O. 
Finally, the azide was reduced by adding 0.5 M Me3P in THF/H2O (180 µL) for 10 
min to the syringes. The reduction was repeated once and then the resin was drained 
and washed thoroughly with DMF and iPrOH. Then the subsequent AAx were coupled 
as already described. The synthesis was terminated by capping the free amine. 
After the synthesis, the resins were washed with iPrOH (3 x) and pentane (3 x).  
In total, 120 members were synthesized by repeating this overall procedure 5 times.  
 
Molecular Formula: C121H157N22O22S2   
MW.: 2335.8 g/mol   Exact mass: 2334.1 Da 
MALDI-TOF. (after photocleavage in EtOH): 2094.3 [M-Trt+H]+, 2115.5 [M-
Trt+Na]+, 2334.9 [M+H]+, 2350.7 [M+O+H]+, 2357.4 [M+Na]+, 2373.4 [M+O+Na]+ or 
[M+K]+ 
[M + K]+ or 
[M + O + Na]+
[M + H]+
[M + Na]+
M – side chain PG
2094.3
2115.5
50
100
999 3000Mass (m/z)
2357.4
2334.9
2373.4
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VIII.3.6. Side chain deprotection of the library 
 
hv spacer
H
N O
O
O
HN
HN
HN
O
NH
NH
NH
Gly
Gly Gly
His(Trt)
Glu(tBu)
Ac
Arg(Pbf)
Met(O)
Ac
Phe
Leu
Ac
TFA/thioansiol/DODT/
TIS/Me2S/H2O/NH4I
(84.5/5/2.5/1/2/5/1.5)
3 h
hv spacer
H
N O
O
O
HN
HN
HN
O
NH
NH
NH
Gly
Gly Gly
His
Glu
Ac
Arg
Met
Ac
Phe
Leu
Ac
IV.33 IV.34
 
 
The procedure is described for the specific case of IV.33 but was applied on all of 
the 120 members. 
The TFA cleavage mixture was prepared by mixing TIS (100 µL), DODT (250 µL), 
Me2S (200 µL) and thioansole (500 µL) with TFA (8.45 mL). For the reduction of 
Met(O), NH4I (230 mg) was dissolved in H2O (500 µL). 
First, the NH4Iaq (10 µL) was added to each member followed by the addition of the 
TFA cleavage mixture (190 µL). The suspension was left for 3 h, after which the beads 
were drained and washed thoroughly. 
From this library, 20 randomly picked members were photocleaved in H2O and 
analysed via HPLC (vide infra). The identity of all the 120 members was confirmed in 
the affinity chromatography experiments were the reaction times were monitored via 
LC-MS. 
 
Molecular Formula: C85H119N22O19S   
MW.: 1785.1 g/mol   Exact Mass: 1783.9 Da 
ES. (after photocleavage in H2O): 892.6 [M+2H]2+, 903.6 [M+Na+H]2+ 
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Confirming the overall purity of the library: 
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VIII.4. Screening of the library: development of the first SPE 
tests 
VIII.4.1. Preparation of Tentagel-bound Tozzi-tetrapeptide 
VIII.4.1.1. Synthesis of protected Tozzi-tetrapeptide 
 
Cl
i) FmocValOH,
DIEA, DCM, 2 h, 85 %
   
ii) 20 % piperidine,
2 X 30 min
O
O
NH2
iii) automated
    synthesis
HO
H
N
N
H
H
N
NH3
O
O
O
O
O
O
HN
NH
H
NPbf
iv) AcOH/TFE/DCM
(1:1:3), 2 h, 60 %
2'-Chlorotrityl
1.55 mmolg-1
V.1
protected Tozzi-tetrapeptide V.2
O
O
 
 
This work was done in cooperation with Drs. S. Figaroli. 
FmocValOH (210 mg, 0.62 mmol, 2 eq) was added to the preswollen 2’-
chlorotritylresin (200 mg, 0.31 mmol, 1 eq). Next, DCM (2 mL) was added and the 
suspension was shaken until all of the FmocValOH was dissolved. After adding DIEA 
(108 µL, 0.62 mmol, 2 eq), the suspension was shaken for 2 h after which the solution 
was drained and the beads thoroughly washed with DMF (3 x), 10 % DIEA/MeOH (3 
x), MeOH (3 x) and DCM (3 x). A loading value of 1.06 mmolg-1 was determined 
which corresponded with a yield of 85 %. 
The Fmoc group was deprotected using a 20 % piperidine/DMF solution for two 
times 30 min.  
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Subsequently an amount of resin (17 mg, 18 µmol) was weighed into a syringe of 2 
mL and put into the reaction block of the Syro I. 
After the automated synthesis, the desired peptide was cleaved from the resin with 
400 µL AcOH/TFE/DCM (1:1:3) for 2 h. The resin was subsequently washed 3 times 
with the cleavage mixture and the combined organic fractions were pooled and 
evaporated. The residual oil was co-evaporated 3 times with hexane, yielding 9.4 mg of 
the protected peptide (60 %)  
 
Molecular Formula: C38H65N7O10S   
MW.: 812.0 g/mol    
ES.: 811.6 [M-H]- 
VIII.4.1.2. Reversing the synthesis order (from C→N to N→C) 
 
spacerNH hυ
i) Succinic anhydride
DIEA, DCM, 18 h
    
ii) PyBOP, DIEA, DMF
3 times 15'Tentagel IV.16 V.3
NH2 spacerNH hυ NH
OBt
O
O
 
 
A solution of succinic anhydride (8.6 mg, 86 µmol, 10 eq) in DCM (400 µL) was 
added to preswollen to IV.16 (40 mg, 8.4 µmol) and after addition of DIEA (30 µL, 170 
µmol, 20 eq), the suspension was shaken for 18 h. Subsequently, the resin was drained 
and washed. 
The free carboxylic acid on the resin (10 mg, 2.1 µmol) was then activated by 
adding 100 µL of a 0.5 M solution PyBOP in DMF (50 µmol, 24 eq) and 25 µL of a 2 
M solution of DIEA in NMP (100 µmol, 48 eq). The resulting suspension was shaken 
for 15 min, after which the solution was filtered and the beads were washed (3 x DMF, 
3 x DCM, 3 x DMF). This activation was repeated 3 times. 
Experimental part  
 182 
VIII.4.1.3. Coupling of V.2 to the preactivated V.3 
 
spacerNH hυ N
H
O
O
Arg Ser Ser Val
O
OH
Tentagel
V.3
V.4
spacerNH hυ N
H
OBt
O
O
i) V.2, DIEA, DMF, 18 h
ii) TFA/TIS/thioanisole/
DODT/H2O (86.5/1/5/2.5/5), 3 h
 
 
The protected peptide V.2 (7.4 mg, 8.5 µmol, 4 eq) was dissolved in DMF (100 µL) 
and added to resin V.3. Next, DIEA (2 µL, 11.5 µmol, 5.5 eq) was added and the 
suspension was vortexed for 18 h. Then, the beads were drained and washed. 
A cleavage mixture containing TFA/TIS/thioanisole/DODT/H2O (86.5/1/5/2.5/5) was 
prepared and 100 µL of this mixture was added to the resin. After 3 h, the beads were 
drained and washed with DMF (3 x), 10 % DIEA/DCM (3 x), MeOH (3 x) and DCM (3 
x) to give resin bound peptide V.4. 
 
Molecular Formula: C25H45N9O10   
MW.: 631.7 g/mol    
ES. (after photocleavage in H2O): 630.4 [M-H]- 
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VIII.4.2. Synthesis on silica 
VIII.4.2.1. Coupling of the photocleavable linker on silica 
 
Silica
+NH2 HO
O
NO2
NHFmoc
OMe
3
O
i) DIC, HOBt
DMF, 18 h
ii) capping
iii) 20 % piperidine
DMF
NH hυ NH2
V.5a
Photocleavable linker  
 
The photocleavable linker (37 mg, 72 µmol) was dissolved in 2 mL DMF and the 
solution was added to the silica material (114 mg). The coupling reagent DIC (10 µL, 
69 µmol) and HOBt (10 mg, 72 µmol) were added. The suspension was shaken for 18 
h. After draining, the silica was washed. Next, the material was capped for 3 h. The 
loading was determined to be 0.471 mmolg-1. 
For the next reaction, the silica material was Fmoc deprotected. 
VIII.4.2.2. Coupling of the spacer Boc-GABA to construct IV.15 
 
HO NHBoc
O
PyBOP, DIEA, DMF
ii) 50% TFA/DCM
i)
NH spacerhυ NH2 NH hυ
V.5a V.5
NH2
 
 
The spacer Boc-GABA (53 mg, 0.26 mmol, 5 eq) and the coupling reagent PyBOP 
(135 mg, 0.26 mmol, 5 eq) were added to the silica material (110 g, 52 µmol, 1 eq). 
DMF (1 mL) was added and the suspension was shaken until the reagents were 
dissolved. The base DIEA (90 µL, 0.52 mmol, 10 eq) was added whereafter the 
suspension was shaken for 3 h.  
After draining and washing the silica the Boc group was deprotected. 
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VIII.4.2.3. Coupling of scaffold IV.1 and subsequent capping 
 
V.5
V.6
hυ spacer HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
spacerNH hυ NH2
i) IV.1, PyBOP,
DIEA, DMF, 18 h
32 %
ii) 0.1 M AcOH/
PyOP in DCM
2 eq DIEA, 1 h
 
 
A solution of IV.1 (21 mg, 21 µmol) and PyBOP (11 mg, 21 µmol) in 0.4 mL DMF 
was prepared. When homogeneous, the solution was transferred to the silica material in 
a eppendorf tube. After adding DIEA (11 µL, 63 µmol) the suspension was vortexed for 
18 h. The silica was isolated via centrifugation and subsequently drained and 
thoroughly washed.. The remaining free spacer-amino groups were capped for 1 h with 
a 0.1 M solution (300 µL) of AcOH and PyBOP in the presence of 2 eq DIEA. The 
ninhydrin test was negative. The loading was 0.060 mmol/g and the amount of Fmoc-
deprotection was 44% (as determined by HPLC). Thus the total loading was 0.107 
mmol/g which correlated (maximal theoretical loading is 0.330 mmolg-1) to a yield of 
32%.  
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VIII.4.2.4. Attachment of the glycine derivatives to V.6 
 
hυ spacer HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHivDde
NHFmocN3
hυ spacer HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
V.6
i) 20 % piperidine/DMF
ii) ivDdeGlyOH, DIC (2:1)
ii) 50% TFA/DCM
iv) FmocGlyOH, DIC (2:1)
v) (PPh3)4Pd, PhSiH3, DCM
vi) N3GlyOH, DIC (2:1)
V.7
 
 
For the incorporation of the glycine derivatives, the same protocol as described in 
 VIII.3.4 was applied. The amount of silica construct V.6 used was 40 mg (4.3 µmol). 
 
Molecular Formula: C70H83N13O12 
MW.: 1298.5 g/mol   Exact mass: 1297.6 Da 
LC-MS. (after photocleavage in EtOH): 1299.2 [M+H]+ 
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VIII.4.2.5. Synthesis of one library member on silica 
 
hυ spacer HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHFmoc
NHivDdeN3
V.7
hv spacer N
H
O O
O
N
H
NH
NH
O
H
N
NH
H
N
Gly
Gly
Gly
V.8
Leu Phe Ac
Glu Phe Ac
OtBu
His Arg Ac
Trt Pbf
Automated
synthesis
 
The automated synthesis was performed in a manner similar to the protocol 
described in Paragraph  VIII.3.5. An amount of 10 mg of construct V.7 (1.1 µmol) was 
subjected to this protocol. MALDI-TOF analysis after photocleavage in EtOH showed 
that a major deletion of the Leu and Met residues had occurred. 
 
Molecular Formula: C125H156N22O22S   
MW.: 2353.8 g/mol   Exact mass: 2349.2 Da 
MALDI-TOF. (after photocleavage in EtOH): 2096.7 [M-Leu-Phe-Pbf+H]+, 2112.7 
[M-Leu-Phe+Na]+, 2127.7 [M-Leu-Phe+K]+ 
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VIII.4.2.6. Side chain deprotection of V.8 
 
hv spacer N
H
O
O
O
HN
HN
HN
O
HN
NH
NH
Gly
Gly
V.8
Gly
His
Glu
Ac
Arg
Phe
Ac
Ac
Trt
Pbf
BuOt
hv spacer N
H
O
O
O
HN
HN
HN
O
HN
NH
NH
Gly
Gly
V.8a
Gly
His
Glu
Ac
Arg
PheAc
Ac
95 % TFA/
2.5 % TIS/2.5 % H2O
4 h, 2 X
 
 
The TFA cleavage mixture was prepared by mixing TIS (250 µL) and H2O (250 µL) 
with TFA. The mixture (200 µL) was then added to the silica construct V.8 (10 mg). 
The suspension was left standing for 4 h. After draining the solution, the resin was 
washed and the deprotection was repeated once. 
Analysis after photocleavage in EtOH revealed that the deprotection of the Trt and 
the Pbf group were not fully completed, even after a doubled deprotection. 
 
Molecular Formula: C74H98N20O17   
MW.: 1538.7 g/mol   Exact mass: 1539.7 Da 
MALDI-TOF. (after photocleavage in EtOH): 1539.5 [M +H]+, 1561.5 [M+Na]+, 
1782.5 [M+Trt+H]+, 2057.6 [M+Trt+Pbf+Na]+ 
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VIII.5. Screening of the library: development of affinity LC 
VIII.5.1. Development of the estradiol column V.11 
VIII.5.1.1. Synthesis of azidohexanoic acid V.9 
 
HO
N3
O
HO
Br
O NaN3
DMF, 85°C, 18 h
81%
 
 
Bromohexanoic acid (6g, 31 mmol, 1 eq) was dissolved in 20 mL DMF. After 
adding NaN3 (4g, 62 mmol, 2eq) the solution was refluxed for 18 h at an oil bath 
temperature of 85°C. After cooling down the solution, DMF was evaporated under 
vacuüm to give an oil that was redissolved in DCM. This organic phase was then 
extracted 3 times with a 0.1 N HCl solution. After drying the organic phase on MgSO4 
and evaporation, 3.96 g of light yellow oil was obtained (81% yield). 
 
Molecular Formula: C6H11N3O2 MW.: 157.09 g/mol 
RF. (DCM + drop AcOH): 0.17   
IR. (KBr-plate): 3075 (br.), 2939 (m), 2866 (m), 2093 (s), 1706 (s), 1254 (m), 910 (m), 
731 (s) cm-1. 
ES. (m/z): 156.5 [M-H]- 
APT (75 MHz, CDCl3): δ 179.5 (C), 51.2 (CH2), 33.8 (CH2), 28.5 (CH2), 26.1 (CH2), 
24.1 (CH2) ppm. 
1H-NMR + COSY (500 MHz, CDCl3): δ 10.37 (1H, br. s), 3.26 (2H, t, J = 6.9 Hz), 
2.86 (2H, t, J = 7.4 Hz), 1.69-1.64 (2H, m), 1.62-1.58 (2H, m), 1.45-1.39 (2H, m) ppm. 
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VIII.5.1.2. Coupling of V.9 to silica 
 
HO
N3
O
5
NH2
Silica 5 µm
i) PyBOP, DIEA
DMF, 18 h
ii) capping
N
H
N3
O
5
V.9 V.10
+
 
 
The silica material (2 g, max. loading 0.73 mmolg-1) was suspended in DMF (10 
mL) and azidohexanoic acid V.9 (691 mg, 4.4 mmol, 3 eq) was then added to this 
suspension. After addition of PyBOP (2.3 g, 4.4 mmol, 3 eq) and DIEA (1.53 mL, 8.8 
mmol, 6 eq) the suspension was shaken for 18 h. Subsequently, the solution was drained 
and the remaining powder was washed thoroughly. After capping, the ninhydrine test 
gave a colourless result, indicating that there was no more free amine left. 
 
IR. (KBr-plate): 3414 (br. s), 2104 (s), 1642 (m), 1111 (br. s), 810 (s) cm-1 
VIII.5.1.3. ‘Clicking’ of ethinylestradiol to V.10 
 
CuSO4.5H20 (20 mol %),
NaAscorbate (40 mol %), 
iPrOH/H20 (1:1), 18h, 40°C
OH
HO
N
H
N3
O
5 HO
OH
N
NN
V.10
V.11
 
 
The silica material V.10 (6 g) was suspended in an iPrOH/H2O (60 mL in a ratio of 
1:1) solution. Ethinylestradiol (4.45 g, 15 mmol, 1 eq) was added to this suspension 
followed by CuSO4.5H2O (749 mg, 3 mmol, 20 mol %) and NaAscorbate (1.2 g, 6 
mmol, 40 mol %). The resulting orange solution was stirred gently in an oil bath of 40 
°C. After overnight reaction, the suspension was filtered and the remaining silica 
material was washed with MeOH (3 x), EDTAaq (3 x), MeOH (3 x) and ether (3 x). All 
the azide functions had reacted as witnessed by the disappearance of the azide 
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absorption (~ 2100 cm-1) in the IR-spectrum. Finally, the silica material V.11 was dried 
at an oven temperature of 60 °C for overnight. 
 
IR. (KBr-plate): 3399 (br. s), 2936 (s), 1670 (s), 1050 (br. s), 800 (s) cm-1 
VIII.5.2. Synthesis of the Tozzi peptides 
VIII.5.2.1. Synthesis of a ‘blanc’ tetraglycine peptide V.13 
 
Cl
2'-Chlorotrityl
O
O
NH2
i) FmocGlyOH,
DIEA, DCM, 2h
79 %      
ii) 20 % piperidine/DMF
2 X 30 min
iii) Automated
synthesis
iv) TFA, 3 h
H3N
Gly Gly Gly Gly OH
CF3CO2 71 %
V.12
V.13O
 
 
FmocGlyOH (92 mg, 0.31 mmol, 2 eq) was added to the preswollen 2’-
chlorotritylresin (100 mg, 0.16 mmol, 1 eq). Next, DCM (1 mL) was added and the 
suspension was shaken until all of the FmocGlyOH was dissolved. After adding DIEA 
(323 µL, 0.31 mmol, 2 eq), the suspension was shaken for 2 h after which the solution 
was drained and the beads thoroughly washed with DMF (3 x), 10 % DIEA/MeOH (3 
x), MeOH (3 x) and DCM (3 x). A loading value of 1.23 mmolg-1 was determined 
which corresponded with a yield of 79 %. 
The Fmoc group was deprotected using a 20 % piperidine/DMF solution for two 
times 30 min. Then the resin was weighed into a syringe of 10 mL and put into the 
reaction block of the Syro I. 
After the automated synthesis, the desired peptide was cleaved from the resin with 
TFA for 3 h and precipitated with ice cold MTBE. After centrifugation, the residue was 
dissolved in H2O. Lyophilisation gave 39.1 mg (96 %) of white powder. 
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Molecular Formula: C12H21N5O6   
MW.: 331.2 g/mol 
LC-MS: 288.5 [M-CO2+H]+, 332.5 [M+H]+ 
VIII.5.2.2. Synthesis of the Tozzi-tetrapeptide V.14 
 
O
O
NH2
V.1
i) Automated
synthesis
ii) TFA/TIS/DODT/H2O/
thioanisole
(86.5/1/2.5/5/5), 0 °C  rT, 3 h
H3N
Arg Ser Ser Val
CF3CO2
92 %
2
V.14O
OH
 
 
Starting from construct V.1, the tetrapeptide V.14 was synthesised by weighing 200 
mg of V.1 into a syringe of 10 mL. This syringe was put into the reaction block of the 
Syro I. 
After the automated synthesis, an ice cold mixture of 
TFA/TIS/DODT/H2O/thioanisole (86.5/1/2.5/5/5) was added to the resin. After 3 h, the 
suspension was dried by applying an Ar stream over the syringe. From the resulting oil, 
the desired peptide was precipitated with ice cold MTBE. To remove all the scavengers, 
this precipitation was repeated 3 times. Centrifugation gave a residue that was 
redissolved in H2O. Lyophilisation gave 149 mg (92 %) of a white powder. 
 
Molecular Formula: C21H41N8O8   
MW.: 533.6 g/mol 
ES: 534.5 [M+H]+ 
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VIII.5.2.3. Synthesis of the Tozzi-hexapeptide V.16 
 
Cl
2'-Chlorotrityl
i) FmocSerOH, DIEA,
DCM, 2 h, 72 % 
   
ii) 20 % piperidine/DMF
2 X 30 min
O
O
NH2
OH
V.15
H3N
Arg Ser Ser Val
CF3CO2
83 %
2
Gly Ser OH
V.16O
i) Automated
synthesis
ii) TFA/TIS/DODT/H2O/
thioanisole
(86.5/1/2.5/5/5), 0 °C  rT, 3 h
3
 
 
FmocSerOH (363 mg, 0.95 mmol, 2 eq) was added to the preswollen 2’-
chlorotritylresin (300 mg, 0.47 mmol, 1 eq). Next, DCM (3 mL) was added and the 
suspension was shaken until all of the FmocSerOH was dissolved. After adding DIEA 
(153 µL, 0.95 mmol, 2 eq), the suspension was shaken for 2 h after which the solution 
was drained and the beads thoroughly washed with DMF (3 x), 10 % DIEA/MeOH (3 
x), MeOH (3 x) and DCM (3 x). A loading value of 0.721 mmolg-1 was determined 
which corresponded with a yield of 72 %. 
The Fmoc group was deprotected using a 20 % piperidine/DMF solution for two 
times 30 min. Then the resin (100 mg) was weighed into a syringe of 10 mL and put 
into the reaction block of the Syro I. 
After the automated synthesis, an ice cold mixture of 
TFA/TIS/DODT/H2O/thioanisole (86.5/1/2.5/5/5) was added to the resin. After 3 h, the 
suspension was dried by applying an Ar stream over the syringe. From the resulting oil, 
the desired peptide was precipitated with ice cold MTBE. To remove all the scavengers, 
this precipitation was repeated 3 times. Centrifugation gave a residue that was 
redissolved in H2O. Lyophilisation gave 54 mg (83 %) of a white powder. 
 
Molecular Formula: C26H48N10O11   
MW.: 676.7 g/mol 
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ES: 339.3 [M+2H]2+, 677.3 [M+H]+ 
VIII.5.2.4. Synthesis of the Tozzi-octapeptide 
 
Arg Ser Ser Val
CF3CO2
69 %
2
Gly Ser Gln Ser OH
V.17O
O
O
NH2
OH
V.15
i) Automated
synthesis
ii) TFA/TIS/DODT/H2O/
thioanisole
(86.5/1/2.5/5/5), 0 °C  rT, 3 h
H3N
3
 
 
Starting from construct V.15, the Tozzi-octapeptide V.17 was synthesised on the 
Syro I. The resin (100 mg) was weighed into a syringe of 10 mL and put into the 
reaction block of the Syro I. 
After the automated synthesis, an ice cold mixture of 
TFA/TIS/DODT/H2O/thioanisole (86.5/1/2.5/5/5) was added to the resin. After 3 h, the 
suspension was dried by applying an Ar stream over the syringe. From the resulting oil, 
the desired peptide was precipitated with ice cold MTBE. To remove all the scavengers, 
this precipitation was repeated 3 times. Centrifugation gave a residue that was 
redissolved in H2O. Lyophilisation gave 56 mg (69 %) of a white powder. 
 
Molecular Formula: C34H61N13O15   
MW.: 891.9 g/mol 
ES: 446.9 [M+2H]2+ 
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VIII.5.3. Development of the norethindrone column V.19 
 
i)
 CuSO4.5H20 (20 mol %), 
NaAscorbate (40 mol %)
 iPrOH:H20 (1:1), 18 h, 40 °CSilica 5 µm
N
H
N3
O
5
HO
O
N
NN
V.10 V.19
HO O
 
 
The silica material V.10 (1 g) was suspended in an iPrOH/H2O (10 mL in a ratio of 
1:1) solution. Norethindrone (756 mg, 2.5 mmol, 1 eq) was added to this suspension 
followed by CuSO4.5H2O (125 mg, 0.5 mmol, 20 mol %) and NaAscorbate (198 mg, 
1.0 mmol, 40 mol %). The resulting orange solution was stirred gently in an oil bath of 
40 °C. After overnight reaction, the green suspension was filtered and the remaining 
silica material was washed with MeOH (3 x), EDTAaq (3 x), MeOH (3 x) and ether (3 
x). Finally, the silica material V.19 was dried at an oven temperature of 60 °C for 
overnight. 
The filtrate was extracted three times with DCM. The organic phases were pooled, 
extracted once with a 10 % Na2CO3 solution and subsequently dried over Na2SO4. After 
filtration, the organic phase was evaporated under reduced pressure to yield 524 mg of a 
white powder. LC-MS and 1H-NMR analysis showed that this was pure norethindrone. 
From this, it was calculated that 232 mg (0.744 mmol) was coupled to the silica; 
resulting in a final loading of 0.609 mmol/g. 
All the azide functions had reacted as witnessed by the disappearance of the azide 
absorption (~ 2100 cm-1) in the IR-spectrum.  
 
IR. (KBr-plate): 3430 (br. s), 2947 (m), 1647 (s), 1092 (br. s), 802 (s) cm-1 
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VIII.5.4. Development of a second generation estradiol column V.23 
VIII.5.4.1. Synthesis of estradiol derivative V.20 
 
O
HO
OH
HO
4
, nBuLi
THF, -42°C    rT, 5h 30', 
53%
4
V.20
 
 
A solution of 1,7-octadiyne (1 mL, 8.29 mmol, 5eq) under Ar was cooled down until 
-42°C (MeCN/CO2). The subsequent addiditon of a 1 M solution of nBuLi in hexane 
(3.52 mL, 8.29 mmol, 5eq) resulted in a white precipitate. After stirring the suspension 
for 30 min, estrone (445 mg, 1.65 mmol, 1eq) was added and the reaction was allowed 
to warm up at rT for 5h. Then the mixture was diluted with NH4Claq and extracted 3 
times with DCM. The combined organic phases were dried with Na2SO4, filtered and 
evaporated. The residue was purified via flash chromatography with ioctane/EtOAC 
(8:2 – 7:3) to yield a white solid (479 mg). However, LC-MS analysis showed that the 
isolated material consisted of 30% estrone and 70% of the desired product. This 
corresponded with the 1H-NMR integration of the two CH3-18 singlets. Thus the overall 
yield was 53%. 
 
Molecular Formula:  C26H32O2 M.W.: 376.53 g/mol 
R.F. (ioctane/EtOAc 1:1): 0.48  Melting Point: 120–122 °C 
I.R.: 3400 (br.), 3303 (s), 2930 (s), 2864 (s), 2245 (w), 2116 (w), 1724 (m), 1610 (s), 
1584 (w), 1499 (s), 1452 (s), 1379 (w), 1355 (w), 1326 (w), 1286 (s), 1246 (s), 910 (s), 
731 (s) 
E.S.-M.S. (m/z): 375.2 [M-H]- 
1H-NMR (500 MHz, CDCl3): δ7.20-7.09 (m), 6.67-6.59 (m), 4.78 (s), 4.73 (s), 2.93-
2.73 (m), 2.55-2.43 (m), 2.43-2.30 (m), 2.30-2.24 (m), 2.24-2.15 (m), 2.15-2.08 (m), 
2.08-1.93 (m), 1.93-1.90 (m), 1.90-1.80 (m), 1.79-1.71 (m), 1.71-1.68 (m), 1.68-1.57 
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(m), 1.57-1.50 (m), 1.50-1.46 (m), 1.46-1.43 (m), 1.43-1.29 (m), 1.28-1.23 (m), 0.90 
(s), 0.86 (s) ppm. 
13C-APT (75 MHz, CDCl3): δ 153.3 (C), 138.3 (C), 132.7 (C), 126.5 (CH), 115.2 (CH), 
112.7 (CH), 85.8 (C), 84.1 (C), 80.1 (C), 68.5 (alkyne-CH), 50.4 (CH), 49.5 (CH), 47.2, 
43.6 (CH), 39.4 (CH), 35.9, 32.9, 31.6, 29.6, 27.7, 27.2, 26.5, 25.9, 22.8, 21.6, 18.3, 
17.9, 13.8 (CH3), 12.8 (CH3) ppm. 
VIII.5.4.2. Lowering the loading of silica 
 
NH2
Silica 5 µm
i) HBTU, DIEA
FmocGlyOH/AcOH (1:5)
DMF, 90'
ii) 20 % piperidine/DMF
N
H
O
NH2
loading ~ 0.066 mmolg-1
V.21
 
 
The silica particles (2.1 g) were put in a plastic falcon tube. Subsequently, DMF (6 
mL) was added followed by the addition of FmocGlyOH (119 mg, 0.4 mmol, 20 
mol%), AcOH (92 µL, 1.6 mmol, 80 mol%), HBTU (759 mg, 2 mmol, 1 eq) and DIEA 
(700 µL, 4 mmol, 2 eq). After shaking for 90 min, the suspension was centrifuged and 
washed thoroughly. Determination of the loading gave a value of 0.066 mmolg-1. 
Next, the Fmoc group was deprotected to give IV.21. The presence of free amine 
groups was confirmed by a positive TNBS test. 
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VIII.5.4.3. Preparation of construct V.22: coupling of azidohexanoic acid 
 
HO N3
O
5
V.9
N
H
O
NH2
loading ~ 0.066 mmolg-1
N
H
O H
N
O
N35
i) 
PyBOP, DIEA, DMF, 4 h
ii) cappingV.21 V.22
 
 
The silica material V.21 (1 g, 0.066 mmol, 1 eq) was suspended in DMF (4 mL). 
PyBOP (260 mg, 0.5 mmol, 7.6 eq), azidohexanoic acid V.9 (79 mg, 0.5 mmol, 7.6 eq) 
and DIEA (174 µL, 1 mmol, 15.2 eq) were subsequently added to this suspension. After 
shaking for 4 h, the solution was drained and the particles were thoroughly washed. 
Though no free amines were detected by the TNBS test, a capping step was still 
performed to make sure that there were no more free amines. 
After subjecting a small sample of the silica material V.22 to a solution of 0.5 M Ph3P 
in THF/H2O at 70 °C for 10 min, the TNBS test turned the particles red, thereby 
proving that the azides were present on the surface. 
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VIII.5.4.4. Preparation of construct V.23: ‘clicking’ of V.20 to V.22 
 
OH
HO
4
N
H
O H
N
O
N35
N
H
O H
N
O
5 N
NN
HO
OH
4
CuSO4.5H20 (1eq),
NaAscorbate (5eq),
iPrOH/H20 (1:1), 18 h, 40 °C
V.20V.22
V.23: HPLC packing material
+
 
 
The silica material V.22 (1 g, 0.066 mmol, 1 eq) was suspended in a solution of 
iPrOH/H2O (10 mL in a ratio of 1:1). Estradiol derivative V.20 (269 mg, 0.5 mmol, 7.6 
eq) was added to this suspension followed by CuSO4.5H2O (25 mg, 0.1 mmol, 1.5 eq) 
and NaAscorbate (99 mg, 0.5 mmol, 7.6 eq). The resulting orange solution was stirred 
gently in an oil bath of 40 °C. After overnight reaction, the green suspension was 
filtered and the remaining silica material was washed with MeOH (3 x), EDTAaq (3 x), 
MeOH (3 x) and ether (3 x). Finally, the silica material V.23 was dried at an oven 
temperature of 60 °C for overnight. 
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VIII.6. Screening of the library: development of new SPE 
cartridges 
VIII.6.1. Synthesis of alkyne substituted components 
VIII.6.1.1. Synthesis of alkyne modified construct V.29 
 
PyBOP, DIEA, DMF,
4 h 30'
ii) 20 % piperidine
i)
NH hυ NH2
IV.15
BocHN OH
O
NHFmoc
4
NH hυ N
H
O
NH2
NHBoc
PyBOP, DIEA, DMF, 
              3 h 30'
iii)
O
HO
NH hυ N
H
O
HN
NHBoc
O
V.28
V.29
 
 
The resin IV.15 (1g, 0.21 mmol, 1 eq) was weighed into a reaction vessel. After the 
addition of DMF (4.6 mL), FmocLys(Boc)OH (539 mg, 1.15 mmol, 5.5 eq) and PyBOP 
(598 mg, 1.15 mmol, 5.5 eq) were added to this suspension. Subsequently, DIEA (400 
µL, 2.30 mmol, 11 eq) was added and the suspension was shaken for 4 h 30’ after 
which the solution was drained and the beads were thoroughly washed. Ninhydrine test 
on a small sample was negative. 
Then the Fmoc group was deprotected to give construct V.28. 
Next, pentynoic acid (68 mg, 0.69 mmol, 3.3 eq), PyBOP (359 mg, 0.69 mmol, 3.3 
eq) and DIEA (241 µL, 1.38 mmol, 6.6 eq) were added to a suspension of V.28 in DMF 
(4.6 mL). The suspension was shaken for 3 h 30 min, drained and the remaining beads 
were washed. Ninhydrine test was negative  
 
Molecular Formula: C16H27N3O4   
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MW.: 325.4 g/mol 
ES. (after photocleavage in EtOH): 348.0 [M+Na] + 
VIII.6.1.2. Coupling of scaffold IV.1 to construct V.29 
 
HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
NH hυ N
H
O
HN
NHBoc
O
i) 50 % TFA/DCM
ii) IV.1, PyBOP
DIEA, DMF,18 h,  58 %
NH hυ N
H
O H
N
O4
V.29
V.30
iii) AcOH, PyBOP, 
DIEA, DMF, 1 h
 
 
Resin V.29 (1.1 g, 0.23 mmol, 1 eq) was weighed into a reaction vessel and Boc 
deprotected. 
A solution of IV.1 (345 mg, 0.35 mmol, 1.5 eq) and PyBOP (180 mg, 0.35 mmol, 
1.5 eq) in 15 mL DMF was prepared. When homogeneous, the solution was transferred 
to the pre-swollen resin and after adding DIEA (181 µL, 1.04 mmol), the suspension 
was shaken for 18 h. The resin was drained and washed thoroughly. The TNBS test 
turned the beads dark-yellow and with NF31 we got red beads. The remaining free 
spacer-amino groups were capped for 1 h with a 0.1 M solution of AcOH and PyBOP in 
the presence of 2 eq DIEA. The ninhydrin test was negative.  
The total loading was 0.101 mmolg-1 which corresponded (maximal theoretical 
loading is 0.173 mmolg-1) to a yield of 58 %.  
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VIII.6.1.3. Attachment of the glycine derivatives to V.30 
 
V.31
hυ
i) 20 % piperidine/DMF
ii) ivDdeGlyOH, DIC (2:1)
ii) 50% TFA/DCM
iv) FmocGlyOH, DIC (2:1)
v) (PPh3)4Pd, PhSiH3, DCM
vi) N3GlyOH, DIC (2:1)
HN O
O
O
NHFmoc
HN
HN
O
NHAlloc
NH
NHBoc
NH hυ N
H
O H
N
O4
V.30
N
H
O
H
N
O
HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHivDde
NHFmocN3
4
 
 
For the incorporation of the glycine derivatives, the same protocol as described in 
 VIII.3.4 was applied. The amount of resin V.30 used was 1.1 g (110 µmol). 
 
Molecular Formula: C77H92N14O13 
MW.: 1421.6 g/mol   Exact mass: 1420.7Da 
LC-MS. (after photocleavage in EtOH): 711.3 [M+2H]2+, 1422.6 [M+H]+ 
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VIII.6.1.4. Synthesis of the ‘best’ receptor V.24 
 
V.31
hυ NH
O
H
N
O
HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHivDde
NHFmocN3
4 i) Automated synthesis
ii) hυ = 360 nm
in DCM, 18 h (5 X)
V.24
'Best' receptor
iii) TFA/thioanisole/Me2S/
TIS/DODT/H2O/NH4I
3 h
iv) Prep. rev. HPLC
total yield: 20 %
H2N
O
H
N
O
4
CF3CO2
2
HN O
O
O
HN
HN
HN
O
NH
NH
NH
Gly
Gly
Gly
Arg
Phe
His
Leu
Met
Glu
Ac
Ac
Ac
 
 
The automated synthesis was performed in a manner similar to the protocol 
described in Paragraph  VIII.3.5. An amount of 100 mg (11 µmol) of construct V.31 
was subjected to this protocol.  
The protected peptide was cleaved from the resin by irradiating the beads with light 
at 360 nm. This was done under continuous vortexing of the beads in DCM (10 mL) for 
18 h. Then the suspension was drained and the beads were washed with DCM (3 x), 
EtOH (3 x) and DCM (3 x). The organic fractions were combined and evaporated. This 
whole procedure was repeated 5 times and the organic fractions were combined in the 
same flask. 
For the side chain deprotection, a mixture of TFA/TIS/DODT/thioanisole/Me2S 
(89.5/1/2.5/5/2) was prepared. After adding 125 µL NH4Iaq (460 mg/ml) to the flask 
containing the protected peptide, 2.5 mL of the TFA mixture was added. The solution 
was stirred for 3 h and then it was evaporated by blowing Ar over the flask. 
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The residue was subsequently dissolved in 10 % AcOH/H2O and this aqueous 
fraction was extracted 3 times with MTBE ether. The water fraction was then 
lyophyilised. 
The residue obtained after lyophilisation was redissolved in 10 % AcOH/H2O (1 
mL). The desired compound was then purified by injecting 500 µL of this mixture on a 
preparative HPLC system (C18 column). A gradient from 0 to 40 % MeCN in 40 min 
was used in combination with a 0.1 % TFAaq solution (from 100 % to 60 % in 40 min). 
After lyophilisation, 4.2 mg (20 %) of V.24 was obtained. 
 
Molecular Formula: C92H127N23O20S 
MW.: 1907.1 g/mol   Exact mass: 1905.9 Da 
MALDI. (after photocleavage in H2O): 1903.6 [M-H]-, 1925.6 [M-H+Na]-, 1940.5 [M-
H+K]- 
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VIII.6.1.5. Synthesis of the ‘worst’ receptor V.25 
 
V.31
hυ NH
O
H
N
O
HN O
O
O
HN
HN
HN
O
NH
NH
NH
O
O
O
NHivDde
NHFmocN3
4 i) Automated synthesis
ii) hυ = 360 nm
in DCM, 18 h (5 X)
V.25
'Worst' receptor
iii) TFA/thioanisole/
TIS/DODT/H2O/Me2S/
NH4I, 3 h
iv) Prep. rev. HPLC
total yield: 16 %
H2N
O
H
N
O
4
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2
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O
HN
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O
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NH
NH
Gly
Gly
Gly
Glu
Leu
Met
Arg
His
Phe
Ac
Ac
Ac
 
 
Starting from 100 mg V.31 (11 µmol), the ‘worst’ receptor V.25 was prepared 
according to the protocol outlined in Paragraph  VIII.6.1.4. 
Purification yielded 3.5 mg (16 %). 
 
Molecular Formula: C92H127N23O20S 
MW.: 1907.1 g/mol   Exact mass: 1905.9 Da 
MALDI. : 1905.1 [M-H]-, 1928.7 [M-H+Na]-, 1942.9 [M-H+K]- 
Chapter  VIII 
 207
min0 2.5 5 7.5 10 12.5 15 17.5 20 22.5
mAU
-600
-400
-200
0
200
400
600
800
1000 1
3.
50
7
13
.5
07
214 nm
254 nm
spacer scaffold
GlyGly Gly
Glu Leu Met
PheHisArg
AcAcAc
O
H2N
V.25 
'Worst' receptor
CF3CO2
2
13
.5
07
13
.5
07
 
spacer scaffold
GlyGly Gly
Glu Leu Met
PheHisArg
AcAcAc
O
H2N
V.25 
'Worst' receptor
CF3CO2
2
1007.0 3406.0
Mass (m/z)
50
100
%
 In
te
ns
ity
1905.1
1928.7
[M-H]-
[M-H+Na]-
%
 In
te
ns
ity
 
Experimental part  
 208 
VIII.6.1.6. Synthesis of construct V.32 
 
O
NH
HN FmocHO
hυ NH2
i)
IV.15
PyBOP, DIEA, DMF, 3 h
(2 X)
ii) 20%  pip/DMF
iii) BocGabaOH, PyBOP
DIEA, DMF, 40'
iv) 50% TFA/DCM
V.32
hυ HN HN spacer NH2
 
 
Resin IV.15 (118 mg, 25 µmol, 1 eq) was weighed into a reaction vessel. Fmoc-
hydrazinobenzoic acid (31 mg, 82 µmol, 3.3 eq) was dissolved in DMF (500 µL) 
together with PyBOP (43 mg, 82 µmol, 3.3 eq). This mixture was added to the beads 
and after the addition of DIEA (28 µL; 164 µmol, 6.6 eq), the suspension was shaken 
for 3 h. Subsequently, the resin was drained and washed. A positive NF31 test indicated 
the presence of unreacted amines. The reaction was repeated once. 
Next, the Fmoc group was deprotected. 
Then, the spacer Boc-γ-aminobutyric acid (21 mg, 105 µmol, 5 eq) was added to a 
suspension of the resin (100 mg, 21 µmmol, 1 eq) in DMF (210 µL). PyBOP (210 µL of 
a 0.5 M solution in DMF, 5 eq) and DIEA (110 µL of a 2 M solution in NMP, 10 eq) 
were added and the resulting suspension was shaken for 40 min. After draining and 
washing, the NFR31 and TNBS test were negative. 
Finally, the Boc group was deprotected. 
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VIII.6.1.7. Synthesis of construct V.35 
 
v) FmocLys(Boc)OH
PyBOP, DIEA, DMF, 40'
vi) 50 % TFA/DCM
vii) IV.31, PyBOP, DIEA, DMF, 40'
viii) 20 % piperdidine/DMF
ix) FmocLys(Boc)OH, PyBOP, 
DIEA, DMF, 60'
x) 50 % TFA/DCM
xi) IV.21, PyBOP, DIEA, DMF, 60' (2 X)
xii) 20 % piperidine
xiii) FmocLys(Boc)OH, PyBOP, 
DIEA, DMF, 60'
xiv) 20 % piperidine
xv) capping, 60'
xvi) 50 % TFA/DCM
xvii) FmocGlyOH, PyBOP, 
DIEA, DMF, 60'
V.32
hυ HN HN spacer NH2
hυ HN HN spacer Lys
NH
GN3
Lys
NH
GivDde
Lys
NH
GFmoc
Ac
V.35
 
FmocLys(Boc)OH (210 µL, 0.5 M in DMF, 5 eq) was added to resin V.32 (100 mg, 
21 µmol, 1 eq). After adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 µL, 
2 M in NMP, 10 eq) the suspension was shaken for 40 min. After draining and washing 
of the beads, a NF31 and TNBS test were negative. 
Then the Boc group was deprotected. 
Azidoglycine IV.31 (11 mg, 108 µmol, 5 eq) was dissolved in DMF (210 µL) and 
added to the resin. After adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 
µL, 2 M in NMP, 10 eq) the suspension was shaken for 40 min. After draining and 
washing of the beads, a NF31 and TNBS test were negative. 
Next, the Fmoc group was deprotected. 
FmocLys(Boc)OH (210 µL, 0.5 M in DMF, 5 eq) was added to the resin. After 
adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 µL, 2 M in NMP, 10 eq) 
the suspension was shaken for 60 min. After draining and washing of the beads, a NF31 
and TNBS test were negative. 
Then, the Boc group was deprotected. 
Experimental part  
 210 
ivDdeGlyOH IV.21 (30 mg, 107 µmol, 5 eq) was dissolved in DMF (210 µL) and 
added to the resin. After adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 
µL, 2 M in NMP, 10 eq) the suspension was shaken for 60 min. After draining and 
washing of the beads, the NF31 test was positive. Consequently, the reaction was 
repeated once to give a negative NF31 test. 
Next, the Fmoc group was deprotected. 
FmocLys(Boc)OH (210 µL, 0.5 M in DMF, 5 eq) was added to the resin. After 
adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 µL, 2 M in NMP, 10 eq) 
the suspension was shaken for 60 min. After draining and washing of the beads, a NF31 
and TNBS test were negative. 
Then, the Fmoc group was deprotected. 
The free amine was capped with Ac2O/pyridine/DCM (1:3:16) for 60 min. The 
subsequent NF31 and TNBS test were both negative. 
Next, the Boc group was deprotected. 
Finally, FmocGlyOH (31 mg, 105 µmol, 5 eq) was dissolved in DMF (210 µL) and 
added to the resin. After adding PyBOP (210 µL, 0.5 M in DMF, 5 eq) and DIEA (110 
µL, 2 M in NMP, 10 eq) the suspension was shaken for 60 min. After draining and 
washing of the beads, the NF31 test was positive. Consequently, the reaction was 
repeated once to give a negative NF31 test. 
 
Molecular Formula: C65H89N15O13 
MW.: 1288.5 g/mol   Exact mass: 1287.7 Da 
LC-MS (after photocleavage in EtOH): 1288.7 [M+H]+, 1371.7 [M+2Ac+H]+ 
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VIII.6.1.8.  Synthesis of V.36 
 
hυ HN HN spacer Lys
NH
GN3
Lys
NH
GivDde
Lys
NH
GFmoc
Ac
Automated 
synthesis
hυ HN HN spacer Lys Lys Lys Ac
HN HN HN
Gly Gly Gly
4 4 4
(Pbf)Arg Phe His(Trt)
Leu Met Glu(tBu)
Ac Ac Ac
V.35 V.36
 
 
The automated synthesis was performed in a manner similar to the protocol 
described in Paragraph  VIII.3.5. An amount of 41 mg (4.3 µmol) of construct V.35 
was subjected to this protocol.  
 
Molecular Formula: C116H163N24O23S2 
MW.: 2325.8 g/mol   Exact mass: 2324.2 Da 
MALDI (after photocleavage in EtOH): 2324.5 [M+H]+, 2339.6 [M+O+H]+, 2345.9 
[M+Na]+, 2363.0 [M+K]+, 1371.7 [M+2Ac+H]+ 
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VIII.6.1.9. Cleavage of V.36 from the resin with propargylamine and subsequent 
side chain deprotection 
 
hυ HN HN spacer Lys Lys Lys Ac
HN HN HN
Gly Gly Gly
4 4 4
(Pbf)Arg Phe His(Trt)
Leu Met Glu(tBu)
Ac Ac Ac
V.36
spacer Lys Lys Lys Ac
NH NH NH
Gly Gly Gly
4 4 4
Arg Phe His
Leu Met Glu
Ac Ac AcV.26
0.9 mg 
11 %
NH
Oi) Cu(OAc)2 (1 eq),
 pyridine (10 eq), DCM
9 eq                    , 18 hNH2
ii) TFA/thioanisole/
TIS/DODT/H2O/NH4I, 3 h
iii) Preparative reversed
phase HPLC
CF3CO2
2  
 
The resin V.36 (4.3 µmol) was suspended in DCM (500 µL). Propargylamine (2.7 
µL, 39.3 µmol, 9 eq) was added followed by Cu(OAc)2 (anhydrous, 0.8 mg, 4.3 µmol, 1 
eq) and pyridine (3.5 µL, 43 µmol, 10 eq). The resulting suspension was left overnight 
open to the air. Then the beads were drained and washed with DCM (3 x). The organic 
fractions were combined and evaporated. 
The residual oil was dissolved in 950 µL cleavage mixture consisting of 
TFA/TIS/DODT/Me2S/thioanisole (89.5/1/2.5/2/5) and then NH4Iaq (50 µL, 460 
mg/mL) was added. This yellow mixture was shaken for 3 h and blown to dryness with 
Ar. 
The black residue was dissolved in 10 % AcOH/H2O and filtered over a small piece 
of cotton wool in a pasteur pipette before purifying via preparative HPLC. The desired 
compound was then purified using a gradient from 0 to 40 % MeCN in 40 min in 
combination with a 0.1 % TFAaq solution (from 100 % to 60 % in 40 min). After 
lyophilisation, 0.9 mg (11 %) of V.26 was obtained. 
 
Molecular Formula: C76H121N22O19S 
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MW.: 1679.0 g/mol   Exact mass: 1677.9 Da 
MALDI.: 1677.6 [M+H]+, 1698.4 [M+Na]+, 1713.7 [M+K]+ 
 
1023.0 3499.0
Mass (m/z)
50
100
%
 In
te
ns
ity
1677.6
1698.4
1713.7
[M+H]+
[M+Na]+
[M+K]+
spacer Lys Lys Lys Ac
NH NH NH
Gly Gly Gly
4 4 4
Arg Phe His
Leu Met Glu
Ac Ac Ac
V.26
NH
O
%
 In
te
ns
ity
 
VIII.6.1.10. Synthesis of alkyne modified Tozzi-tetrapeptide V.27 
 
O
O
NH2
V.1
i) Automated
synthesis
O
O
Val-Ser-Ser-Arg-Gaba-NH2
tBu tBu Pbf
ii) Pentynoic acid, 
PyBOP, DIEA, DMF, 10 h
iii) TFA/thioanisole
TIS/H2O/DODT, 3 h
0 °C    rT
HO
O
ArgSerSerVal Gaba N
H
O
CF3CO2
V.37
V.27, 92 %  
 
Resin V.1 (235 mg, 0.25 mmol) was weighed into a 10 mL syringe, that was placed 
in the reaction block of the Syro I. The automated synthesis was performed in a manner 
similar to the protocol described in Paragraph  VIII.3.5. The process was stopped at the 
stage of V.37. Then, pentynoic acid (74 mg, 0.75 mmol, 3 eq) was added manually to 
the syringe followed by HBTU (284 mg, 0.75 mmol, 3 eq), DIEA (0.75 mL, 1.50 mmol, 
6 eq) and DMF (2. mL). Next, the suspension was shaken for 10 h after which the 
solution was drained and the beads were washed. 
Subsequently, the resin was transferred to a flask, mixing it with 5 mL of freshly 
prepared TFA/thioanisole/TIS/H2O/DODT (86.5/5/1/5/2.5) at 0 °C. The resulting 
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suspension was stirred gently and after 5 min the ice bath was removed and the 
suspension was stirred for 3 h at ambient temperature. Then the filtrate was isolated and 
blown to dryness with Ar. From the residual oil, the peptide V.27 was precipitated 3 
times with cold MTBE. After isolation, the peptide was dissolved in H2O and 
lyophilised to give V.27 as a white foam (176 mg, 92 %). 
 
Molecular Formula: C26H44N8O9 
MW.: 612.3 g/mol 
ES.: 611.5 [M-H]- 
VIII.6.1.11. Lowering the loading of silica (particle size 50 µm) 
 
NH2
Silica 50 µm
i) HBTU, DIEA
FmocGlyOH/AcOH
(1:5), DMF, 90'
ii) 20 % piperidine/DMF
NH
O
NH2
loading ~ 0.110 mmolg-1
NH
O
NH
O
N3
5
V.39
HO
N3
O
5
V.9i) 
PyBOP, DIEA,
DMF, 4 h
ii) capping
 
 
A protocol similar as described in Paragraph  VIII.5.4.2 was applied on 2.35 g of 
aminopropylsilica with a particle size of 50 µm.  
 
IR. (KBr): 3450 (br. s), 2106 (m), 1643 (s), 1089 (br. s), 798 (s) 
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VIII.6.1.12. ‘Clicking’ of V.25 to silica 
 
N
NN
sc
af
fo
ld
Gly
Gly
Gly
Glu
Leu
Met Phe
His
Arg
Ac
Ac
Ac
V.41 20 mg silica
loading: ~ 52 µmol/g
CuSO4.5H2O, NaAscorbate
H2O, 40°C, 48 h, 70 %
V.25
'Worst' receptor
N
H
O H
N
O
N35
V.39
 
 
First, a UV-calibration curve was determined by making different concentrations 
(9.8 µM, 4.9 µM, 2.5 µM, 2.0 µM and 1.0 µM) of V.25 in H2O. By measuring the 
absorbance of the different concentrations, the following equitation was determined: 
Abs = 63.082 x [V.25]aq – 0.0544 (R2 = 0.9999) 
R2 = 0.9999
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.0 2.0 4.0 6.0 8.0 10.0 12.0
A
bs
or
ba
nc
e 
(m
A
u)
Concentration (µM)
A
bs
or
ba
nc
e 
(m
A
u)
 
Next, CuSO4.5H2O (5.5 mg, 22 µmol) and NaAscorbate (8.71 mg, 44.0 µmol) were 
dissolved in H2O (20 mL). From this stock solution, 200 µL (16 mol % CuSO4.5H2O 
and 32 mol % NaAscorbate) was pipetted in an eppendorf containing V.25 (3.5 mg, 
1.64 µmol, 8.2 mM 1 eq) and V.39 (20 mg, 2.20 µmol). The resulting mixture was 
vortexed at 40 °C. 
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After 48 h, 3 µL of the reaction mixture was transferred to a UV cuvette and 2997 
µL H2O was added. For the blanc sample, 3 µL from the CuSO4.5H2O stock solution 
was diluted up to 3 mL in a UV cuvette. The absorbance from this sample was 0.121 
mAu, correlating to a concentration of 2.8 mM. From this value, a loading of ~ 52 
µmol/g was determined. 
The silica material V.41 was isolated via centrifugation and subsequent decantation 
of the liquid. The material was washed thoroughly water (3 x), EDTAaq (3 x) and iPrOH 
(3 x). 
VIII.6.1.13. Clicking of V.24 to silica 
 
N
NN
sc
af
fo
l d
Gly
Gly
Gly
Arg
Phe
His Glu
Met
Leu
Ac
Ac
Ac
V.40 20 mg silica
loading:~ 40 µmol/g
CuSO4.5H2O, NaAscorbate
H2O, 40°C, 48 h, 44 %
V.24
'Best' receptor
N
H
O H
N
O
N35
 
 
An approach similar as in Paragraph  VIII.6.1.12 was applied on 20 mg silica V.39 
and 4.2 mg V.24 (1.97 µmol, 9.9 mM, 1 eq). 
After 48 h, an absorbance of 0.313 mAu was measured, correlating to a 
concentration of 5.8 mM. From this value, a loading of ~ 40 µmol/g was determined. 
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VIII.6.1.14. ‘Clicking’ of V.26 to silica 
 
N
NN
Lys
Lys
Lys
Ac
N
H
N
H
N
H
Gly
Gly
Gly
4
4
4
Arg
Phe
His
Leu
Met
Glu
Ac
Ac
Ac
CuSO4.5H2O, NaAscorbate
H2O, 40°C, 48 h, quant.
V.42 20 mg silica
loading: ~ 24 µmol/g
V.26
N
H
O H
N
O
N35
 
 
An approach similar as in Paragraph  VIII.6.1.12 was applied on 20 mg silica V.39 
and 0.9 mg V.26 (0.47 µmol, 2.4 mM, 1 eq). In 200 µL H2O was added CuSO4.5H2O 
(2.3 mg, 9.4 µmol, 20 eq) and NaAscorbate (3.72 mg, 18.8 µmol, 40 eq). After 48 h, no 
ES-signal of V.26 was observed anymore when 2.5 µL of the reaction mixture was 
injected directly. Therefore, a loading value of ~ 24 µmol/g was obtained.  
VIII.6.1.15. ‘Clicking’ of V.27 to silica 
 
N
NN
Gaba Arg Ser Ser Val
O
OHCuSO4.5H2O, NaAscorbate
H2O, 40°C, 48 h, quant.
V.43 50 mg silica
loading: ~ 110 µmol/g
V.27
Tozzi-tetrapeptide
N
H
O H
N
O
N35
 
 
An approach similar as in Paragraph  VIII.6.1.12 was applied on 50 mg silica V.39 
(5.5 µmol, 1 eq) and 21 mg V.27 (28 µmol,5 eq). A solution of CuSO4.5H2O (0.6 µmol, 
20 mol%) and NaAscorbate (1.2 µmol, 40 mol%) in 500 µL H2O was added and the 
suspension was vortexed for 48 h. The reaction proceeded quantitatively as witnessed 
by the disappearance of the azide absorption in the IR spectrum. The new material V.43 
was obtained with a loading of ~ 0.110 µmol/g. 
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IR. (Kbr): 3466 (br. s), 2106 (m), 1643 (s), 1093 (br. s), 803 (s) 
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